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Abbreviations 
 
 
 Å    Ångström ( 1Å = 10-10 m)  
 A600    absorption at 600 nm 
 Amp    Ampicillin 
 aqua bidest.   double destillated water 
 ArcTGT   TGT involved in archaeosine modification 
 CATH    Protein Structure Classification Database 
     (Class Architecture Topology Homology) 
 Cm    Chloramphenicol 
 CMC    critical micellar concentration  
 DMSO   dimethylsulfoxid 
 dNTP    desoxynucleosidtriphosphate 
 DTT    dithiothreitol 
 E. coli    Escherichia coli 
 ECY2    unmodified E. coli tRNATyr 
 EDTA    ethylendiamintetraacetate 
 FAE    follicle-associated epithelia 
 h    hour 
 HEPES   2-[4-(2-hydroxyethyl)piperazino]ethansulfonic acid 
 IPTG    isopropylthio-β-galactosid 
 kb    kilo bases 
 kDa    kilo Dalton 
 Kic    competitive inhibition constant 
 Kiu    uncompetitive inhibition constant  
 Km    kanamycin 
 LB    Luria - Bertani complex medium 
 M    molarity (mol ⋅ L-1) 
 MES    2-morpholinoethansulfonic acid 
 min    minute 
 NTP    nucleosidtriphosphate 
 PAGE    polyacrylamide gel electrophoresis 
 PAI    pathogenicity island 
 PEG    polyethylenglycol 
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 PCR    polymerase chain reaction 
 PDB    PROTEIN DATA BANK 
 P. horikoshii   Pyrococcus horikoshii 
 PPase   inorganic pyrophosphatase 
 preQ0    7-cyano-7-deazaguanine 
 preQ1    7-aminomethyl-7-deazaguanine 
 Q    7-(((4,5-cis-dihydroxy-2-cyclopenten-1-yl)amino) 
     methyl)-7-deazaguanosine 
 QueA    S-adenosylmethionine:tRNA-ribosyltransferase-
     isomerase    
 QueTGT   TGT involved in Q modification 
 SCOP    Structural Classification of Proteins Database 
 SDS    sodiumdodecylsulfate 
 S. flexneri   Shigella flexneri 
 SPB    standard phosphate binding motif 
 SPR    surface plasmon resonance 
 TCA    trichloroacetic acid 
 TGT    tRNA-guanine transglycosylase 
 TIM-barrel    triose-phosphate isomerase (TIM) / (βα)8 barrel  
 T. maritima   Thermotoga maritima 
 Tris    tris-(hydroxymethyl)-aminomethan 
 w/v    weight per volume 
 w.t.    wild type 
 YadB    glutamyl-queuosine tRNAAsp synthetase 
 Z. mobilis   Zymomonas mobilis 
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1. Introduction and Motivation 
 
 
1.1    Structure-based drug design and TGT 
 
Structure-based drug design profits from the enormous amount of available protein 
crystal structures. In May 2006 36,400 structures were deposited in the protein data 
bank (PDB; http://www.rcsb.org). It is, however, not only the discovery of new 
proteins that provides valuable information. Also multiple crystal structures of the 
same protein in complex with different substrates or of homologous or structurally 
related proteins from other species are of enormous value. In many cases, the 
comparison of these structures gives insight into the characteristics and the 
properties of the protein of interest. The currently available crystal structures can be 
divided into 8,800 groups with a sequence identity of more than 40%, indicating 
similar fold and related functions (PDB-SELECT: May, 2006). Thus, on average for 
each deposited structure four structurally related entries are available. 
TGT, the tRNA – guanine transglycosylase is a relevant target for the design of 
inhibitors against Shigella, the causative agent of bacterial dysentery. Computer- 
based drug design, including the method of virtual screening, enabled the discovery 
of compounds from structurally very different classes that were capable to inhibit 
TGT [Grädler et al., 2002; Brenk et al., 2003; Brenk et al., 2004]1-3. Some of these 
compounds were suited for crystal structure analysis in complex with the TGT from 
Zymomonas mobilis. These structures form a pool of 33 available TGT crystal 
structures, including structures of TGT in complex with various substrate molecules, 
TGT mutants and TGTs from two other bacterial species (PDB; May 2006). In 
addition to these crystal structures, currently 131 tgt gene sequences have been 
deposited in the UniProt Knowledgebase (SwissProt & TrEMBL; 
http://www.expasy.org). 
The careful analysis of these structures and sequences in combination with kinetic 
data of substrates and inhibitors is fruitful in two mutually related ways. Firstly, it 
provides a profound understanding of the structural prerequisites necessary for 
catalysis [Xie et al., 2003]4. In particular innate protein flexibility has to be considered 
in this context. But also water molecules can be identified to be relevant for catalysis 
or for the stabilization of alternative binding geometries [Brenk et al., 2003]2. 
1.2    Shigellosis 
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Secondly, the knowledge of deviating binding competent conformers can be 
implemented in the further development of available inhibitor series or in the 
computer-based search of new inhibitor classes [Brenk et al., 2004]1. Such attempts 
might finally result in a potent antibiotic against Shigella TGT, that allows to minimize 
the symptoms of bacterial dysentery. 
1.2    Shigellosis 
 
1.2.1 Disease and treatment 
 
Shigellosis or bacillary dysentery is caused by bacteria belonging to the genus 
Shigella. Oral uptake of contaminated drinking water or food possibly initiates an 
infection. The bacteria pass through the stomach, the small intestine and finally reach 
the colon where they invade the colon epithelium and the mucosa. This results in a 
destructive recto-colitis which is responsible for the dysenteric symptoms like watery 
diarrhoea, fever, intestinal cramps and emission of mucopurulent and blood stools 
[Sansonetti et al., 2001]5. Due to infiltration of inflammatory cells in the colon 
epithelium mucosal ulcers are often observed [Mathan & Mathan, 1991]6. In the 
absence of an effective treatment, secondary complications may occur like 
septicaemia, pneumonia or haemolytic uremic syndrome [Bennish, 1991]7. 
Shigellosis is a global burden with an estimated annual number of 165.7 million 
episodes. Only 1.5 million cases occur in industrialized countries, many of them 
endemically in children day care centres, custodial institutions or as traveller’s 
diarrhoea. Almost no fatalities are observed. The vast majority of 163.2 million 
episodes takes place in developing countries, often epidemically, with a death rate of 
1.1 million. Most of the episodes occur in displaced populations. Civil war in areas 
with dense population and natural disasters (flooding, drought) often cause hunger 
and poverty forcing people to leave their home. Mostly, these displaced people are 
crowded in areas with poor sanitation and insufficient supplies of clean water. 
Concomitant malnutrition is widely spread. Children are affected most severely from 
such conditions. Thus, 69 % (112.6 million) of all episodes and 61 % (660.000) of all 
fatalities involve children under 5 years of age [Kotloff et al., 1999]8. Particularly in 
Africa the interference with HIV / AIDS is a serious problem. 
For effective treatment clean water, sufficient food supply and hygiene conditions 
avoiding the fecal – oral spreading route are inevitable. This includes washing of 
1.2    Shigellosis 
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hands as well as the use of separate dishes and towels for patients and other 
members of the household. Additionally, the control of houseflies by bait and trap 
strategies significantly reduces the spreading of Shigella. Houseflies are a key vector 
for the faecal contamination of human food [Cohen et al., 1991]9. 
Antibiotics can be used to treat shigellosis and reduce the period of bacterial 
excretion from the patient. In developing countries they are used to stop epidemic 
spreading [Jennison & Verma, 2004]10. A major problem for shigellosis treatment is 
the extraordinary ability of Shigella to acquire plasmid-encoded resistance to 
antimicrobial drugs that constituted the first-line therapy. Sulfonamides, tetracycline, 
ampicilline and trimethoprim-sulfamethoxy-azole were highly efficient drugs two 
decades ago, but are becoming more and more ineffective [Kotloff et al., 1999]8. For 
trimethoprim the resistance rate rose from 3 % in 1975 to 98 % in 1988 [Heikkila et. 
al., 1990]11. A survey from Israel reported for the period 1991 - 2000 high resistances 
to trimethoprim (94 %) and ampicillin (85 %), significantly increased resistances to 
tetracycline (23 % to 87 %) and emerging resistances to quinolones (0.5-2 %) 
[Ashkenazi et al., 2003]12. During an epidemic outbreak in Zaire in 1994 a Shigella 
strain was identified that was resistant to all commonly used antibiotics [Goma 
Epidemiology Group, 1995]13. These findings underline the need to monitor 
resistance and to develop new, innovative antibiotics that maintain the ability of 
successful treatment.  
A further important goal is the development of vaccines that prevent infection. Since 
the 1940s this has been attempted with little success. Current research approaches 
using deeper insight into Shigella pathogenicity, however, made promising progress. 
But still these vaccines do not yet fulfil efficacy and safety requirements for the 
treatment of humans [Jennison & Verma, 2004]10. 
 
1.2.2 Shigella – Escherichia relationship 
 
 
Shigellae are GRAM-negative, nonsporulating, facultative anaerobic bacilli. The 
genus Shigella is divided into four different ‘species’ and a varying number of 
serotypes, based on biochemical differences and variations in their O-antigen 
[Sansonetti, 2001]14. All four ‘species’ are spread world wide, although significant 
regional differences are observed [Kotloff et al., 1999]8. 
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Shigella flexneri (6 serotypes) 
 is the most abundant species worldwide (median value of 60 %). It dominates 
 in developing countries with 55 - 85 % (industrialized countries: 16 %). 
Shigella sonnei (1 serotype) 
 is the next most common species (15 %). It is the most abundant species in 
 industrialized countries (77 %), responsible for predominantly endemic 
 episodes. In developing countries it is limited to 5 - 30%. 
Shigella boydii (8 serotypes) 
 is less common (6 %) and almost equally distributed all over the world with a 
 slight peak in the Middle East (15 %). 
Shigella dysenteriae (16 serotypes) 
 is as common as Shigella boydii (6 %) in average. In industrialized countries it 
 is rarely observed (1 %). Significant peaks are found in South Asia (27 %) and 
 sub-Saharan Africa (31 %). These peaks result from often deadly epidemic 
 episodes caused by S. dysenteria subtype 1 (“Shiga bacillus”). This subtype 
 produces Shiga toxin, a potent cytotoxin. Shiga toxin comprises two subunits 
 and is capable to induce severe inflammations. Upon release from the bacilli it 
 spreads all over the body of the patient  damaging organs like kidneys, brain 
 as well as red blood cells. This causes  severe additional complications for the 
 diarrhoea patient like haemorrhagic colitis and the haemolytic uremic 
 syndrome (HUS) [O’Loughlin & Robins- Browne, 2001]15. 
 
The genus Shigella belongs to the family of Enterobacteriaceae. Strictly speaking it 
does not constitute a separate genus. Genetic analysis revealed that Shigella 
belongs to the core of Escherichia coli strains [Escobar-Páramo et al., 2004]16. Thus, 
it would be more appropriate to consider Shigella as a subtype of E. coli and call it 
‘enteroinvasive E. coli ‘ (EIEC).  
 
1.2.3 Cellular and  molecular pathogenicity 
 
 
Shigellae are very infective. Only 10 – 100 bacteria can cause a disease in an adult. 
After passage through the stomach and the small intestine they are capable to 
invade the colon epithelium. The passage is not possible through the apical side of 
the epithelial cells (Fig. 1.1a). Invasion occurs indirectly via M cells. They are 
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specialized to transport antigens (bacteria, etc.) through the colon epithelium to 
present them to macrophages which are in tight association with them. Both are 
located in follicle-associated epithelia (FAE). The FAE overly the mucosa-associated 
lymph nodes that are responsible for intestinal immunity. Shigella have the unusual 
capacity to enter the M cell associated macrophages without being damaged. After 
phagocytic uptake by the macrophage, they escape from the phagosome. Inside the 
macrophages they induce apoptosis. Upon apoptotic death inflammatory interleukins 
(IL-1β and IL-18) are produced and released into the mucosa after lysis, together 
with the intact Shigella. The bacteria then enter the colon epithelial cells from the 
basal side. Once inside these cells they propagate and spread from cell to cell – well 
protected from immune cells. Infected epithelial cells release IL-8. This interleukin, 
together with the two above mentioned ones, attracts macrophages and 
polymorphonuclear leucocytes (PMN) from subepithelial tisues. The latter disrupt the 
integrity of the epithelial barrier and facilitate further Shigella invasion from the colon. 
Thus, in a sort of ‘snowball effect’ the initial inflammatory reaction is amplified and 
results in an uncontrolled tissue destabilization. Nevertheless, in contrast to 
macrophages, PMN are able to kill Shigella inside their phagosomes. Together with 
NK cells and T lymphocytes,  immune cells attracted by IL-18, they eventually cope 
with the infection. In addition IL-18 triggers the production of  the interferon IFN-γ 
which activates the immune system. [Sansonetti et al., 2001; Sansonetti et al., 2001; 
Jennison & Verma, 2004]5, 10, 14.  
In order to enable cell entry, intracellular mobility, cell spreading and induction of 
apoptosis Shigella produces virulence factors. These virulence factors are used to 
reprogram the cellular machinery of epithelial as well as immune cells by activating 
innate transport and signalling pathways [Fernandez & Sansonetti, 2003; Van Nhieu 
et al., 2000]17, 18.  
The first step of invasion into an epithelial cell is the interaction of a tube like type III 
secretion apparatus with the host cell membrane (Fig 1.1b). A pore is formed on the 
tip of the secretion apparatus by the virulence factors IpaB and IpaC. Exposure of 
IpaC into the host cell cytoplasm activates a Src tyrosine kinase. A further signalling 
cascade results in actin dependent filopodia and lamellipodia formation. These 
structures form in the surrounding of the secretion apparatus tip and finally enclose 
Shigella, resulting in macropinocytotic uptake. To provide lamellipodia with enough 
actin and to avoid polymerization in the secretion apparatus contact region, IpaA is 
1.2    Shigellosis 
____________________________________________________________________ 
16 
secreted through the secretion tube porus into the host cell cytoplasm. Within the cell 
IpaA binds to vinculin and available F-actin from adjacent cytoskeleton elements of 
the host cell is depolymerised. 
After the uptake of Shigella into the host cell the macropinocytotic vacuole lyses and 
the bacterium is released into the cytoplasm. To enable intracellular mobility the 
virulence factor IcsA is produced.  It is located in the bacterial cell wall, exposed to 
the host cell cytoplasm. Binding of the host cell proteins N-WASP and ARP2/3 results 
in actin polymerization that pushes the bacteria through the cytoplasm. 
The described virulence factors are only the most prominent ones among a vast set 
of further virulence factors involved in generating pathogenicity. 
 
C
CB AV
F-actin
S
A
S
A
A
Epithelial cell
Shigella
Filopodia
B
 
      a                                                                                       b 
 
Fig. 1.1  a) Pathway of epithelial colonization and disintegration – figure modified from 
Sansonetti (2001)5;  b)  macropinocytotic uptake of Shigella, A: ipaA, B: ipaB,  C: ipaC,         
V: vinculin, S: Src kinase, red: Shigella virulence factors, black: host cell proteins 
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1.2.4 Regulation of pathogenicity 
 
The virulence factor genes are located on a 214-kb virulence plasmid, which was 
isolated and sequenced from S. flexneri. Coding sequences are scattered all over the 
plasmid. One block of 30 kb shows a particular dense pattern of genes and is called 
pathogenicity island (PAI). The mxi / spa- and ipa-loci found in this region code for 
proteins necessary to establish the type III translocon and to allow cell entry 
[Sansonetti, 2001]5. The expression of virulence genes is organized hierarchically 
[Dorman & Porter, 1998]19.  VirF and VirB are the key transcription activators for 
virulence gene expression. The virF and virB genes are plasmid encoded. 
Expression of virF directly activates the transcription of virulence factor genes like 
icsA as well as the transcription of the virB-gene. The virB-gene product then 
activates the transcription of the mxi / spa- and ipa-genes. Thus, VirF is in the centre 
of pathogenicity regulation (Fig. 1.2).  
 
virF VirFvirF-mRNA
virB
icsA
mxi spa ipa
temperature   pH
osmolarity Arg /Met
H-NS (-)
IHF   (+)
transcription translation
> treshold
level
gyrase
Q-tRNA (+)
ms2i6A37-tRNA (+)novobiocin (-)
superhelicity
 
 
Fig. 1.2  Regulation of VirF expression 
 
Remarkably, it is not the absence or presence of VirF that regulates virulence. 
Instead, a threshold level for VirF exists above which virulence factors are produced. 
The amount of VirF depends on various environmental and internal factors. Such 
environmental factors are pH, osmolarity, temperature and nutrition factors. Below 
30° C Shigella is not virulent. The virF-gene transcription is fully activated at 37° C, 
pH 7.4, physiological osmolarity and in the presence of free amino acids (arginine / 
methionine). The virF- gene promoter is positively regulated by the transcription 
factor IHF and negatively by H-NS. Both transcription factors are encoded by the 
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chromosome and their expression is sensitive to the mentioned environmental 
factors [Dorman & Porter, 1998; Durand et al., 2000; Durand & Björk, 2003]19-21. 
Apart from this ‘classical’ regulation the virF level also depends on an accurate 
transcriptional and translational machinery [Durand et al., 2000]21. Each intervention 
affecting this machinery may also influence VirF expression. The antibiotic 
novobiocin for instance inhibits gyrase, thus decreasing negative superhelicity in 
DNA. This results in decreased virF levels. On the translational level the expression 
of virF can be influenced as well. Efficient translation of virF-mRNA at the ribosome 
requires the presence of modified tRNA molecules. Modification of tRNA bases is 
very common in nature [Björk, 1996]22. Two modifications were demonstrated to 
exhibit major influence on the virF mRNA translational speed. In specific tRNA 
molecules the highly modified nucleosides queuosine (Fig. 1.4) in position 34 (the 
anticodon wobble position) or 2-methylthio-N6-isopentenyladenosine (ms2i6A37) in 
position 37 (adjacent to the anticodon) have to be present (Fig. 1.3). Shigella mutants 
lacking one of these modifications show significantly reduced virulence. This was 
tested in mutational studies where gene knock-out in the tRNA modification pathway 
resulted in the absence of these modifications. The first step of A37 modification is 
catalyzed by the miaA gene product. Mutation of the miaA gene reduces the VirF 
level to 10%, and the haemolytic activity to 10 - 20% compared to the wild type 
[Durand et al., 1997]23. In tRNA position 34 the tgt / (vacC)-gene product catalyzes 
the incorporation of a queuine precursor into tRNA. Mutation of the tgt-gene reduces 
both, VirF level and haemolytic activity, to 50 - 60% of the wild type [Durand et al., 
1994; Durand et al., 2000]21, 24. Thus, tRNA modifying enzymes could represent 
promising targets for the development of antibiotics. Inhibition of such specific tRNA 
modification steps should result in significantly reduced virulence of Shigella.  
For E. coli the tgt-gene product and its function has been characterized in detail 
(chapter 2.1). It codes for the tRNA – guanine transglycosylase (TGT). A crystal 
structure of this protein for the structurally very similar Zymomonas mobilis TGT is 
available [Romier et al., 1996]25. Thus, this TGT can be used for structure-based 
drug design to develop potent inhibitors and finally to test the hypothesis of 
significant virulence reduction. 
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1.3    Queuosine-modification 
 
1.3.1 tRNA-modification 
 
Transfer RNA (tRNA) maturation involves a series of post-transcriptional processing 
steps resulting in fully functional tRNA molecules. Among these maturation steps 
nucleoside modification is the most remarkable one. For tRNA a wealth of structural 
changes of canonical nucleosides has been described. Typically ~ 10 % of all 
nucleosides are modified in tRNA, but as many as 25 % can be affected. More than 
80 modifications have already been described so far [Björk, 1995]26. Many of them 
are conserved across broad phylogenetic boundaries. These modifications range 
from methylations and thionylations to extensive ‘hypermodifications’ of canonical 
bases in multiple enzymatic steps. Examples for such ‘hypermodifications’ are 
queuosine, wybutosine or  2-methylthio-N6-isopentenyl-adenosine (Fig. 1.3 and 1.4).  
The role of such modifications depends on their position. Modifications outside the 
anticodon region are thought to influence structural integrity or to serve as 
recognition determinants for the ribosome. Modifications within or around the 
anticodon are proposed to fine-tune translational speed and fidelity or to influence the 
occurence of frame-shifting events. Nevertheless, the present understanding is still 
rudimentary [Björk et al., 1999; Iwata-Reuyl, 2003]27, 28.   
 
 
 
Fig. 1.3   Examples for modified and ‘hypermodified’ tRNA bases (from: The RNA 
Modification Database: http://medlib.med.utah.edu/RNAmods/) 
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1.3.2  Queuosine-modification pathway 
 
The modification of tRNA in position 34 with queuosine (7-(((4,5-cis-dihydroxy-2-
cyclopenten-1-yl)amino)methyl)-7-deazaguanosine = Q ; Fig. 1.4) is one of the most 
pronounced modifications known to date. Queuosine is found in most eubacterial and 
eukaryotic species. Only few species are not capable of Q-synthesis, among them 
Saccharomyces cervisiae and the eubacterial division of Actinobacteria 
(Mycobacerium, Corynebacerium, Streptomyces, Bifidobacterium) [Reader et al., 
2004]29. 
Queuosine is found in four specific tRNAs with an anticodon constituted by G in 
position 34, U in position 35 and a variable base in position 36 (G34U35N36, N = 
A,C,G,U). These four tRNAs are coding for the amino acids asparagine, aspartic 
acid, histidine and tyrosine [Okada & Nishimura,1979; Okada et al., 1979]30, 31. 
The physiological relevance of the Q-modification is not yet fully understood. E. coli 
mutants defective in Q-synthesis exhibit an apparently normal phenotype and growth 
rate during favourable growth conditions. Upon entry into stationary growth phase 
viability drops significantly, but the physiological background remains elusive 
[Noguchi et al., 1982]32. In mammals the transcription of phenylalanine hydroxylase, 
involved in tyrosine biosynthesis, was shown to be Q-dependent [Marks & Farkas, 
1997]33. The absence of queuine might result from an mRNA mistranslation [Iwata-
Reuyl, 2003]28. Together with the knowledge of Q-dependent VirF translation it can 
be assumed that the Q-modification influences anticodon base pairing.                    
Q-modification in tRNA seems to increase efficiency of interactions of the wobble 
position with specific mRNAs thus resulting in increased translational speed and 
correct frame-shifting.  
In Eubacteria Queuosine-tRNA is produced in a multi step reaction (Fig. 1.4). The 
initial step of tRNA modification is performed by the enzyme tRNA – guanine 
transglycosylase (QueTGT). It specifically recognizes the four tRNAs mentioned 
above by a common U33G34U35 sequence. [Nakanishi et al., 1994; Curnow & Garcia, 
1995]34, 35 QueTGT replaces guanine 34 (G34) by the Q-precursor preQ1                  
(7-(aminomethyl)-7-deazaguanine) [Okada & Nishimura,1979]30. Most probably, 
preQ1 is produced from guanosine triphosphate (GTP), [Kuchino et al., 1976]36, by 
means of the queC-, queD-, queE- and queF-gene products. These genes have been 
identified in a comparative genomics study [Reader et al., 2004]29. The involvement 
of QueC in preQ1 biosynthesis has been demonstrated in detail [Gaur & Varshney, 
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2005]37. The roles of the qeuD- and queE-gene products are still unclear. QueF 
performs the reaction step previous to QueTGT. The NADPH-dependent enzyme 
catalyzes the reduction of preQ0 (7-cyano-7-deazaguanine) to preQ1 [Van Lanen et 
al., 2005]38. Surprisingly, both bases, preQ0 and preQ1, are capable of binding to 
QueTGT, however, preQ1 is preferentially incorporated into tRNA [Hoops et al., 
1995]39. After incorporation preQ1 is transformed to the functional base queuine in 
two steps [Iwata-Reuyl, 2003].28, 40. The first one is performed by                     
S-adenosylmethionine:tRNA ribosyltransferase-isomerase (the QueA enzyme). QueA 
transfers a ribosyl moiety from S-adenosylmethionine to preQ1 resulting in 
epoxyqueuosine formation (oQ, (7-((N-(2,3-epoxy-4,5-cis-dihydroxycyclopent-1-
yl)amino) methyl)-7-deazaguanosine). In the second step epoxyqueuosine is reduced 
by a still unknown cofactor B12-dependent enzyme to Q In some bacterial species, 
among them E. coli and EIEC, queuosine-tRNAAsp is further modified to          
glutamyl-queuosine by YadB, a glutamyl-queuosine tRNAAsp synthetase [Blaise et al., 
2004; Campanacci et al., 2004; Dubois et al., 2004; Salazar et al., 2004]41-44. YadB 
aminoacetylates one of the hydroxyl groups of the queuosine-pentenyl moiety via the 
transfer from glutamyl-AMP. The glutamylation is prone to hydrolysis and has a 
rather short half-life.  
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Fig. 1.4        Queuine modification pathway (* which OH-group is glutamylated is not known) 
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Degradation of Q-tRNAs in E. coli is performed by the enzyme ‘Colicin E5’. It 
specifically releases queuosine from tRNA by cleaving the phosphodiester bonds to 
U35 and U33 [Lin et al., 2005]45. 
Crystal structures are available of the enzymes QueF from Bacillus subtilis [Swairjo 
et al., 2005]46 and QueTGT from Zymomonas mobilis [Romier et al., 1996]25 and 
Thermotoga maritima (PDB-code: 2ASH). Of QueA from B. subtilis (PDB-code: 
1YY3) and T. maritima (PDB-code: 1VKY) coordinates are deposited in the PDB. 
In Eukaryota queuosine is present in the same four tRNAs in position 34 as in 
Eubacteria. Nevertheless, the Q-modification process differs fundamentally. 
Eukaryota are not capable to synthesize queuosine de novo. Thus, the base queuine 
is a nutrition factor. It has to be acquired by food or from bacterial commensals of the 
digestive apparatus. This assumption was indicated by reduced queuosine levels in 
proliferating eukaryotic tissue cells. During growth the amount of free queuine is 
limited and cannot be restored quickly enough. The incorporation of queuine into 
tRNA is performed in a single step reaction. It is performed by the eukaryotic 
QueTGT accepting queuine as substrate, in contrast to eubacterial TGT which is 
accepting preQ1. For Eukaryota further modifications of queuine are described 
resulting in glycosylations of the pentenyl hydroxyl groups. However, the enzymes 
responsible for the formation of these glycosylated  β-D-mannosyl-Q-tRNAs and β-D-
galactosyl-Q-tRNAs are still unknown [Iwata-Reuyl, 2003]28. 
 
 
1.3.3 Archaeosine-modification in Archaebacteria 
 
In Archaebacteria no queuine modified tRNAs are found. Nevertheless, central parts 
of the Q-modification pathway are present in Archaebacteria as well (Fig. 1.5). 
Deviating from Eubacteria and Eukaryota the tRNA – guanine transglycosylase from 
Archaebacteria (ArcTGT) incorporates the preQ1 precursor preQ0 into position 15 of 
the dihydrouridine loop (D-loop) of archaebacterial tRNAs. For ArcTGT crystal 
structures are available in complex with preQ0, guanine and full length tRNAVal 
[Ishitani et al., 2002; Ishitani et al., 2003]47, 48.  
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Fig. 1.5  Archaeosine-modification pathway 
 
The further modification steps of preQ0 differ significantly from Eubacteria and 
Eukaryota. In yet unknown steps, preQ0 is modified to archaeosine (7-formamidino-7-
deazaguanine), a modified base found in virtually all of the archaebacterial tRNAs 
[Sprinzl et al., 1998]49.  
G15 or archaeosine15 is buried in the tRNA core and involved in the formation of salt 
bridges between the positively charged formamidino group of archaeosine and RNA 
phosphate backbone groups. Archaeosine modification is thought to stabilize the 
canonical L-shape of tRNA under the predominantly high temperature most 
Archaebacteria are exposed to [Gregson et al., 1993; Iwata-Reuyl, 2003]28, 50. 
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1.4    Aim of the project 
 
In two preceding PhD projects structure-based design resulted in the development of 
inhibitors of the QueTGT from Z. mobilis. A test system was established, [Grädler, 
PhD Thesis, 2000]51, and by the combination of classical structure-based design with 
computer-based methods various classes of TGT inhibitors have been discovered 
[Brenk, PhD Thesis, 2003]52.  
QueTGT and ArcTGT crystal structures in complex with tRNA which became 
available in recent time, however, provide deeper insight into the molecular 
foundations of the base exchange reaction and substrate specificity. In particular the 
Z. mobilis TGT crystal structure in complex with a tRNA substrate unravelled the 
misinterpretation of previous data [Xie et al., 2003]4. Asp280 instead of the initially 
suggested Asp102 was identified as nucleophile of the base exchange reaction. 
Additionally, kinetic analysis revealed that the reaction pathway follows a ping-pong 
mechanism [Goodenough-Lashua & Garcia, 2003]53. Therefore, the assumed model 
of the base exchange mechanism required revision. However, the newly collected 
evidence has not been discussed in literature with respect to important mechanistic 
details.  
 
In the first part of this thesis structural and functional analysis attempt to integrate the 
current knowledge to a comprehensive picture concerning the structural basis of the 
base exchange reaction in TGTs. This is relevant as the binding pocket in the 
surrounding of the nucleophile Asp280 is intended to be addressed in structure-
based design approaches. 
Detailed analysis of the available structural and sequence data should provide a new 
functional model concerning the molecular basis of the reaction mechanism.  
TGTs from the three kingdoms of life exhibit pronounced differences in substrate 
specificity. In a mutant study the molecular basis for substrate promiscuity in 
QueTGT, discovered in the previous study, will be investigated by means of crystal 
structure and kinetic analysis. 
The occurrence of dimers in QueTGT crystal structures and the putative functional 
relevance of such dimers, indicated by the crystalline complexes with bound tRNA, 
will be assessed by means of structure and sequence analysis. 
Finally, the comparison of the available TGT crystal structures in an evolutionary 
context should give a more comprehensive understanding of this enzyme family.  
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In the second part of this thesis the consequences of the recently collected 
knowledge concerning the reaction pathway will be implemented in structure-based 
design approaches to develop more potent inhibitors. 
An appropriate binding assay has to be developed taking competitive and 
uncompetitive inhibition contributions into consideration. They are relevant in a ping-
pong reaction mechanism and were not considered in the previous assay. 
Additionally, the revalidation of relevant members of compound classes studied in 
previous investigations is required to adjust  structure – activity relationship.  
Based on a quinazolinone scaffold, developed in a previous study, new lead 
structures will be developed. This effort continues the successful collaboration with 
the group of Prof. Diederich (ETH Zürich) on the design and synthesis of potent 
inhibitors. 
A virtual screening hit should be evaluated in more detail to test the relevance of a 
surprising binding mode suggested by docking. Systematically, structural 
modifications of this hit should be developed and tested. For synthesis a cooperation 
has been initiated with the group of Prof. Link (University of Greifswald). 
A series of TGT binders has been discovered in plant extracts by the ligand fishing 
method developed in the group of Prof. Matusch (University of Marburg). These 
compounds should be characterized by means of kinetic and crystal structure 
analysis. 
 
In chapter 2 results from the structural and functional analysis will be presented. In 
chapter 3 necessary modifications of the assay, revalidated previous inhibitor series 
and results from structure-based design approaches will be presented. In chapter 4 
the results of this study will be summarized. The applied methods will be presented in 
chapter 5. 
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2. Structural and Functional Analysis 
2.1    QueTGT – ArcTGT: base exchange reaction 
 
Crystal structures of QueTGT and ArcTGT in complex with tRNA became available 
during this thesis [Xie et al., 2003; Ishitani et al., 2003]4, 48. The key impact of these 
structures was the discovery of a misinterpretation of previous data. Asp280, instead 
of Asp102, is the nucleophile of the base exchange reaction [Xie et al., 2003]4. 
Therefore, the model of the base exchange mechanism requires revision. However, 
no comprehensive interpretation is available. Analyses of TGT crystal structures and 
sequences provide a new functional model concerning the molecular basis of the 
reaction mechanism and the residues involved in this process. These results have 
already been published in Stengl et al. (2005)54. 
2.1.1 TGTs in the tree kingdoms of live 
 
Although tRNA – guanine transglycosylases (TGT) are present in all three kingdoms 
of life they accept deviating bases as substrates incorporated at different positions 
into tRNA (Fig 2.1). Nevertheless, their principal architecture and the underlying 
reaction mechanism are highly conserved among the three kingdoms [Stengl et al., 
2005]54.   
Structurally all TGTs adopt the highly populated triose-phosphate isomerase (TIM)-
type (βα)8-barrel fold with specific insertions involved in tRNA recognition and 
binding. These insertions are an N-terminal antiparallel β-sheet and a ‘zinc binding’ 
site close to the C-terminus (Fig. 2.1) [Romier et al., 1996; Romier et al., 1997; 
Ishitani et al., 2002]25, 47, 55. The overall shape of TGTs is sufficiently unique to form a 
homologous superfamily within the TIM-barrel fold (SCOP database (version 1.65)  
[Andreeva et al., 2004]56; CATH database (version 2.5.1) [Pearl et al., 2000]57). The 
TGT superfamily is subdivided into two groups, QueTGT and ArcTGT. QueTGT 
includes the eubacterial and the eukaryotic TGTs. They are both involved in the 
modification of tRNA in position 34 with queuine. Structurally they are very similar 
and share the additional insertion β7-α6. In contrast, the archaebacterial TGT is part 
of the archaeosine modification pathway in position 15 of tRNAs, thus it is referred to 
as ArcTGT. Apart from the deviating modification site also some remarkable 
structural differences can be noted. In ArcTGT three supplementary C-terminal 
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domains are present (C1, C2, C3 = PUA) and the insertion β7-α6 is missing [Stengl 
et al., 2005]54. 
 
 
 
 
 
Fig 2.1   ArcTGT/QueTGT secondary structures and substrate specificity 
 
Crystal structure analyses of ArcTGT and QueTGT in complex with tRNA substrates 
allowed to extract valuable information about substrate recognition [Xie et al., 2003; 
Ishitani et al., 2003]4, 48. At first glance, a direct comparison of substrate recognition 
by ArcTGT and QueTGT is rather difficult. The two guanine residues, 15 and 34, 
recognized and replaced by the two TGTs are located at completely different 
positions in the tRNA strand. As a consequence, the overall binding geometry of 
tRNA with respect to the catalytic domain is remarkably different (Fig. 2.2a). 
Nevertheless, the substrate binding pockets of both, QueTGT and ArcTGT, 
accommodate a trinucleotide sequence. It consists of the guanine nucleotide 
addressed by the respective enzyme as well as of the directly preceeding and the 
following nucleotide. Thereby, the QueTGT bound trinucleotide, the specificity 
regulating UGU-sequence, is present in a very similar conformation as the one bound 
to ArcTGT (Fig. 2.2b) [Stengl et al., 2005]54. To make these bases addressable by 
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TGTs, in both cases tRNAs have to undergo specific conformational changes (Fig. 
2.2c). In case of QueTGT the tRNA anticodon loop bends to the opposite direction 
compared to uncomplexed tRNA molecules. In contact with ArcTGT the D-arm of the 
tRNA protrudes in order to allow modification of the usually buried G15 residue. The 
tRNA then adopts an unusual conformation called λ-conformation stabilized by a new 
structural element called ‘DV’-helix (details are given in chapter 2.1.4.1). 
 
     a                                         b                                    c 
Fig. 2.2  a) ArcTGT/QueTGT global recognition of tRNA;  b) trinucleotide recognition of G34 
and G15;  c) conformational changes of tRNA bound to TGT  
 
All TGTs share a common mechanism indicated by the high degree of structural 
conservation in the surrounding of the central guanine residue (G15 or G34 
respectively) and the active site (Asp280). Most of the residues involved in QueTGT 
and ArcTGT catalysis are retained or at least conservatively replaced. The sequence 
alignment of Table 2.1 gives an impression of the degree of conservation. The 
following numbering refers to Z. mobilis TGT representative for QueTGTs (residuesQ) 
and P. horikoshii TGT representative for ArcTGTs (residuesA). The most important 
residues of QueTGT are Asp 280Q, the catalytic nucleophile, and the residues 
contributing to the recognition of the guanine-like skeleton of the substrates: 
Asp102Q, Asp156Q, Gln203Q and Gly230Q. With Asp249A, Asp95A, Asp130A, Gln169A 
and Gly196A they have identical counterparts in ArcTGTs.  
The TGT superfamily exhibits a pronounced difference in substrate specificity and 
promiscuity [Okada & Nishimura, 1979; Hoops et al., 1995; Shindo-Okada et al., 
1980, Bai et al., 2000, Watanabe et al., 1997] .30, 39, 58-60 . Although every TGT has a 
preferred substrate (Fig. 2.1) some TGTs show an extended reservoir of substrates.  
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While ArcTGT exclusively accepts preQ0, eubacterial QueTGT accepts preQ0 and 
preQ1, however with a significant preference for preQ1. Eukaryotic QueTGT, 
additionally to queuine also accepts preQ0 and preQ1 as substrates (Tab.2.2). This 
results from differences in the constitution of the specificity region in the binding 
pocket of the three TGTs (Tab. 2.1). The reason for these deviating specificities will 
be discussed in detail in chapter 2.2. It is important to understand these differences 
in order to be able to develop selective inhibitors that may address the eubacterial 
Shigella TGT but not the eukaryotic human TGT.  
 
Tab. 2.1  Sequence alignment of important QueTGT and ArcTGT residues from 
  Z. mobilis, E. coli, Homo sapiens, Saccharomyces cervisiae,  
  Pyrococcus horikoshii and Archaeoglobus fulgidus 
 
Species 
 
Guanine binding site 
 
Zinc binding site 
 
 
 102 104 106 156 203 230 231 260 318 320 323 349  
Zymomonas D G Y D Q G L M C C C H 
Escherichia D G F D Q G L M C C C H 
QueTGT 
(eub.) 
Homo D G F D Q G L M C C C H 
Saccharomyc. D G F D Q G L M C C C H 
QueTGT 
(euk.) 
Pyrococcus D S F D Q G V F C C C H 
Archaeoglobus D S F D Q G V F C C C H 
ArcTGT 
  
Ribose 15/34 binding site 
 
Substrate specificity 
 
 45 68 70 107 258 261 280 158 232 233 234 235  
Zymomonas V L N Q Y G D C A V G E 
Escherichia V L N Q Y G D C A V G E 
QueTGT 
(eub.) 
Homo V L N Q Y G D V S G G E 
Saccharomyc. V L N Q Y G D V S G G E 
QueTGT 
(euk.) 
Pyrococcus V I N Q H G D P V P L M 
Archaeoglobus 
 
V I N Q H G D P V P L M 
ArcTGT 
 
Tab. 2.2  Substrate specificity and promiscuity in TGTs 
 
Enzyme 
 
Guanine[a] 
 
preQ0[a] 
 
preQ1[a] 
 
Queuine[a] 
Archaebacterial TGT  + [b] + - - 
Eubacterial TGT + + + - 
Eukaryotic TGT + + + + 
 
[a]    for chemical formulae see Figure 2.1 
[b]      +: is accepted as substrate    – : is not accepted 
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2.1.2  Eubacterial QueTGT 
 
2.1.2.1   Introduction into the tRNA – QueTGT complex  
 
As in other enzymes with this fold the active site of TGT is located in the C-terminal 
centre of the TIM-barrel structure (Fig. 2.3a). Upon binding of tRNA multiple 
interactions are formed with residues from the ‘zinc binding’ site [Xie et al., 2003]4. 
The tRNA trinucleotide sequence, U33G34U35, which is strictly conserved in all          
Q-specific tRNAs is specifically recognized (Fig. 2.3b). U33 and U35 are forming polar 
interactions via functional groups of the uracil base. As U33 is present in all tRNAs, in 
particular the amino acids interacting with U35 are highly conserved to guarantee 
specific recognition. In contrast to the flat binding region of U33, U35 is located in a 
buried subpocket [Xie et al., 2003]4. 
 
 
Fig. 2.3  Substrate recognition by TGT:  a) anticodon recognition;  b) UGU recognition 
sequence;  c) TGT⋅preQ1;  d) nucleophilic attack by Asp280;  e) hydrophobic subpocket 
accepting  the ribose(34) 2’OH-group 
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The residues involved in G34 / preQ1 binding can be subdivided into two groups. The 
residues contributing to the recognition of the guanine-like skeleton of QueTGT 
substrates are Asp102, Ser103, Asp156, Gln203 and Gly230 and Leu231. The 
residues Tyr106 and Met260 perform a sandwich-type hydrophobic stacking with the 
base of the substrate (Fig. 2.3c). Asp280 is the nucleophile of the base exchange 
reaction. It is well stabilized by H-bonds formed with Tyr258 and Gly261 (Fig. 2.3d). 
The nucleophile is located adjacent to a small hydrophobic subpocket formed by 
Val45 and Leu68 which is important for the stabilization of an intermediate 
conformation during the base exchange reaction (Fig. 2.3e).   
2.1.2.2 New model for the base exchange mechanism in QueTGT 
 
The base exchange catalyzed by TGT follows a ping-pong reaction mechanism   
resulting in the irreversible incorporation of preQ1 [Goodenough-Lashua & Garcia, 
2003]53. In a first step, tRNA binds to TGT and G34 is cleaved off the tRNA. In the 
intermediate reaction state tRNA ribose 34 is covalently bound to TGT. In a second, 
reverse reaction step, preQ1 replaces G34 in the active site and is incorporated into 
the tRNA (Fig. 2.4).  
The comparison of available crystal structures of Z. mobilis TGT in complex with 
tRNA substrate, preQ1 and a guanine-type inhibitor allowed to deduce single steps of 
the catalytic reaction. They enabled to develop a detailed, new functional model for 
the course of the base exchange reaction. Previous assumptions, discussing Asp102 
as the catalytic nucleophile are corrected and functional roles are assigned for 
residues that were previously unconsidered [Stengl et al., 2005]54. 
Following the reaction pathway TGT recognizes the tRNA substrate via the           
‘zinc binding’ site and G34 is specifically recognized in the active site by Asp102, 
Asp156, Gln203 and Gly230 (Fig. 2.4a). A polar contact towards the peptide NH 
group of Ala 232 is mediated via a water molecule (W1). G34 is buried in the active 
site via hydrophobic stacking interactions with Met260 and Tyr106.  
Asp280, instead of the previously assumed Asp102, located adjacent to the ribose 
ring 34, acts as catalytic nucleophile. This residue is well kept in position by Tyr258 
and Gly261. Tyr258 itself is arrested and kept in position through several 
hydrophobic interactions (Met43, Leu100, Met153, Phe199, Met260, Met278). 
Asp280, Gly261 and Tyr258 as well as its neighbouring hydrophobic residues are 
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conserved in eubacterial and eukaryotic TGTs emphasizing their particular role to 
guarantee accurate adjustment of the nucleophile [Xie et al., 2003]4.  
The Asp280 carboxylic oxygen attacks the C1 carbon of ribose 34 in an SN2 reaction 
and pulls the ribose ring towards Asp280 [Xie et al., 2003]4. The ribose performs a 
40° rotational movement anchored by adjacent ribose phosphate groups P34 and P35 
(Fig. 2.3e). The rotation causing the rupture of the covalent bond between C1 and 
G34 is controlled by Asp102 with its carboxy group H-bonded to the 2’OH-group of the 
rotating ribose. The 2’OH group is finally released towards a hydrophobic cleft 
formed by Val45 and Leu68 [Stengl et al., 2005]54. In this orientation the polar group 
cannot form any H-bond to the enzyme and experiences only weak and rather 
unfavourable interactions (Fig. 2.3e). Supposedly, the unfavourable intermediate 
occupancy of the hydrophobic pocket through the 2’OH group serves as a kind of 
tense spring state and stores energy for the conformational movements required for 
the reverse reaction step during the ping-pong reaction pathway. Thus, this geometry 
guarantees a sterically favoured but electrostatically unfavoured intermediate state 
orientation.  
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Guanine is reprotonated in the binding pocket after cleavage from tRNA, either in 
position 7 or in position 9. Reprotonation in position 7 could be supported by water 
molecule W1, which is then forming a hydroxy-anion (Fig. 2.4b). The fact that the 
methyl group of Ala232 in the amide-exposing conformation reduces the available 
space of the binding pocket and perfectly shields this water molecule, speaks in 
favour of this position [Stengl et al., 2005]54. Alternatively, reprotonation in position 9 
is possible as well, then supported by Asp102 serving as general acid. Another water 
molecule, W2, bridging Asp102 with Gln107 at the upper rim of the binding pocket 
would be suited to shuffle a proton into the active site [Xie et al., 2003]4. 
After reprotonation guanine and W1/OH- leave the binding pocket and are replaced 
by preQ1. To be able to accommodate preQ1, the Leu231-Ala232 peptide bond 
supposedly undergoes a flip which is controlled by Glu235 acting as acid/base 
system (Fig. 2.4b-c) [Stengl et al., 2005]54. PreQ1 is bound in a similar fashion as 
guanine except of the aminomethyl group that directly interacts with the flipped 
Leu231 carbonyl oxygen. For activation preQ1 is deprotonated in position 9 by 
Asp102 then acting as a general base. The proton is shuffled from the active site 
supposedly mediated by water molecule W2. In a reverse SN2 reaction step the now 
activated preQ1 nucleophilically attacks the C1 carbon of ribose 34. Upon product 
formation the covalent bond towards Asp280 is cleaved and the ribose 34 2’OH 
group is pushed out of its unfavourable environment, stabilized via H-bond formation 
with Asp102 (Fig. 2.4c-d). In this process the Asp102 carboxy group rotates and 
expels W2 from the active site followed by the final release of the preQ1-modified 
tRNA from TGT. Accordingly, Asp102 in addition to its function as general acid/base 
imposes a strong directional driving force thus controlling the structural changes 
upon product formation. Finally, the modified tRNA is released from the binding 
pocket and TGT is ready for a new base exchange cycle. 
 
2.1.3  Eukaryotic QueTGT 
 
Eukaryotic QueTGTs show a high sequence identity compared to eubacterial TGTs; 
e.g. 43%  between H. sapiens and Z. mobilis [Deshpande & Katze, 2001]61. 
Concerning the overall sequence composition they differ from eubacterial QueTGTs 
by a conserved 18 amino acid C-terminal extension. With respect to the active site, 
all residues involved in catalysis are highly conserved (Tab. 2.1). Thus, it can be 
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assumed that the overall tertiary structure as well as the course of the base 
exchange reaction is identical to eubacterial QueTGTs. 
Nevertheless, eukaryotic QueTGT exhibits an extended substrate specificity (Tab. 
2.2). The preferred substrate is the spatially expanded base queuine, in addition to 
preQ0 and preQ1. However, Eukaryota are not capable of queuine synthesis and 
acquire this base by specific uptake. Therefore, the two Q-precursors should not be 
present in eukaryotic cells. The further extended substrate specificity towards 
queuine results from a spatial extension of the binding pocket. A homology model 
based on the C. elegans sequence suggested that the replacement of Val233 from 
eubacterial TGT to Gly233 in eukaryotic TGT significantly enlarges the binding 
pocket (Tab. 2.1). This allows the binding of extended preQ1-type substrates such as 
queuine [Romier et al., 1997]55.  
 
a                                                                   b  
 
Fig. 2.5  a)  Specificity pocket in eubacterial Z. mobilis QueTGT with bound preQ1;                   
b)  homology model of human eukaryotic QueTGT bound to queuine; Q was modelled into 
the binding pocket with MOLOC (Eubacteria and Eukaryota  specific residues in orange) 
 
A more recent homology model of the human TGT based on the structure of Z. 
mobilis TGT was produced using MODELLER with the help of Andreas Evers (group 
of Prof. Klebe, University of Marburg). It suggests a set of residues involved in the 
modification of the QueTGT binding pocket. Presumably, a Pro160Ser and 
Tyr161Ser exchange facilitate the entry of  the queuine pentenyl moiety into the 
binding pocket, due to an extended and more flexible entry site. The exchange of 
Val233Gly extends the volume of the binding pocket allowing the accommodation of 
the pentenyl moiety. Finally, the Cys158Val / Ala232Ser modifications might fully 
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adapt the binding pocket for queuine recognition, indicated by minimization of Q into 
the modelled binding pocket of human TGT (Fig. 2.5 and Tab. 2.1).  
In literature for the eukaryotic QueTGT hetero complex formation with a 60kDa 
protein is described. However, the nature of this complex remains obscure. The 
protein belongs to the family of ubiquitin-specific processing proteases (USB). The 
expression rate of this protein is elevated in leukemic and colon cancer cells. 
Whether there is any regulatory relationship QueTGT is involved in, still has to be 
elucidated [Ishiwata, 2004]. 
 
2.1.4 Archaebacterial ArcTGT 
2.1.4.1 Introduction into the tRNA – ArcTGT complex 
 
The catalytic domains of archaebacterial ArcTGTs share only about 20 – 25 % 
sequence identity with eubacterial QueTGTs [Romier et al., 1997]55. Nevertheless, 
the tertiary structure is highly conserved (Fig. 2.1). In addition to the catalytic domain, 
ArcTGT is characterized by three supplementary C-terminal domains required to 
address the deviating tRNA modification site (Fig. 2.1 and 2.6a) [Ishitani et al., 
2002]47. In order to modify the buried G15 residue the tRNA conformation has to 
undergo an enormous rearrangement [Ishitani et al., 2003]48. Crystal structure 
analysis of the archaebacterial TGT from Pyrococcus horikoshii in complex with 
tRNAVal showed that this rearrangement produces the so-called λ-shaped tRNA. It 
exhibits a conformation which has never been observed before. In canonical             
L-shaped tRNAs G15 is positioned in the D-loop. As it is involved in the formation of 
tertiary stacking interactions with the bases C48 and A59, it is buried within the tRNA 
core. In the λ-shaped conformation the usually rigid D-arm protrudes and the D-loop 
becomes accessible. The conformation is stabilized via a specific helical element that 
is not found in canonical L-shaped tRNA. This so-called ‘DV’-helix is formed by bases 
from the variable loop and bases normally involved in formation of the D-stem (Fig. 
2.6b). As a consequence of this spatial rearrangement, the former position of G15 is 
now occupied by G23 at the end of the ‘DV’-helix. The observation of this tRNA 
conformation gave reason to postulate an additional function of the variable loop with 
respect to tRNA maturation.  
In order to enable these conformational changes in tRNA the supplementary           
C-terminal domains are required. Within the C2-domain the β18-β19 hairpin is 
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interacting with tRNA core bases after ‘DV’-helix formation and supposedly crucial for 
the stabilization of the λ- conformation. The C-terminal domain C3 represents a PUA 
(pseudouridine synthase and archaeosine TGT) domain, widespread among RNA 
binding proteins (Fig. 2.6a) [Ferré-D’Amaré, 2003]62. Nevertheless, the PUA domain 
seems not to be fully relevant for tRNA recognition. An ArcTGT mutant with a 
deletion of the PUA domains maintains reduced catalytic activity [Sabina & Söll, 
2006]63. 
 
a                                                                                    b 
Fig. 2.6  a)  tRNA stabilization by ArcTGT in λ- conformation requires dimer formation;        
b) λ- tRNA is stabilized via ‘DV’-helix formation 
 
Catalytic functionality of archaebacterial TGTs requires dimer formation, resulting in  
a 2:2 complex of ArcTGT with tRNA (Fig. 2.6a). Both TGT subunits forming the dimer 
are involved in the recognition of an attached tRNA substrate molecule. While one 
TGT subunit recognizes the tRNA and stabilizes the λ- shape via its three C-terminal 
domains, the other subunit catalyzes the base exchange after accommodation of G15 
in the active site of its catalytic domain. 
 
 2.1.4.2 New model for the base exchange mechanism in ArcTGT 
 
The catalyzed base exchange reaction in ArcTGT slightly differs form QueTGT. Here, 
preQ0 is incorporated into tRNA in position 15. Similar to QueTGT also in ArcTGT a 
trinucleotide sequence is recognized in the surrounding of the active site (Fig. 2.2b). 
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However, G15 addressed by ArcTGTs is not embedded within a conserved sequence 
motif. In the crystal structure of P. horikoshii TGT·tRNAVal complex, binding of A14 
and U16, both flanking G15, is mainly achieved through hydrophobic interactions 
between the bases and amino acid residues lining the substrate binding pocket. This 
feature obviously permits ArcTGTs a pronounced promiscuity in base recognition. In 
this respect it should be noted that not in all archaebacterial tRNAs, containing a 
guanine at position 15, this residue is modified. The structural prerequisite for G15 
modification in archaebacterial tRNAs is still unknown but is supposedly associated 
with “DV”-helix formation ability [Ishitani et al., 2003]48. 
The structure of the active site and the residues responsible for the base exchange 
reaction in ArcTGT are largely conserved compared to QueTGT (Tab. 2.1). The 
detailed analysis of ArcTGT and QueTGT crystal structures revealed many 
similarities but also some differences in the observed substrate binding modes 
[Stengl et al., 2005]54. Following the numbering of P. horikoshii TGT (residueA) 
Asp95A, Ser96A, Asp130A, Gln169A and Gly196A contribute to the recognition of the 
guanine-type skeleton of preQ0 (Fig. 2.7a). Phe229A, corresponding to Met260Q in 
QueTGT (residueQ), hydrophobically stacks with the base of the substrate. Phe99A 
corresponding to Tyr106Q cannot perform a similar stacking onto the substrate base 
in P. horikoshii TGT. This is caused by the peptide backbone of Phe99A which is 
slightly shifted off from the recognition base. This difference in recognition results 
from the most remarkable difference between ArcTGT and QueTGT guanine binding 
pockets, namely a Gly105Q / Ser98A exchange (Tab. 2.1). It causes a deviating 
stabilization pattern of specific binding pocket residues. While in Z. mobilis TGT 
Ser103Q is H-bonded to Asp156Q (Fig. 2.3c), in P. horikoshii TGT the Ser96A side 
chain is H-bonded to Ser98A within the same loop resulting in a deviating loop 
geometry and subsequently in an altered substrate recognition pattern (Fig. 2.7a). 
Due to the fact that no crystal structure of a covalent intermediate with an ArcTGT is 
available, residues likely to be important for catalysis can only be suggested taking 
reference to QueTGT [Stengl et al., 2005]54. Asp249A is in an equivalent position to 
Asp280Q and supposedly performs the nucleophilic attack onto the ribose carbon. An 
aspartic acid in this position is conserved in the TGTs of all kingdoms (Tab 2.1). 
Similar to QueTGT, in the available ArcTGT structures the side chain position of 
Asp249 is stabilized via H-bonds with two adjacent residues (Fig. 2.7b): On one side 
to His227A, a residue only conserved in archaebacteria, on the other side via the 
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backbone NH of Gly230A. In QueTGT the conserved Tyr258Q occupies the 
equivalent position of His227A. Gly230A is structurally conserved in all three 
kingdoms and corresponds to Gly261Q. While in Z. mobilis TGT Asp280Q is firmly 
clamped by Tyr258Q and Gly261Q (Fig. 2.3d), in P. horikoshii TGT the Asp249A side 
chain distances of the carboxy group towards the two residues His227A and Gly230A 
fall into a range of 2.5 - 3.5Å depending on the presence of the bound tRNA 
substrate.  
The tRNA-ribose 15 moiety is able to place its 2’OH into a hydrophobic pocket of  
ArcTGTs in a similar way as observed for tRNA-ribose 34 when bound to QueTGT. 
In ArcTGTs, this pocket is composed by the conserved residues Val39A and Ile61A, 
corresponding to Val45Q and Leu68Q in Z. mobilis TGT (Fig. 2.7b and 2.3d).  
The binding mode of Asp95A in ArcTGT, a further residue conserved across all 
kingdoms, is equivalent to Asp102Q in QueTGT, but adopts a slightly different 
geometry. It does not form an H-bond to the 2’OH group in the complex with bound 
tRNA.  
 
a                                                                               b                        
 
Fig. 2.7 a) ArcTGT⋅preQ0 binding site;  b) residues assumed to be involved in the base 
exchange mechanism 
    
Summarizing the observations all features necessary to perform the base exchange 
reaction are similarly exhibited in both, QueTGT and ArcTGT. Hence, an 
evolutionarily highly conserved mechanism must be assumed originating from an 
ancient ancestor already existing before the separation of the three kingdoms (see 
chapter 2.4). 
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2.2    QueTGT – ArcTGT: substrate specificity 
 
2.2.1 QueTGT – ArcTGT: regulation of substrate specificity  
 
Eubacterial QueTGT exhibits to some degree substrate promiscuity (Tab. 2.2). In 
addition to the natural substrate preQ1 it also accepts its biosynthetic precursor 
preQ0. Z. mobilis TGT crystal structures in complex with preQ0 and preQ1 clearly 
demonstrate the capability of both bases to bind to this TGT [Brenk et al., 2003]64. 
Substrate promiscuity results from a functional and sterical adaptation of the binding 
pocket caused by the reorientation of the Leu231/Ala232 peptide bond (Fig. 2.8).  
 
 
a                                                                          b 
Fig. 2.8  a) Z. mobilis TGT binding to preQ1;  b) Z. mobilis TGT binding to preQ0 
 
From the analyses of several Z. mobilis TGT crystal structures in complex with 
different substrates a structural explanation for the observed extended substrate 
specificity can be provided [Stengl et al., 2005]54. During the base exchange reaction 
replacement of guanine by preQ1 requires an adjustment of the binding pocket 
geometry (chapter 2.1.2.2 and Fig. 2.4). To achieve this, the Leu231/Ala232 peptide 
bond undergoes a flipping movement. Binding of guanine(34)-tRNA results in the W1 
mediated contact to the amide group of Ala232. As the available tRNA-bound TGT 
crystal structure has no sufficient resolution this structural features has been 
extracted from the pyridazindione-type inhibitor (H6) bound crystal structure (see 
chapter 3.2.1 and 3.2.2) [Brenk et al., 2003]2. This inhibitor includes the key structural 
elements of guanine. Upon binding of preQ1 the properties of the binding pocket are 
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altered. Proper recognition of the aminomethyl group of preQ1 requires the NH donor 
functionality to be exchanged by the CO acceptor functionality via rearrangement of 
the Leu231/Ala232 peptide bond switch. Furthermore, the new orientation of the 
methyl group of Ala232 extends the size of the binding pocket allowing to 
accommodate the kinked aminomethyl group of preQ1.  
 
a                                             b                                       c 
Fig. 2.9  a) Leu231/Ala232 peptide switch, allowing subsequent binding of guanine and 
preQ1 is controlled by Glu235;  b) water molecules in uncomplexed TGT structures at pH 5.5 
(blue) and pH 8.5 (grey) indicate two spatially deviating interaction sites favourable to 
accompdate polar groups of preQ0 and preQ1; c) substrate recognition in ArcTGT⋅guanine 
and ArcTGT⋅preQ0   
 
The peptide switch is stabilized from the side opponent to the binding pocket by the 
side chain carboxy group of Glu235, which is strictly conserved in all QueTGTs 
[Stengl et al,. 2005]54. Depending on the protonation state of this carboxy group, 
Glu235 either donates an H-bond towards the backwards exposed carbonyl group or 
accepts an H-bond from to the amide group of the reoriented peptide bond thus 
serving as a general acid/base mediating the peptide switch (Fig. 2.9a). As expected 
for such a general acid/base, the peptide switch gated by Glu235, can already be 
triggered in uncomplexed QueTGT depending on the applied pH conditions (Fig. 
2.9b). In Z. mobilis TGT, crystallized at pH 5.5, Glu235 is protonated and hydrogen-
bonds the CO group of the peptide bond. In consequence, the NH group is exposed 
towards the binding pocket. At pH 8.5, Glu235 experiences deprotonation which 
triggers the switch of the peptide bond now binding the Glu235 carboxylate via its 
amide group. Accordingly, the CO group is exposed towards the binding pocket. 
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Associated with the peptide flip in the uncomplexed crystal structures two water 
molecules (W1 and W1’) are bound to either the carbonyl- or the amide-group 
exposed to the binding pocket. They are found at two deviating, clearly distinct 
positions and indicate within a narrow spatial range the favourable, putative binding 
sites of preQ1, preQ0 or the W1 assisted binding mode of the pyridazindione-inhibitor 
H6 (Fig. 2.9b). From these findings it can be concluded that the binding pocket 
conformation suited for guanine binding additionally allows the binding or preQ0 by 
replacing W1, thus explaining the extended substrate specificity of QueTGT. 
In contrast to QueTGT, ArcTGT features an exclusive substrate specificity towards 
guanine and preQ0, (Tab. 2.2). This results from a significantly reduced adaptability 
of the binding pocket [Brenk et al., 2003]64. The peptide bond corresponding to 
Leu231Q/Ala232Q which performs the peptide flip in QueTGTs is represented by 
Val197A/Val198A in ArcTGT and presents an amide donor group towards the 
substrate (Tab. 2.1 and Fig. 2.9c). At its back side, this peptide bond lacks a group 
gating a peptide switch, as observed in QueTGTs, due to an entirely different 
stabilization geometry. In P. horikoshii TGT, the two invariant backbone NH-bonds of 
Leu200A and Leu201A, which will not support a peptide switch as mediated by 
Glu235Q, are present in the second sphere of amino acids around the active site (Fig. 
2.9c). Additionally, Pro199A increases the rigidity of this loop geometry. For ArcTGTs 
the peptide switching functionality is not required. The interstitial water molecule 
which in the binary P. horikoshii TGT·guanine complex bridges guanine with the 
Val197A/Val198A peptidic NH group, can directly be replaced by the acceptor nitrile 
group of preQ0. This binding mode is similar to that of preQ0 in QueTGT (Fig. 2.9b/c).  
Apart from the fact that Archaebacteria are not capable to synthesize preQ1, 
incorporation of this base into tRNA by ArcTGT is also not observed under 
experimental conditions. From the analysis of the ArcTGT crystal structures two 
explanations can be provided. Firstly, with the invariant NH donor group no 
functionality suited for binding is exposed to the binding pocket. Secondly, the 
hydrophobic side chain of Val198A is limiting the available space of the binding 
pocket and disables the binding of the kinked preQ1 amino-methyl group. This 
provides a conclusive explanation why ArcTGT exhibits no substrate promiscuity 
similarly to QueTGT.  
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2.2.2 QueTGT substrate selectivity – TGT(E235Q) mutant 
 
2.2.2.1 Introduction 
 
The eubacterial QueTGT exhibits the above-described substrate promiscuity. 
QueTGT accepts, additionally to the natural substrate preQ1, also its biosynthetic 
precursor preQ0. Promiscuity results from the Leu231/Ala232 peptide switch gated 
from the opponent side of the binding pocket by the general acid/base Glu235 (see 
chapter 2.2.1). PreQ0 and preQ1 are simultaneously present in the cell. Therefore, 
the eubacterial QueTGT has to distinguish between the two substrates to guarantee 
the selective incorporation of preQ1 into tRNA. In E. coli TGT Km values for preQ1 and 
preQ0 have been determined [Hoops et al., 1995]39. The Km of preQ1 (0.4 µM) is six 
fold lower than that of preQ0 (2.4 µM). For Z. mobilis TGT no kinetic data have yet 
been determined.  
 
       a                                                                     b 
Fig. 2.10  a)  Z. mobilis TGT binding to H6; Glu235 is H-bonded to the peptide switch;         
b)  Z. mobilis TGT binding to preQ0; Glu235 stacks on top of the hydrophobic face of the 
peptide switch (for Val233 only the backbone is shown) 
 
The preQ0 and preQ1 bound crystal structures of Z. mobilis TGT provide no clear 
explanation for the selective incorporation of preQ1 [Brenk et al., 2003]64. For binding 
of preQ1 charge assistance might be relevant. The positively charged amino-methyl 
group of preQ1, binding to the carbonyl group of the Leu231/Ala232 peptide switch, 
could compensate the negative charge of Glu235. In the latter TGT⋅preQ1 complex, 
the carbonic acid functional group of Glu235 is in close contact to the amide group of 
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Ala232 (2.8 Å) suggesting this functional group to be deprotonated (Fig. 2.9a). In the 
crystal structure of TGT⋅preQ0 the acceptor nitrile group of preQ0 is H-bonded to the 
amide group of Ala232. However, an unexpected and unique orientation of the 
terminal acid functional group of Glu235 is observed. The Glu235 side chain stacks 
with its hydrophobic surface on top of the Leu231/Ala232 peptide bond. Additionally, 
the side chain shift provokes the Glu235/Gly236 peptide bond to flip [Brenk et al., 
2003]64. This new geometry is stabilized by an H-bond to the amide of Val233 (Fig. 
2.10b). The short distance of 2.8 Å for this H-bond suggests deprotonation and 
charged state of the carboxylate group of the Glu235 side chain in this orientation. In 
all other available TGT crystal structures with the amide group of Ala232 exposed to 
the binding pocket, the side chain of Glu235 is binding to the carbonyl group of 
Leu231 and it occurs most presumably in its protonated state. This is suggested by 
the interaction geometry observed in the TGT⋅H6 complex [Brenk et al., 2003]2. The 
Glu235 side chain is in short contact with the carbonyl group of Leu231 (2.8 Å) and 
forms a longer interaction (3.2 Å) with the amide group of Val233 (Fig. 2.10a). This 
binding mode supports the assumption that the carbonic acid functionality is present 
in its protonated state. 
Due to the missing kinetic data for Z. mobilis TGT the influence of these structural 
modifications on the binding of preQ0 and preQ1 remains unresolved. Therefore, the 
kinetic parameters for both substrates were determined to estimate the influence of 
the observed binding pocket conformations on selectivity in this species. Additionally, 
a TGT(E235Q) mutated enzyme was constructed and crystallized in complex with 
preQ0 and preQ1. As the terminal amide functionality of Gln235 will be permanently 
present in a protonated state it should stabilize and firmly fix the peptide switch  by 
forming a hydrogen bond to the carbonyl group of Leu231. Thus, it should arrest the 
peptide switch it the amide-exposing conformation, independent of applied pH 
conditions or substrates. Selectivity is expected to be modulated in favour of preQ0 
binding. 
2.2.2.2 Results 
 
The E235Q mutated Z. mobilis TGT was constructed by site-directed mutagenesis. 
Details for the construction are given in chapter 5.2.4. The purification of 
TGT(E235Q) followed the standard protocol for wild type TGT (chapter 5.2.5). The 
mutated TGT(E235Q) enzyme crystallized under similar conditions and in the same 
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space group as the wild type. For TGT(w.t.) structures of crystals grown at pH 5.5 
and 8.5 are available. Therefore, crystallization attempts were performed for 
TGT(E235) at different pH conditions as well (for conditions see chapter 5.5.1). 
Crystals of the uncomplexed TGT(E235Q), suited for X-ray analysis, grew at two     
pH values (pH 6 and pH 8.5). In contrast to TGT(w.t.) crystals at pH 5.5 could not be 
obtained. At pH 8.5 the crystal structure of uncomplexed TGT(E235Q) was 
determined to a maximum resolution of 1.55Å. The structure of crystals grown at pH 
6 was resolved to a maximum resolution of 1.57Å. Crystallographic data are given in 
Table 6.2.1. Details of data collection and structure solution are given in chapter 
5.5.2 and 5.5.3. In both crystal structures the residues in the vicinity of the active site, 
including the mutated Gln235, are well defined and adopt virtually identical 
orientations. The amide group of Ala232 is exposed to the binding pocket. The 
terminal amide group of Gln235 stacks with its hydrophobic surface on top of the 
Leu231/Ala232 peptide bond. The Glu235 side chain is H-bonded to the amide 
function of Val233 and the carbonyl function of Gly230. A detailed discussion of the 
interaction pattern, particularly in comparison with other structures, follows in the next 
chapter. To investigate the binding modes of preQ0 and preQ1, co-crystallisation 
experiments of TGT(E235Q) with both bases were performed at pH 6 (for conditions 
see chapter 5.5.1). Applying lower pH values in cocrystallization attempts with both 
bases was already successful for the wild type enzyme [Brenk et al., 2003]. At this 
pH, Asp102 rotates into the binding pocket and forms a double hydrogen bond with 
the substrate. Only preQ0 could be successfully cocrystallized with TGT(E235Q) 
resulting in a crystal structure with a maximum resolution of 1.7 Å. PreQ0 is well 
defined in the binding pocket. The crystal structure of the respective cocrystallization 
experiment of TGT(E235Q) with preQ1 was refined to a maximum resolution of 1.6 Å. 
Although all binding pocket residues are well defined, no electron density of a bound 
ligand could be identified. The observation of a split conformation for Asp102, 
resulting from the rotation of the side chain into the binding pocket indicates, 
however, the limited ability of preQ1 binding. The Asp102 rotation is only observed 
upon ligand binding and has been described in similar fashion for inhibitor-bound 
crystal structures [Brenk et al., 2004]1. Supposedly some parts of the crystal have 
been populated by bound preQ1, however, the population is not sufficient to assign a 
distinct binding geometry.  
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Kinetic parameters for the wild type and the mutated TGT(E235Q) have been 
determined with respect to preQ0, preQ1, guanine and tRNA. For the latter two 
substrates the determination is based on the monitoring of tritium labelled [8-3H]-
guanine which is incorporated in tRNA at position 34 via TGT catalysis. After labelling 
tRNA is precipitated and monitored via liquid scintillation counting. The applied 
procedure is described in chapter 5.3.1/5.3.2 and has recently been published by us 
in Meyer et al. (2006)65. For preQ0 and preQ1 this method can not be applied. 
Therefore, an appropriate enzyme kinetic assay had to be developed. In this assay 
[8-3H]-guanine-labelled tRNATyr was previously produced and then used as substrate 
for TGT to monitor the base exchange against preQ0 or preQ1. The decreasing level 
of labelled tRNA can be monitored and from these data kinetic parameters can be 
derived. Details about the procedure and the production of labelled tRNA are given in 
chapter 5.3.2. 
In Tab. 2.3 the kinetic data for Z. mobilis TGT with respect to the four substrates is 
given. TGT(E235Q) as well as the wild type enzyme incorporate preQ0 and preQ1 
into tRNA. For the wild type enzyme the main difference between the two substrates 
is the turn-over rate. Values for kcat  differ by a factor of 10. For TGT(E235Q) a 45 fold 
decrease in Km for preQ1 has been determined with respect to the wild type. kcat 
values, however, remain virtually identical to those of the wild type. 
 
Tab. 2.3  Kinetic paramteters for TGT(w.t.) and TGT(E235Q) 
___________________________________________________________________ 
 
___________________________________________________________________ 
TGT (w.t.) tRNATyr [3H]-guanine preQ1 preQ0 
 
Km [µM] 
 
0.9 ± 0.2 
 
1.2 ± 0.2 
 
0.7 ± 0.2 
 
0.9 ± 0.2 
kcat [s-1] 2.7⋅10-2 2.8⋅10-2 5.1⋅10-2 0.6⋅10-2 
kcat/Km [µM-1s-1] 3.0⋅10-2 2.3⋅10-2 7.3⋅10-2 0.6⋅10-2 
TGT (E235Q) tRNATyr [3H]-guanine preQ1 preQ0 
 
Km [µM] 
 
1.0 ± 0.1 
 
3.3 ± 0.3 
 
32 ± 7 
 
< 0.5  
kcat [s-1] 3.5⋅10-2 3.8⋅10-2 5.0⋅10-2 0.3⋅10-2 
kcat/Km [µM-1s-1] 3.5⋅10-2 1.2⋅10-2 0.2⋅10-2 > 0.5⋅10-2 
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2.2.2.3 Discussion of the kinetic data 
 
The Km values for preQ0 and preQ1 show no significant difference (Tab. 2.3). Within 
the error  bars preQ0 (Km = 0.9 µM) binds equally well as the natural substrate preQ1 
(Km = 0.7 µM). However, a significant difference results for the speed of their 
incorporation into tRNA. PreQ1 is incorporated almost ten times faster than preQ0. 
Obviously Z. mobilis TGT achieves substrate selectivity not via binding affinity but via 
the turn-over rate. The Km of guanine (1.2 µM) is slightly reduced compared to that of 
preQ1 and also kcat is only half the value observed for preQ1. However, the latter 
value refers to the exchange of guanine by tritium-labelled guanine, which is 
reversible. As the incorporation of preQ1 into tRNA is reported to be irreversible, the 
backwards base exchange reaction can be neglected for this case [Okada et al., 
1979]31.  
 
 
Tab. 2.4  Comparison of natural substrates and quinazolinone-based inhibitors 
___________________________________________________________________ 
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Results from inhibition experiments of  quinazolinone-based inhibitors to Z. mobilis 
TGT support the assumption of an approximately two-fold affinity difference for 
guanine and preQ1 (Tab. 2.4). In the crystal structures of TGT with 6-amino-
quinazolinone (Q1) the binding pocket conformation is similar to that in the complex 
with preQ1 [Brenk et al., 2004]1. TGT bound to quinazolinone (Q2), however, exhibits 
a binding pocket similar to the one expected for guanine [Meyer et al., 2004]66. For 
Q1 (Kiu = 0.6 µM) and Q2  (Kiu = 1.7 µM ) the binding affinity differs by a factor of 
three [Meyer et al., 2006]65. For details concerning crystal structures and affinity data 
see chapters 3.2.1 and 3.2.3.  
The similar Km values for preQ0 and preQ1 in Z. mobilis TGT indicate virtually 
identical energy contents for the two observed binding pocket conformations. For E. 
coli TGT a six-fold difference in Km values for preQ1 (0.4µM) and preQ0 (2.4µM) was 
reported [Hoops et al., 1995]39. No clear explanation for the affinity differences 
between both species could be identified. The kinetic data were determined using a 
method which is comparable to this study.  
In the TGT(E235Q) mutated enzyme Km for preQ0 is virtually identical to that of the 
wild type (0.9 µM vs. < 0.5 µM). Due to the limited accuracy of the assay this value 
could not be determined more precisely. In contrast to preQ0, the Km of preQ1 
significantly increases from 0.7 to 32 µM, whereas the values for tRNATyr and 
guanine are not significantly altered. Even though Km is strongly affected, the kcat 
values for preQ0 and preQ1 remain virtually identical. Still preQ1 is significantly faster 
incorporated than preQ0. Both rates differ by approximately a factor of 20. This 
suggests that substrate recognition is obviously gated by Glu235. However, once 
accommodated in the active site, the reaction rate of the base exchange is 
determined by other factors. Regarding kcat/Km as indicator for the catalytic efficiency, 
the overall selectivity is inverted in favour of preQ0 for TGT(E235Q). 
kcat values for preQ1, guanine and preQ0 are similarly decreasing in TGT(w.t.) and 
TGT(E235Q). From this finding it can be concluded that the deviating binding modes 
of the three bases exhibit only minor influence on the turn-over rates. Most 
presumably the innate ability of these bases to perform a nucleophilic attack is 
responsible for the observed trend in reactivity. Nitrogen N9 of the respective bases 
nucleophilically attacks C1 of the covalently bound tRNA ribose 34 (for chemical 
formulae see Fig. 2.4; for mechanism see chapter 2.1.2.2). N9 in preQ1 is the most 
potent nucleophile, as it is in no conjugation with the exocylic amino methyl group. 
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N9 in guanine is less potent due to an electron withdrawing effect of N7 being in 
conjugation with N9. PreQ0 is the least potent base in this series. Here the exocylcic 
cyano group is in conjugation with the endocyclic nitrogen, resulting in an even more 
pronounced electron withdrawing effect.  
Surprisingly, in E. coli TGT Vmax for preQ0 (4.2 µM s-1 mg -1) is virtually identical to 
that of preQ1 (2.6 µM s-1 mg-1), although the latter base is the preferred substrate for 
this TGT [Hoops et al., 1995]39. However, the comparison with Z. mobilis TGT 
provides no satisfactory explanation for this observation. 
 
2.2.2.4 Discussion of TGT(E235Q) crystal structures 
 
The crystal structures of uncomplexed TGT(E235Q) revealed an unexpected binding 
mode for the mutated glutamine residue. All residues in the vicinity of this residue are 
well defined in the crystal structure (Fig. 2.11a). However, Gln235 is not H-bonded to 
the carbonyl group of Leu231 as expected. Instead, the Gln235 side chain stacks 
with its hydrophobic surface on top of the Leu231/Ala232 peptide bond. Together 
with the side chain of Tyr161 it is involved in a sandwich-like stacking interaction (Fig. 
2.11b). The Glu235 side chain is additionally stabilized via two H-bonds formed with 
the amide function of Val233 (3.0 Å) and the carbonyl function of Gly230 (2.9 Å). 
Concerning the peptide switch, the Leu231/Ala232 peptide bond exposes the Ala232 
amide function to the binding pocket stabilizing water molecule (W1). 
The superposition with the uncomplexed TGT(w.t) crystal structure derived at pH 5.5 
illustrates the differences with respect to the glutamate / glutamine side chain 
geometry. These differences are likely supported by a Gln235/Gly236 peptide flip. 
(Fig. 2.11d). While the orientation of Ala232 including W1 is nearly identical in both 
structures, the 235 side chains adopt significantly different geometries. Although 
Glu235 is supposed to be protonated at this pH and thus structurally highly isosteric 
to glutamine, deviating geometries are found in both structures.  
The crystal structures of TGT(E235Q) reveal another significant difference to the wild 
type enzyme. In the TGT(w.t.) the orientation of the Leu231/Ala232 peptide switch 
can be triggered in a pH dependent manner, regulated by the Glu235 protonation 
state. The E235Q mutated enzyme, however, permanently seems to expose the 
amide function of Ala232 towards the binding pocket, at least under the conditions 
screened in the experiments. The two structures found in crystals grown at pH 6 and 
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pH 8.5 are virtually identical with respect to the orientation of Leu231 - Gln235 (Fig 
2.11c). Thus, conformational rearrangements seem not to be relevant for 
TGT(E235Q) compared to the wild type (Fig. 2.9a). 
 
Fig 2.11  a)  Electron density of the G230-G236 loop in apo TGT(E235Q) crystallized at pH 
8.5 and contoured at 1.3σ in a 2|Fo| - |Fc| map;  b)  hydrophobic stacking stabilizing the 
geometry of Q235; c)  superposition of TGT(E235Q) crystallized at pH 8.5 and pH 6;             
d) superposition of G230 - G236 in apo TGT(E235Q) crystallized at pH 8.5 and apo 
TGT(w.t.) crystallized at pH 5.5 
 
Cocrystallization of TGT(E235Q) at pH 6 with preQ0 was successful, in contrast to 
the attempts with preQ1. PreQ0 is well defined in the TGT(E235Q) binding pocket 
displaying distinct interactions with Asp102, Asp156, Gln203, Gly230 and Ala232 
(Fig. 2.12a). The superposition with the uncomplexed crystal structure at pH 6 
provides an explanation for this result (Fig. 2.12b). Both binding pocket geometries 
are virtually identical. Independent of pH, TGT(E235Q) provides a binding pocket 
suited to accommodate preQ0. Upon binding of this base, the water molecule W1 is 
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expelled from the binding pocket and Asp102 is rotated towards the ligand. Thus, 
almost no binding pocket rearrangement is required for binding. This finding is 
supported by the kinetic analysis. Km of preQ0 in TGT(E235Q) is low, with some care, 
supposedly slightly lower than for the wild type.  
 
Fig 2.12  a)  Binding mode of preQ0 in TGT(E235Q) contoured at  3σ in the |Fo| - |Fc| map 
refined in the last cycle excluding ligand coordinates; b) structural alignment of apo 
TGT(E235Q) crystallized at pH 8.5 and TGT(E235Q)⋅preQ0;  c) structural alignment of 
TGT(w.t.)⋅preQ0  and TGT(E235Q)⋅preQ0;  d)  the same alignment viewed from another 
direction 
 
In case of preQ1, however, cocrystallization was not successful. No electron density 
of a bound ligand could be identified. Due to a split conformation of Asp102, it can be 
assumed that preQ1 has partly populated the crystal. The increased Km of 32µM for 
preQ1 in TGT(E235Q) reflects its limited binding competence. Nevertheless, the 
binding mode of preQ1 remains elusive. Whether preQ1 is accommodated in the 
binding pocket facing the exposed amide nitrogen or whether the peptide switch is 
still in operation to expose the Leu231 carbonyl group remains unresolved. 
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The superposition of the crystal structures of the wild type and TGT(E235Q) in 
complex with preQ0 show almost identical conformations for Glu235 and Gln235. 
Even the 235/236 peptide flip is found with almost identical geometries (Fig. 2.12c).  
Nevertheless, the detailed comparison reveals some significant differences. They 
result from the deviating orientations of the ethylene linker of glutamate and 
glutamine (Fig. 2.12d). In case of the wild type TGT, complexed with preQ0, the 
carbonic acid function adopts a geometry that disables H-bond formation with the 
carbonyl group of Gly230. Instead a short contact is formed with the amide of Val233 
(2.8 Å), suggesting Glu235 to be negatively charged. This might explain why Glu235 
avoids short contact to the carbonyl group of Gly230. In this geometry even the 
stacking with Tyr161 is less perfect than in the crystal structure of the mutated 
enzyme.  
Based on the available crystal structures, the following conclusions can be drawn. In 
uncomplexed TGT(w.t.) Glu235 binds to the peptide switch. It changes its protonation 
state whether it is faced by a hydrogen-donor or -acceptor functionality of the peptide 
switch. Supposedly, this situation is also given if a guanine or preQ1 are 
accommodated in the binding pocket. However, upon binding of preQ0 this interaction 
mode is not preserved. Most presumably the negatively polarized cyano group of 
preQ0 that interacts with the amide group of Ala232 modifies the local dielectric 
conditions. This prevents Glu235 to pick up a proton and to form a hydrogen bond to 
the carbonyl of the peptide switch. Therefore, the Glu235 side chain has to find an 
alternative geometry. The negative charge on the Glu235 carboxylate function 
disables favourable interactions with the carbonyl group of Gly230. Accordingly, only 
a hydrophobic stacking with the neighbouring peptide bond of the switch remains as 
binding geometry. In contrast the terminal amide group of Gln235 in the mutated 
enzyme is capable to form a hydrogen bond via its carboxamide protons to Gly230. 
Additionally, also the geometry for stacking with Tyr161 is more favourable. 
Obviously, the binding mode of Gln235, clearly distinct from the binding geometry of 
Glu235 in its protonated state, is rather favourable and is conserved across different 
pH conditions. One may speculate, as no direct contact to the peptide switch is 
formed, whether the switch is still operational in the mutant. At least, the kinetic 
experiments indicate, that preQ1 is still recognized as substrate, even though with 
much less efficiency. 
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In summary these considerations provide an explanation for the significantly 
modulated selectivity in favour of preQ0 in the mutated enzyme. The crystal 
structures of both isoforms recognize preQ0 comparably. However, the mutated 
enzyme adopts already in the uncomplexed state a geometry suited for preQ0 
binding. In contrast, the wild type adopts this conformation only once the nucleobase 
enters the active site.  
2.2.2.5 Summary and outlook 
 
The crystal structure analysis of the TGT(E235Q) clearly demonstrated that kinetic 
data from mutational studies have to be discussed carefully and cautiously. By 
means of protein engineering a more conservative exchange than glutamic acid / 
glutamine can hardly be performed. The present example shows that kinetic data is 
reflected as expected, but structural biology demonstrates that nature finds for this 
exchange an unexpected solution. 
Nevertheless, this study also shows that a single mutation enables the inversion of 
selectivity in TGT. The fact that turn-over rates are hardly affected by the mutation 
clearly indicates that selectivity regulation in TGT is a multifactorial process.  
The successful modulation of selectivity is an important step towards the 
understanding of selectivity and specificity determining features in TGTs. Mutational 
studies with E. coli TGT replacing Asp156 by various other amino acids altered the 
specificity towards xanthine in case of the TGT(D156N) mutated enzyme. However 
the catalytic activity was reduced [Todorov & Garcia, 2006]67. In this context it might 
be interesting to study mutational exchanges in the close neighbourhood of the 
attacking nucleophile Asp280. In QueTGT this residue is tightly kept in position by    
H-bonds formed with Gly261 and Tyr258 (Fig. 2.3d).  In the archaebacterial ArcTGT 
the tyrosine is replaced by a strictly conserved histidine. Likely, this exchange will 
have pronounced influence on the catalytic properties. 
These considerations provide a perspective towards an ambitious goal: the 
modification of substrate specificity towards bases other than preQ0 or preQ1 and 
their efficient incorporation into tRNA. This would allow to study the translational 
process in more detail via well designed modification of the accuracy of the wobble 
base pairing.  
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2.3    Homodimer formation in QueTGT 
 
The crystal structures of TGT from two species (Z. mobilis, Thermotoga maritima) 
exhibit homodimers. This prompted us to investigate the structural properties of these 
dimers, in particular their occurrence among TGTs of other species and their possible 
functional relevance.  
2.3.1 Dimer formation in solution and in crystals 
 
During the initial biochemical characterization of TGT enzymes from different species 
dimer and multimer formation in pure TGT solutions has been observed. However, 
their occurrence is controversially discussed [Reuter & Ficner, 1995]68. E. coli TGT 
seems to form dimers at low protein concentrations and multimers at higher 
concentrations. For Z. mobilis TGT a molecular mass of 55 kDa was determined by 
gel filtration. This value falls between monomer (43 kDa) and dimer (86 kDa). 
Whether the presence of TGT as dimer has any functional relevance or whether it is 
only formed upon tRNA binding, possibly in a species dependent manner, has not yet 
been examined. 
Uncomplexed TGT crystallizes in the space group C2 with one TGT molecule per 
asymmetric unit. In this space group two-fold symmetry imposes homodimer 
formation with a buried solvent accessible surface of 1,667Å2 [Romier et al., 1996]25.  
Within the unit cell, two symmetry related pairs of TGT dimers are present due to C 
centering (Fig. 2.13a). The crystal structure of tRNA-bound Z. mobilis TGT also 
shows a homodimer, however not imposed by symmetry. It binds a tRNA anticodon 
stem loop within the asymmetric unit (Fig. 2.13b – TGTA, TGTB) [Xie et al., 2003]4. 
Superposition of this tRNA-bound homodimer with the uncomplexed C2 symmetrical 
TGT dimer reveals an identical contact interface geometry (Fig. 2.13d).  
The recently determined crystal structure of Thermotoga maritima TGT (PDB-code: 
2ASH) also exhibits a homodimer in the asymmetric unit. The enzyme of the 
thermophilic eubacterium shares a sequence identity of 47% (63% homology) with 
TGT from Z. mobilis (retrieved from SWISS-PROT, [Boekmann et al., 2003])69. All 
essential residues in the active site are conserved which indicates an unchanged 
enzyme function (Tab. 2.5). The superposition of this structure with the C2 
symmetrical dimer reveals an identical orientation of all structural elements (Fig. 
2.13c/d). 
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Fig. 2.13  a)  Uncomplexed Z. mobilis TGT crystal structure: unit cell content in space group 
C2 formed by four symmetry equivalents;  b) crystal structure of Z. mobilis TGT in complex 
with tRNA anticodon stem loop: two TGT molecules binding on stemloop are found in the 
asymmetric unit; c)  superposition of crystal structures of Z. mobilis and T. maritima TGT 
coloured by structural elements; d) superposition of uncomplexed Z. mobilis TGT (dimer 
formed by two fold symmetry – green), Z. mobilis TGT in complex with anticodon stem loop 
(dimer from asymmetric unit – blue) and uncomplexed T. maritima TGT (dimer from 
asymmetric unit – yellow/orange) 
 
2.3.2 Sequence comparison of 21 TGTs from different species 
 
The structural superposition of the dimer interfaces from Z. mobilis and T. maritima 
TGT indicated that the involved residues are highly conserved (Fig. 2.14a). To collect 
further evidence for the presence of a conserved interface, a sequence alignment 
was performed based on 21 TGT sequences retrieved from SWISS-PROT and 
aligned using CLUSTAL_W [Boekmann et al., 2003] (Tab. 6.1)69. The sequences 
originate from 21 species and were selected as representatives of major eubacterial 
and eukaryotic subdivisions. The selection followed a recently presented global 
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phylogeny using knowledge from 191 sequenced genomes [Ciccarelli et al., 2006] 70. 
For reasons of comparison, at first the residues of the active site were aligned (Tab. 
2.5 – following Z. mobilis numbering). The composition of the active site is highly 
conserved among all TGTs, except for Chlamydia species. Here, the active site 
exhibits some notable differences. Furthermore, a Chlamydia-specific insertion of 18 
residues between position 114 and 115 deviates from all other TGTs and suggests a 
slightly different function (Tab. 6.1). Thus, the Chlamydia TGT was excluded from 
any further considerations. Across eubacterial TGTs the core of residues, forming the 
dimer interface, is highly conserved (Tab. 2.6).  Lys52, Leu74, Pro78, Phe92 from the 
TIM-barrel site of the interface and Tyr330, His333, Leu334, Glu339, Leu345 from 
the zinc-binding subdomain have identical interaction partners in most eubacterial 
divisions. At position 49 (Gly/Ala), 50 (Thr/Ser/Cys), 326 (Phe/Tyr/Trp), 329 (Ala/Ser) 
and 341 (Leu/Phe) homologous residues are found. These results suggest that in 
Eubacteria dimer formation as general property of TGTs seems likely.  
In eukaryotic TGTs Lys52, Leu74 and Pro78 are conserved and at positions 50 
(Thr/Ser), 92 (Phe/Met), 329 (Ala/Ser), 330 (Tyr/Phe), 339 (Glu/Asn) and 345 
(Leu/His) residues similar to those in Eubacteria are found (Tab. 2.6). Although, the 
overall degree of conservation is smaller, compared to Eubacteria, dimer formation is 
possibly also given in Eukaryotes. 
 
2.3.3 Functional model for the QueTGT dimer 
 
In contrast to QueTGT, the archaebacterial TGT is known to form functional dimers 
upon catalysis. This has been described in detail in chapter 2.1.4.1. However, the 
structural superposition of P. horikoshii TGT with Z. mobilis TGT revealed a 
completely different composition of the dimer interface. This may result from 
significantly different tRNA binding geometries and modification sites resulting in a 
2:2 complex of TGT with tRNA. Although a direct analogy between the 
archaebacterial and eubacterial enzyme is not given, the fact of a functional dimer for 
Archaebacteria together with the presence of a highly conserved dimer interface in 
Eubacteria suggests that dimer formation is required for function also for the latter 
class. In the 2:1 complex of Z. mobilis TGT with tRNA, a TGT homodimer (TGTA, 
TGTB) is bound to an elongated anticodon stem loop which served as substitute for 
full-length tRNA [Xie et al., 2003]4. In the crystal structure, the U33G34U35 recognition 
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sequence of the anticodon forms strong interactions to TGTA. As the two active sites 
of TGTA and TGTB pack closely together only one tRNA anticodon loop is bound in 
this crystal form. Although TGTB is not involved in the recognition of the tRNA 
substrate, it forms an interaction with the anticodon stem loop. Arg77 is H-bonded to 
the phosphate groups of C27 and is found in close contact to the phosphate group of 
G26. This arginine is highly conserved among all eubacterial and eukaryotic TGTs 
(few exceptions: Lys/Gln – Tab. 2.6).  
 
 
a                                                                   b 
Fig. 2.14  a)  Structural alignment of the dimer interfaces in Z. mobilis TGT (blue/slate blue) 
and T. maritima TGT (yellow/orange); b)  structural superposition of tRNAPhe from yeast onto 
the tRNA anticodon stem loop from the tRNA-complexed Z. mobilis TGT crystal structure; 
residues from TGTB assumed to interact with tRNA are coloured in green 
 
To analyze further putative interaction sites of TGTB with respect to full-length tRNA, 
the geometry of tRNAPhe (PDB code: 1EHZ) was modelled onto the anticodon stem 
loop (Fig. 2.14b). This superposition shows two positively charged residues, Lys125 
and Arg132, of TGTB to be well placed to interact with phosphate groups of the tRNA 
D-stem bases in position 11 and 12. The two residue side chains were manually 
adjusted towards tRNA to demonstrate their ability to form H-bonds with the tRNA. 
Lys125 and Arg132 are located in a TIM-barrel insertion (β7-α6) characterized by 
three antiparallel β-strands. This insertion is conserved among eubacterial and 
eukaryotic TGTs [Stengl et al., 2005]54. Even though Lys125 and Arg132 are not 
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strictly conserved among Eubacteria and Eukaryota, at both positions predominantly 
Arg or Lys are found (Tab. 2.6).  
As these putative interaction sites with the bound tRNA seem to be widely 
conserved, it can be concluded that the eubacterial (and most presumably also 
eukaryotic) TGTs form functional dimers upon catalysis. While only one molecule 
performs the base exchange reaction, the other serves to stabilize the bound tRNA in 
its geometry via interactions with Arg77 and insertion β7-α6. This hypothesis would 
explain why the residues in the dimer interface are remarkably conserved across 
various species. 
2.3.4 Outlook 
 
The performed sequence and structural alignments provide strong indications for 
functional dimer formation in TGT. However, this hypothesis still has to be tested 
experimentally. Gelfiltration experiments are a good starting point for such 
investigations. Initial experiments performed with a Superdex 200 10/30 prepgrade 
column indicate that Z. mobilis TGT is present as monomer in solutions of 
uncomplexed TGT. Further experiments performed with TGT in the presence of full 
length tRNATyr indicate the formation of dimers and multimers. However, the results 
from these experiments are not yet conclusive enough, as the applied conditions 
require further validation. Dynamic light scattering could offer an alternative to assess 
complex formation. Additionally, mutational studies modifying the structure and 
integrity of the dimer interface could verify the above-discussed assumptions.  
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Tab. 2.5 Alignment of residues involved in substrate recognition, base exchange and complexation of zinc from 21 TGT 
sequences retrieved from SWISS-PROT  
 
species Guanine 34 / preQ1 binding site Ribose 34 binding site / catalytic site zinc binding site classification 
 
 102 106 107 156 203 230 231 235 260 45 47 68 70 73 258 261 280 282 318 320 323 349 Eubacteria 
Escherichia D F Q D Q G L E M V T L N H Y G D V C C C H 
Vibrio D F Q D Q G L E M V T L N H Y G D V C C C H 
Pseudomonas D F Q D Q G L E M V T L N H Y G D V C C C H 
 
γ-Proteobacteria 
Neisseria D F Q D Q G L E M V T L N H Y G D V C C C H β-Proteobacteria 
Agrobacterium D F Q D Q G L E M V T L N H Y G D V S C S H 
Rickettsia D F Q D Q G L E M V T L N H Y G D V C C C H 
Zymomonas D Y Q D Q G L E M V T L N H Y G D V C C C H 
 
α-Proteobacteria 
Helicobacter D F Q D Q G L E M V T L N H Y G D V C C C H ε-Proteobacteria 
Gloeobacter D F Q D Q G V E M V T L N H Y G D V C C C H Cyanobacteria 
Thermotoga D F Q D Q G L E M V T L N H Y G D V C C C H Thermotogae 
Chlamydia p. D F Q D H G S R L V T F N H H G D S C C C H 
Chlamydia t. D F Q D H G S K L V T F N H H G D S C C C H 
Chlamydiae 
Treponema D F Q D Q G L E M V T L N H Y G D V C C C H Spirochaetes 
Bacillus D F Q D Q G L E M V T L N H Y G D V C C C H 
Lactobacillus D F Q D Q G L E M V T L N H Y G D V C C C H 
Clostridium D F Q D Q G L E M V T L N H Y G D V C C C H 
Firmicutes 
                       Eukaryotes 
Schizosacch. D F Q D Q G L E M V T L N H Y G D V C C C H Fungi 
Caenorhabditis D F Q D Q G L E M V T L N H Y G D V C C C H 
Drosophila D F Q D Q G L E M V T L N H Y G D V C C C H 
Ecdysozoa 
Mus D F Q D Q G L E M V T L N H Y G D V C C C H 
Homo D F Q D Q G L E M V T L N H Y G D V C C C H 
Vertebrata 
 
2.3    Homodimer formation in QueTGT 
____________________________________________________________________                                                                                               
59 
___________________________________________________________________________________________________________ 
Tab. 2.6 Alignment of residues suggested to be involved in dimer formation and tRNA stabilization from 19 TGT sequences 
retrieved from SWISS-PROT  
 
   
species TIM-barrel side zinc binding subdomaine side TGTB - tRNA classification 
 
 49 50 52 74 78 92 326 329 330 333 334 339 341 345 77 125 132 Eubacteria 
Escherichia G T K L P F Y A Y H L E L L R R P 
Vibrio G T K L P F Y S Y H L E L L R R K 
Pseudomonas G T K L P F F A Y H L E L L R A K 
 
γ-Proteobacteria 
Neisseria G S K L P F F A Y H L E L L R K K β-Proteobacteria 
Agrobacterium G T K L P L Y A Y H L E L L R K L 
Rickettsia G T K L P F Y A Y H L E L L Q S K 
Zymomonas A T K L P F W A Y H L E L L R K R 
 
α-Proteobacteria 
Helicobacter G C K M P F Y A Y H L E T L R K K ε-Proteobacteria 
Gloeobacter A T K L P F F A Y H L E L L Q R L Cyanobacteria 
Thermotoga A S K L P F F S Y H L E L L K R K Thermotogae 
Treponema A T K L P F Y A Y H L E L L R Q R Spirochaetes 
Bacillus A T K L P F Y A Y H L E F L R R K 
Lactobacillus A S K L P F F A Y H L E F L R K K 
Clostridium G V K L P F Y A Y H L E L L R N R 
Firmicutes 
                  Eukaryotes 
Schizosacch. A S K L P F E A Y N S E V L K L P Fungi 
Caenorhabditis G T K L P M Y A Y H S E V L R E M 
Drosophila G T K L P F Y S Y H I E V L R R Q 
Ecdysozoa 
Mus A T K L P F H A F A L N T H R R E 
Homo A T K L P F H A F A L N A H R R E 
Vertebrates 
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The tRNA bound crystal structures of ArcTGT and QueTGT allow, due to their 
substrate binding modes, the extraction of valuable information about the 
evolutionary origin of TGTs within the TIM-barrel fold. Taking the available amino 
acid sequence data of TGTs and further enzymes involved in the tRNA modification 
pathway into consideration, also the relationship within the superfamily can be 
elucidated. The presented results have already been summarized in Stengl et al. 
(2005)54. 
 
2.4.1 Evolutionary origin of the TGT superfamily 
 
The TGT superfamily is grouped together with enzymes adopting a triose-phosphate 
isomerase (TIM)/(βα)8 barrel-like fold. This fold is very abundant and approximately 
10 % of all enzymes share this geometry [Gerlt, 2000]71. The biological roles of 85 % 
of the known reaction types performed by TIM barrel enzymes are associated with 
metabolism [Nagano et al., 2002]72.  
During the last two decades, several evolutionary classification models for TIM-barrel 
enzymes have been proposed [Farber & Petsko, 1990; Lesk et al., 1989]73, 74. Recent 
considerations favour the model of divergent evolution starting from a common 
ancestor, rather than convergent evolution. For about a dozen of the assumed 26-29 
homologous superfamilies, sequential, structural and functional evidence has been 
presented to support this assumption [Copley & Bork, 2000; Nagano et al.,       
2002]72, 75. Among these, presumably closer related superfamilies, a standard 
phosphate binding (SPB) motif, involved in the recognition of substrate phosphate 
groups, is widely spread. Thus, it was used as one criterion to achieve higher order 
classification. This structural element ranges from the 7th β-strand to the 8th α-helix of 
the TIM barrel motif, characterized by a high structural homology. Additionally 
conserved phosphate binding positions at the ends of the adjacent 7th and 8th TIM 
barrel strands are present. 
A straight-forward assignment of TGTs to the TIM barrel fold is difficult. As TGTs 
catalyze reactions attributed to the information pathway, they constitute one of the 
few examples for TIM barrel enzymes not involved in metabolism. Furthermore, due 
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to unusual insertions into the TIM barrel responsible for RNA binding, TGTs form a 
separated superfamily (see chapter 2.1.1). Furthermore, almost no global structural 
relationship to other superfamilies could be detected. However, detailed analysis of 
this fold with specific structural alignment methods revealed that TGTs share the 
standard phosphate binding motif with some other mutually related superfamilies 
[Nagano et al., 2000]. For Z. mobilis TGT the overall Cα-RMSD with respect to the 
SPB motif is only 1.7Å-2.0Å. Gly261Q and Val262Q at the end of strand β-13 (≡ 7th 
TIM barrel strand), as well as Val282Q at the end of strand β-14 (≡ 8th TIM barrel 
strand) were predicted to be in conserved positions for substrate phosphate binding 
via backbone interactions. 
 
       a                                                               b 
Fig 2.15  a) Conserved SPB- motif in QueTGT and triose-phosphate isomerase;                 
b)  conserved SPB- motiv in QueTGT and ArcTGT 
 
The tRNA complexed QueTGT structure revealed that the predicted Val282Q is 
indeed involved in binding of the substrate’s phosphate group of G34. The second 
residue, Gly261Q, is involved in binding of a substrate ribose hydroxy group [Stengl et 
al., 2005]54. A structural alignment of the SPB motif of QueTGT and triose-phosphate 
isomerase (TIM) from Gallus gallus, with their respective ligands shows equivalently 
positioned phosphate groups, binding residues and orientation towards Val282Q and 
Gly232TIM (Fig. 2.15a). Furthermore, in QueTGTs Val282Q is one of the well 
conserved residues next to the active site. In the available ArcTGT structure from P. 
horikoshii Ala251A, corresponding to Val282Q, displays a similar phosphate binding 
mode, however, to the phosphate group of G15 (Fig. 2.15b). This finding supports the 
preQ1(34)-
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A
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allocation of the TGT superfamily to other presumably homologous SPB containing 
superfamilies.  
The SPB motif is also a key structural element to understand why TGT is not 
involved in metabolism as most of the other TIM barrel enzymes. Comparison of 
evolutionarily related TIM barrel enzymes involved in metabolism shows no strict 
correlation with the metabolic pathway they are involved in. Often related enzymes 
perform tasks in different metabolic pathways. An evolutionary model suggests a 
process called ‘enzymatic recruitment’ between different metabolic pathways as one 
possible driving force to develop new protein functions [Copley & Bork, 2000]75. This 
model requires an ancient enzyme possessing a broader substrate specificity as 
starting point. New functions can evolve in case of different compounds sharing a 
common structure and being accepted as substrates by this enzyme. Specific groups 
(e.g. phosphate groups) represent such common substructures. Duplication and 
diversification of the respective gene finally result in two distinct protein functions 
involved in different metabolic pathways. 
Applying this evolutionary model to TGT results in the following consideration. The 
ancient predecessor of nowadays existing TGTs was possibly involved in central 
metabolism accepting and binding phosphorylated substrates via its SPB motif. Due 
to the presence of phosphate moieties in tRNA molecules they could have served as 
some sort of ‘accessory’- substrate for this ancestor. After gene duplication and 
evolutionary modification, one such copy could have evolved with specific tRNA 
recognition and modification properties as primordial TGT. This could explain why the 
TGT ancestor has possibly departed from pure metabolism and developed as a 
catalyst with a function rather unusual for an enzyme with a TIM barrel fold (Fig. 
2.16). 
 
2.4.2 Classification within the TGT superfamily 
 
The presence of TGTs across broad phylogenetic boundaries indicates the 
evolutionary origin of the primordial TGT in a prokaryotic predecessor before the 
separation of the three kingdoms of life. The further evolution of TGT within the three 
kingdoms, resulting in deviating substrate specificities, however, is not certain at all. 
The following considerations try to fit the current knowledge to a consistent picture 
(Fig. 2.16). 
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Due to the fact that QueTGT and ArcTGT are involved in different tRNA modification 
pathways it can be speculated that the initial split between the eubacterial and the 
archaebacterial lineage took place before the two pathways have been fully 
established. Thus, for the last common ancestor it only seems clear that its TGT was 
involved in tRNA modification.  It is uncertain at which tRNA position the modification 
was performed. It is also uncertain whether preQ0 or preQ1 was accepted as 
substrate. The lower number of required steps for biosynthesis of preQ0 argues in 
favour of this base. The less complex architecture of QueTGT speaks in favour of 
preQ1, although this assumption is challenged by the fact that QueTGT accepts 
preQ0 as substrate as well. However, in Eubacteria QueTGT was finally located in 
the Queuine-pathway influencing transcription and in Archaebacteria ArcTGT was 
integrated into the Archaeosine-pathway increasing tRNA stability.  
 
 
precursor enzyme
metabolism, TIM-barrel, SPB-motif
PO4Rn-binding
primordial TGT
tRNA modification, Zn-subdomain
substrate: preQ0 / preQ1 (?)
ArcTGT
G15-tRNA, PUA domain
preQ0 archaeosine pathway
QueTGT
G34-tRNA,
preQ1 queuine pathway
euk. QueTGT
G34-tRNA,
queuine incorporation
external source
Archaebacteria Eukaryota Eubacteria
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loss
metabolic enzymes
TIM-barrel, SPB-motif
PO4Rn-binding
eub. QueTGT
secondary
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Fig. 2.16  Evolutionary model of the TGT superfamily 
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The following lineage split took place between Archaebacteria and Eukaryota 
[Ciccarelli et al., 2006] 70. As in Eukaryota neither orthologs of arctgt nor of queC–E 
genes involved in preQ0 synthesis are found, a primary loss of the enzymes involved 
in tRNA modification in the initial Eukaryota has to be assumed. Secondarily 
however, in a later evolutionary stage the Eukaryota reacquired a single tgt-gene, 
most presumably by horizontal gene transfer. The gene was of eubacterial origin, 
indicated by the high degree of structural and functional identity of eukaryotic and 
eubacterial TGT. Most presumably the quetgt-gene of the primordial Eukaryota 
originated from an eubacterial endosymbiont, which further evolved towards the 
mitochondria of the present Eukaryota. This evolutionary process was possibly 
assisted by multiple gene translocation events from the mitochondria chromosome 
towards the eukaryotic chromosome. This hypothesis has been investigated in detail 
for proteins of the nuclear pore complex and the splicosome [Martin & Koonin, 
2006]76.  As solely the quetgt-gene was transferred, de novo Q-synthesis was 
disabled for Eukaryota. Thus, Eukaryota were still dependent on external queuine 
sources and substrate specificity had to be modified towards queuine. Due to the fact 
that the initial Eukaryota were highly mobile predators of bacterial cells, queuine 
could be provided by nutrition. Even for the Metazoa with eubacterial commensals in 
their digestive apparatus queuine could be provided in sufficient amounts. The only 
present eukaryotic organisms that are known to lack queuine are green plants, 
obviously not possessing an external queuine source, and Saccharomyces 
cerevisae, a yeast living predominantly from vegetal sources.  
These considerations corroborate the evolutionary history within the TGT superfamily 
and form a complex but nevertheless consistent picture.  
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3. Structure-based Inhibitor Design 
 
 
The new knowledge from the functional analysis was implemented in structure-based 
inhibitor design. As a consequence of the detailed insight into the base exchange 
reaction an appropriate binding assay had to be developed taking competitive and 
uncompetitive inhibition contributions into consideration, which were not considered 
in the previous assay (chapter 3.1). Therefore, inhibition constants of relevant 
inhibitor classes detected and developed in previous studies were revalidated to 
adjust  structure – activity relationship (chapter 3.2). Based on these results, a 
quinazolinone-based inhibitor series was further developed resulting in several new 
lead compounds (chapter 3.3). In chapter 3.4 a virtual screening hit detected earlier 
was further investigated by means of structure-based design. Finally, a compound 
class, isolated from plant extracts by an HPLC assisted ligand-fishing method using 
TGT as trap, was tested with respect to their inhibition potency (chapter 3.5). 
3.1    Modifications of the binding assay 
 
 
The determination of inhibition constants in TGT is based on monitoring of tritium 
labelled [8-3H]-guanine which is incorporated in tRNA catalyzed by TGT. Labelled 
guanine is used as alternative substrate instead of natural preQ1, for which no 
labelled material is available. The inhibition of TGT reduces the amount of 
incorporated tritium-labelled guanine in tRNA which can be monitored by liquid 
scintillation counting. From the reduction of the initial velocity of the base exchange 
reaction inhibition constants can be derived [Grädler et al., 2001]3. However, the 
determination of inhibition constants is complicated by several factors. Firstly, low 
solubility might result in non-specific inhibition. Such effects can be avoided by the 
addition of detergents. As a secondary effect the protein solubility is improved 
(chapter 3.1.1). Secondly, as described above, the inhibition mechanism in TGT is 
more complex than previously assumed. As the base exchange follows a ping-pong 
mechanism competitive and uncompetitive inhibition contributions have to be 
considered in dependence on the ligand properties (chapter 3.1.2 - 3.1.3). To face 
these complications the previously used assay was modified (chapter 3.1.4). All 
necessary modifications of the assay setup recently have been published by us in 
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Meyer et al. (2006)65. In a short outlook an alternative approach will be presented 
that might be suited to replace the radioactive assay (chapter 3.1.5).  
 
3.1.1 Detergents effect ligand and protein solubility 
3.1.1.1  Detergents and non-specific inhibition 
 
Many of the tested compounds exhibit low solubility under the applied assay 
conditions, especially those coming from the class of pteridines and quinazolinones 
(chapter 3.2). Effects of low solubility can be manifold. As a consequence of possible 
precipitation, the resulting inhibition potency could be underestimated. However, also 
the opposite could be observed, as reported recently. Compound with low solubility 
might also exhibit unspecific inhibition. The risk of such inhibition exists for a large 
variety of compounds and has been referred to as “promiscuous inhibition” 
[McGovern et al., 2002]77. Such compounds show up repeatedly as inhibitors of 
various enzymes in biological assays and do not follow a target-specific mode of 
action. Instead, such behaviour is thought to result from compound agglomeration 
that adsorbs the enzyme onto its aggregated surface. In consequence, the enzyme is 
inactivated. Adding detergents, such as Tween 20 or Triton X-100, to the respective 
assay solutions obviously reduces aggregate formation and thus allows to distinguish 
“promiscuous” from specific inhibitors [McGovern et al., 2002]77.  To avoid possible 
effects of “promiscuous” or non-specific inhibition as well as other undesired 
precipitation effects in the aqueous TGT assay, Tween 20 was added in 5% of its 
critical micellar concentration (CMC) of 59 µM (chapter 5.3.1). The amount of Tween 
20 used is based on the results reported by Ryan et al. (2003)78. An example for the 
influence of Tween 20 on affinity data in TGT is presented in chapter 3.5. 
 
3.1.1.2  Detergents and TGT solubility 
 
As a supplementary effect, the use of detergents influences not only ligand but also 
protein solubility [Ryan et al., 2003]78. In particular Tween 20 was described to 
reduce protein absorption onto plastic surfaces of cups usually used for kinetic 
measurements. Such artificial immobilization results in a reduced effective enzyme 
concentration in the assay solution. Therefore, the kinetic parameters for TGT were 
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re-examined to quantify the possible impact of Tween 20 (Tab. 3.1 and chapter 
5.3.2). Furthermore, accurately determined kinetic parameters are required to derive 
inhibition constants.  Km values for TGT with respect to both substrates tRNATyr and 
[8-3H]-guanine remain within the range already published for Z. mobilis TGT 
(Km(tRNATyr): 0.2-1.0 µM; Km([8-3H]-guanine): 0.38-1.3 µM)  [Reuter & Ficner, 1995;  
Brenk et al., 2003]64, 68.  In contrast kcat obtains higher values than reported 
previously.  Most likely, this observation results from a higher effective TGT 
concentration in the Tween 20-containing assay solution. Accordingly, it can be  
assumed that the principal catalytic properties are not affected by added Tween 20. 
 
Tab. 3.1  Kinetic parameters for TGT(w.t.) in the presence and absence of  
  Tween 20 (previous values from Brenk et al. (2003)64) 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
3.1.1.3 Detergents and inhibitor preincubation 
 
Preincubation of Z. mobilis TGT with a putative inhibitor was reported to affect the 
initial velocity of the enzyme-catalyzed reaction [Brenk et al., 2003]64. A 10 minute 
preincubation of TGT with the inhibitor to be tested prior to the addition of substrate 
showed reduced initial velocity by about 50%.  In contrast to this finding, the addition 
of Tween 20 (c = 5% CMC) rather resulted in a slight increase of the initial velocity 
after a 10 minute preincubation and increased the initial velocity in the absence of 
Tween 20 by a factor of three. It can be assumed that the previously observed 
preincubation effect resulted from a superimposed slow adsorption/desorption 
process of the enzyme on the plastic cup surface which is unmasked by the use of 
Tween 20. 
TGT (w.t.) tRNATyr previous 
values 
[8-3H]-
guanine 
previous 
values 
 
 
Km [µM] 
 
0.9 ± 0.2 
 
1.0 ± 0.4 
 
1.2 ± 0.2 
 
0.4 ± 0.1 
 
kcat [s-1] 2.7*10-2 1.4*10-2 2.8*10-2 1.1*10-2  
kcat/Km [µM-1s-1] 3.0*10-2 1.4*10-2 2.3*10-2 2.9*10-2  
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3.1.2 Inhibition of a ping-pong reaction 
 
Detailed analyses of the TGT base exchange reaction by means of kinetic and 
crystallographic studies provided a better insight into the molecular details of the 
reaction pathway (chapter 2.1.2.2). The base exchange reaction follows a ping-pong 
mechanism [Goodenough-Lashua & Garcia. 2003]53. Subsequently, TGT accepts two 
substrates, tRNA and preQ1. For each substrate the enzyme provides a distinct 
binding pocket arrangement. While tRNA interacts with uncomplexed TGT, preQ1 
binds into a modified binding pocket partially formed upon the covalent binding of 
tRNA to Asp280. In a ping-pong reaction two modes of inhibition are possible (Fig. 
3.1a). Either the binding of tRNA is prevented (inhibition of the first reaction step), or 
the binding of preQ1 is prevented (inhibition of the second reaction step).   
 
a                                                                           b 
Fig. 3.1  a) Inhibition modes in the TGT ping-pong reaction pathway;  b)  structural 
superposition of covalent TGT-tRNA intermediate stabilized by 9-deazaguanine and Q13 
binding to uncomplexed TGT; the Q13 substituent would interfere with the ribose binding site 
(for chemical formula in Fig. 3.3) 
 
The molecular bases for the inhibition of the second reaction step can be extracted 
from the crystal structure of TGT in complex with a tRNA anticodon stem loop 
stabilized by 9-deazaguanine. The structure of the “ternary” complex revealed that 
this base served as non-reactive substrate mimic for preQ1. 9-Deazaguanine 
accommodates the binding pocket via non-covalent interactions and stabilizes the 
covalent TGT-tRNA intermediate state (Fig. 3.1b).  Accordingly, this site can either 
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accommodate active substrates (e.g. guanine or preQ1) or other small non-reactive 
ligands. In the series of already studied inhibitors, some compounds exhibit 
molecular dimensions similar to the natural substrates, thus competing with preQ1 for 
binding. These considerations appear in particular relevant for a quinazolinone-based 
inhibitor series of TGT. Therefore, this inhibitor class was used by us as a test case 
[Meyer et al., 2006]65. Competition with preQ1 binding is expected for the 
quinazolinone lead structures Q1 and Q2 (for chemical formulae see Fig. 3.3). 
However, once decorated by additional substituents, as in Q13, steric clashes with 
the covalently bound tRNA ribose moiety at position 34 might occur. Accordingly, it 
can be assumed that these extended compounds compete only with tRNA binding to 
uncomplexed TGT (inhibition of the first reaction step) (Fig. 3.1b). 
 
3.1.3 Detection of the inhibition modes 
 
To verify the assumption of two independent modes of inhibition, a trapping 
experiment was performed (chapter 5.3.3). It is based on the study of Xie et al. 
(2003)4 where the covalent TGT-RNA intermediate was stabilized by 9-
deazaguanine. In this analysis 9-deazaguanine was replaced by Q1 and Q2. In 
different reaction mixtures, TGT was first incubated with an excess of tRNA together 
with two small sized (Q1 and Q2) and substituted inhibitors (Q5 and Q13). Then, an 
SDS-PAGE analysis of these mixtures was performed (Fig. 3.2). Bands are observed 
for uncomplexed TGT at 43.5 kDa (lane 2). Incubation of TGT with tRNA results in 
two additional, faint, retarded bands at about 70 kDa (lane 3). These bands 
correspond to covalent TGT-tRNA complexes [Nonekowski & Garcia, 2001]79. The 
detection of two bands for the covalent complex results from different tRNA 
conformers present under the applied PAGE conditions as already reported 
elsewhere [Kung & Garcia, 1998]80. The occurrence of well-defined bands for TGT-
tRNA in the presence of small inhibitors such as Q1 and Q2  (lane 6 and 7) 
demonstrates the potential of these ligands to stabilize the covalent intermediate 
similarly to 9-deazaguanine. Once exposed to inhibitors exhibiting a large substituent 
at their basic scaffolds such as Q5 and Q13 (lane 4 and 5), the respective bands are 
only very faint similar to the situation when uncomplexed TGT is mixed with tRNA in 
absence of a small molecule inhibitor (lane 3). This finding indicates that inhibitors of 
the size of Q5 and Q13 are not capable to stabilize the covalent TGT-tRNA complex. 
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                     1         2        3        4         5          6         7 
 
 
Fig. 3.2  Trapping experiments with quinazolinone-based inhibitors 
 
3.1.4 Modification of tRNA-based tritium labelling assay 
 
In consequence of the size-dependent inhibition model with respect to the two 
substrates tRNA and [8-3H]-guanine, replacing preQ1 in the assay, the procedure to 
determine inhibition constant had to be modified (chapter 5.3.3 and 5.3.4). Inhibitors 
with large side chains are expected to be competitive only with tRNA substrate 
binding to TGT (competitive inhibition with respect to tRNA). Small inhibitors of 
comparable size to the natural nucleobase substrates, however, exhibit a more 
complex inhibition profile (Fig. 3.3). They either occupy the base exchange site prior 
to tRNA binding to TGT (competitive inhibition with respect to tRNA). It can be 
concluded hat this type of binding is possible considering the formation of binary 
TGT⋅inhibitor complexes observed in many crystal structures [Brenk et al., 2004; 
Meyer et al., 2004]1, 66. Alternatively, these ligands compete with preQ1 or guanine 
after tRNA is covalently attached to TGT (uncompetitive inhibition with respect to 
tRNA; competitive inhibition with respect to preQ1 / [8-3H]-guanine). Accordingly, to 
compare small guanine-sized and larger, extended inhibitors, their binding constants 
determined with respect to tRNA binding are required to provide directly comparable 
inhibitory values. Thus, for inhibitors of the guanine-type size two inhibition constants 
(competitive inhibition constant: Kic ; uncompetitive inhibition constant: Kiu) have to be 
defined that fully characterize their TGT inhibition potency with respect to tRNA 
binding. 
Following the modified protocol, inhibition constants were determined with respect to 
tRNA. Thus,  the tRNATyr concentration was now limiting, while [8-3H]-guanine was 
used in excess. Due to the fact that in the previously applied assay protocol, 
inhibition constants have been determined with respect to [8-3H]-guanine as limiting 
substrate (competitive inhibition with respect to preQ1 / [8-3H]-guanine), also 
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inhibition constants for relevant compounds acting as sole competitive inhibitors from 
previous design approaches had to be re-determined (chapter 3.2) [Meyer et al., 
2006]65.  
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Fig. 3.3  Size-dependent competitive (Kic) and uncompetitive (Kiu) inhibition modes with 
respect to tRNA binding 
3.1.4.1 Determination of non-competitive inhibition 
 
Small-sized inhibitors, such as Q1 and Q2, act as competitive and uncompetitive 
inhibitors with respect to tRNA binding. They can be identified by trapping 
experiments (chapter 3.1.3). The competitive/uncompetitive inhibition process can be 
described by a double reciprocal Lineweaver-Burk plot according to equation (1).   
1
v0
Km
Vmax
1+
1
[S]
1
Vmax
( ( )][= · [I]Kic) · + 1+
[I]
Kiu
·
 
vo: initial velocity of [8-3H]-guanine incorporation, Km of tRNATyr, Vmax: maximum velocity of 
the uninhibited [8-3H]-guanine incorporation, [I]: inhibitor concentration, Kic: competitive 
inhibition constant, [S]: tRNA concentration, Kiu: uncompetitive inhibition constant 
 
This relationship exhibits two inhibition constants, Kic and Kiu. While competitive 
inhibition results in a raise of Km, uncompetitive inhibition decelerates Vmax. Both 
inhibition constants contribute to the total inhibition of TGT with respect to tRNA 
binding. To describe the suppression of the readout of the assay, namely the velocity 
of the incorporation of [8-3H]-guanine in tRNA replacing unlabeled guanine (vo), both 
(1) 
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have to be considered. In the literature, such a composite type of inhibition is referred 
to as mixed or non-competitive inhibition [Segel, 1993; Bisswanger, 2000]81, 82. 
The two inhibition constants can be calculated using the tritium-labelling assay by 
monitoring the initial velocity vo of the base exchange reaction at various inhibitor and 
tRNA substrate concentrations. Kic rises Km towards the apparent value Kmapp and Kiu 
reduces Vmax towards the apparent value Vmaxapp. By applying formula (2) and (3) the 
inhibition constants Kic and Kiu can be calculated from the kinetic parameters of the 
uninhibited reaction together with the apparent kinetic parameters determined in the 
presence of inhibitor. 
Km 1+(· [I]Kic)=Km
app
 
Vmaxapp
Vmax
( )1+ [I]Kiu
=
 
3.1.4.2 Determination of competitive inhibition 
 
For inhibitors with a large side chain such as Q5 or Q13 the competitive inhibition 
constant Kic is supposedly sufficient to fully describe their inhibition properties as 
these compounds are too large to be significantly accommodated by the binding 
pocket as long as the covalent TGT-tRNA adduct is formed.  Kiu is hardly relevant in 
this case, and the respective inhibition type can be described as predominantly 
competitive.  Equation (4) describing the latter situation results from a simplification 
of equation (1). The competitive inhibition constant Kic either for guanine-sized or 
substituted inhibitors describes in both cases the potential to impede tRNA binding to 
TGT.  Thus, the Kic values for both types of inhibitors are directly comparable. 
1
v0
Km
Vmax
1+
1
[S]
1
Vmax
( ][= · [I]Kic) · +
(4)
 
The procedure to determine the inhibition constants follows the protocol developed 
by Grädler et al. (2001)3, however, with minor modifications. As limiting substrate 
now tRNATyr is used and for the calculation of the inhibition constants the Km value of 
tRNATyr in the presence of Tween 20 is applied (Tab. 3.1). 
A detailed discussion of the newly determined inhibition constants of Q1, Q2, Q5 and 
Q13 will be presented in chapter 3.2.3. 
(2)
 
 
 
(3)
(4) 
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3.1.5 SPR-based binding assay 
 
The tritium-labelling assay follows a sophisticated and time-consuming procedure. 
The number of compounds for which inhibition constants can be determined is limited 
to approximately two per day. Furthermore, the amounts of consumed material and 
its disposal (radioactive waste) makes the procedure quite expensive. Therefore, it is 
an important goal to search for alternative binding assays. Initial attempts to establish 
a fluorescence based assay were not successful [Brenk, PhD Thesis, 2003]52.  
Another alternative is the development of a surface plasmon resonance (SPR)-based 
binding assay [Brenk, PhD Thesis, 2003]52. The surface plasmon resonance 
spectroscopy allows to follow the interactions of molecules. One of the interaction 
partners is immobilized on a chip with a gold surface. Interactions of the mobile 
partner with the immobilized partner change the refraction index of total refraction in 
the solution next to of the gold surface. This change can be detected and used for 
the calculation of binding constants [Rich & Myszka, 2000]83.  
 
Fig 3.4  a)  SPR-based assay design using TGT and streptavidin (S);  b)  chemical structure 
of the linker L1;  c)  results from an SPR-based binding experiment using linker G1.  
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To adjust this method for TGT, an assay system was developed (Fig. 3.4a). The 
selected interaction partners for TGT is streptavidin. This protein is a strong binder of 
biotin and usually forms homodimers. To enable binding of TGT to streptavidin a set 
of spacer molecules was synthesized by C. Herforth (group of Prof. Link, University 
of Greifswald). The terminus of the spacer molecule G1, labelled by a guanosine 
moiety (‘G’ for guanosine), is suited to bind to TGT. The other end bears a biotin 
moiety, suited to bind to streptavidin (Fig. 3.4b). The spacers bridging between both 
ends had a length that should allow binding to both active sites. In an initial test using 
the tritium-labelling assay G1 was shown to bind to TGT.  
The assay procedure was designed as following (Fig. 3.4c). In a first step, 
streptavidin is immobilized on a biotinylated gold surface. In a second step, the linker 
is added. With its biotinylated end it binds to the remaining free binding pocket of 
streptavidin, then TGT is added. Due to the binding of TGT to the guanosine 
terminus of the linker, the refraction of the gold surface is altered, which can be 
monitored. In the presence of inhibitor less TGT should be available for binding to 
G1, thus a smaller change of refraction should be monitored. Unfortunately, in initial 
attempts no binding of TGT to the linker could be observed [Brenk, PhD Thesis, 
2003]52.   
 
In collaboration with M. Hartmann (group of Prof. M. Keusgen, University of Marburg) 
the experiment with G1, the compound with the longest available spacer, was 
repeated (chapter 5.4). In these experiments binding of 10pg TGT / mm2 to the gold 
surface could be monitored. This finding demonstrates, that this assay is principally 
suited to replace the radioactive assay. However, one major problem remains. The 
SPR-assay is only suitable for aqueous solutions and does not tolerate DMSO. Due 
to the low solubility of many of the present TGT inhibitors, DMSO has to be added to 
the assay solutions. Thus, before inhibition can be recorded either DMSO has to be 
substituted or more soluble inhibitors have to be developed. Nevertheless, this 
technique provides a promising starting point for a new assay setup. 
 
 
 
 
3.2    Revalidation of structure – affinity data 
____________________________________________________________________                      
75
3.2    Revalidation of structure – affinity data 
 
Due to the necessary modifications concerning the assay protocol, inhibition 
constants for already crystallized and characterized compounds had to be re-
determined and their structure – activity relationship had to be revised. Competitive 
and uncompetitive contributions towards inhibition with respect to tRNA binding have 
to be considered separately (see chapter 3.1 and 5.3.1 - 5.3.4). The previously 
published values refer to competitive inhibition with respect to guanine binding. 
Therefore, they are not comparable to the values resulting from the modified method. 
Due to the elaborate assay procedure it was not yet feasible to redetermine inhibition 
constants for all previously reported compounds. Although the previously determined 
values are not discriminative with respect to the inhibition mode, they roughly reflect 
the trends in the binding properties correctly. In the following tables, values referring 
to the former method are marked with a star (*), values referring to the modified 
method are given in bold. 
In the first section of this chapter, binding competent conformations of the TGT 
binding pocket will be systematized. Due to structural adaptations of the binding 
pocket upon inhibitor binding, identified in previous studies, four relevant 
conformations have to be considered (chapter 3.2.1). A quinazolinone based inhibitor 
series, developed in a previous study, served as a starting point for the development 
of new TGT inhibitor series (chapter 3.3). Accordingly, reevaluation of inhibition 
constants and structure – activity relationship of virtually all compounds of this series 
is relevant for further design approaches (chapter 3.2.3). Of other series only 
selected representatives were tested (chapter 3.2.2). 
 
3.2.1 TGT binding pocket conformations 
 
The TGT binding pocket performs some pronounced adaptations upon substrate or 
inhibitor binding. Deviating binding pocket geometries are relevant for different 
inhibitor classes. The combinations of two adaptive sites result in four binding pocket 
geometries relevant for inhibitor binding which are systematically presented in Figure 
3.5. These conformations have been observed in crystal structures of pyridazindione- 
and quinazolinone-based inhibitor classes in complex with TGT [Grädler et al., 2001; 
Brenk et al., 2003; Brenk et al., 2004; Meyer et al., 2004]1-3, 66. The first adaptation 
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results from the Leu231/Ala232 peptide switch, which has already been described in 
chapter 2.2. Either a carbonyl donor or an amide accepter functionality is exposed 
towards the binding pocket and modifies the size of the pocket. The second 
adaptation refers to Asp102. In uncomplexed structures, this residue points out of the 
binding pocket and is involved in an H-bonding network with Asn70 and Thr47. Upon 
substrate binding of e.g. preQ1 the side chain of Asp102 rotates into the binding 
pocket and forms two hydrogen bond with the substrate. As a consequence, the size 
of the guanine recognition pocket is significantly decreased, distinct active site water 
molecules are expelled and the properties exposed to the binding site are 
fundamentally altered. Furthermore, the rotational movement of Asp102 provokes a 
reorientation / disordering of the side chains of Asn70 and Thr47 [Brenk et al., 2003; 
Brenk et al., 2004]1, 64.  
 
 
Fig. 3.5   Binding pockets of TGT relevant for inhibitor binding differ in the Leu231/Ala232 
peptide switch and in the orientation of Asp102 (in/out) 
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3.2.2 Revalidation relevant compound classes 
 
3.2.2.1 Pyridazindione-based inhibitor series 
 
In the first rational design approach performed with Z. mobilis TGT, the 
pyridazindione H1 (‘H’ for hydrazide) has been discovered as a promising starting 
point for the development of TGT inhibitors [Grädler et al., 2001]3. This compound 
showed an inhibition constant of 8.3 µM, following the former assay, and crystal 
structure analysis in complex with TGT was successful (Fig. 3.5a). Due to its lead-like 
scaffold the structure was used for further design. Modifications resulted in 
compound H2 and H3 with similar binding properties as H1 (Tab. 3.2).  
All compounds bind to the Leu231 carbonyl exposing / Asp102out conformation with 
the waters W4 and W5 present in the binding pocket (Fig. 3.5a). Attempts, to address 
the catalytic nucleophile Asp280 by substituting the scaffold H1 had only limited 
success. Crystal structures of H4 and H5 in complex with TGT revealed that the 
triazole-based substituents were not well oriented in this pocket. Both compounds 
were weaker binders of TGT [Grädler et al., 2001]3. 
Searches for alternative pyridazindione-type leads in the NNC-database revealed H6 
and H7 as the most promising hits [Brenk et al., 2003]2. With a inhibition constant of 
83µM, following the former assay, H6 was a ten-fold weaker binder than H1 (Tab. 
3.2). Nevertheless, a well defined crystal structure in complex with TGT could be 
obtained of compound H6 [Brenk et al., 2003]2. Surprisingly, it shows a modified 
binding mode compared to H1. The binding pocket adopts the Ala232 amide 
exposing / Asp102out conformation and an interstitial water molecule (W1) is 
bridging towards Ala 232 (Fig. 3.5b). This crystal structure was very important for the 
investigation of the base exchange mechanism and substrate promiscuity (chapters 
2.1 and 2.2). Of H7 no crystal structure in complex with TGT could be obtained, 
probably due to the low solubility of the compound. Nevertheless, H7 was used as 
lead for a structure-based design approach [Brenk et al., 2003]84. Modifications of the 
scaffold resulted in H8 and H9 with similar or slightly improved affinity. Substitution of 
H8 resulted in H10, but no stronger binding was observed. Due to the low solubility in 
water, of H8 – H10 no crystal structures in complex with TGT are available. 
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Tab. 3.2 Pyridazindione-based inhibitors  
___________________________________________________________________ 
 
H10
H9
H8
H7
H6
9.4 ± 0.1*
0.7 ± 0.1*
5.6 ± 0.4*
5.0 ± 1.2*
62 ± 40 
83 ± 18*
---1.4Å
unpub.
(hd04)
38 ± 1*H5
---2.1Å
unpub.
(hd03)
54 ± 14*H4
---1.95Å
unpub.
(ug01)
0.3 ± 0.1*H3
unpub.
(ln01)
1.95Å
1F3E
73 ± 13 
0.3 ± 0.1*
H2
2.1Å
1N2V
1.95Å
1ENU
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8.3 ± 0.4*
H1
NH2
O
O
NH
NH
NH2
O
O
NH
NH
NH2
NH
NH
O
O
NH2
N
N
NH
NH
NH2
O
NH
OS
N
N
NH
NH
NH2
O
NH
OS
NH2
NH
NH
O
O
N
N
H
S
N
H
NH
NH
O
OO
N
N
NH
NH
O
O
N
H
NH
NH
O
OO
OH
N
H
NH
NH
O
OO
O
NH
 
_______ ____________________________________________________________ 
  Kic in [µM] with average error;    (*): former assay;     bold: modified assay;       
 crystal structures: PDB-code and maximum resolution 
 
Inhibition constants for H1, H2 and H6 were revalidated following the new assay 
procedure. Trapping experiments revealed that uncompetitive inhibition (stabilization 
of the covalent TGT-tRNA complex) is not relevant for this compound class, although 
similar molecular dimensions as preQ1 are given. This may result from the fact that in 
the tRNA-bound complex Asp102 is rotated into the active site (Fig. 3.1b). The 
pyridazindiones, however, require Asp102 to point out of the binding pocket (Fig. 
3.5b/d). The redetermination of competitive inhibition constants revealed that the 
pyridazindiones were overestimated in their binding properties by the previously used 
assay. The affinity differences, observed for H1 and H6, resulting from the 
Leu231/Ala232 peptide switch could not be confirmed. Instead, the new data 
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suggests that the orientation of the Leu231/Ala232 peptide switch has only minor 
influence on binding affinity.  
3.2.2.2 Pteridines and virtual screening hits 
 
A virtual screening campaign was performed on Z. mobilis TGT based on the crystal 
structure of TGT⋅H6 and TGT⋅H1 to create a composite pharmacophore hypothesis 
[Brenk et al., 2003]2. It included the binding pocket information for the Leu231/Ala232 
peptide switch in both orientations. Nine compounds were finally selected and tested 
for TGT inhibition (Tab.3.3). Pteridine-based ligands were retrieved which showed 
micromolar inhibition (Tab. 2.4; P1 - P3; ‘P’ for pteridine). Further groups of 
compounds had a guanine like scaffold (S1 – S3 ; ‘S’ for screening) or only low 
similarity to the natural substrates (S4; S5). They all were significantly weaker 
binders compared to the pteridines. For all compounds no crystal structure in 
complex with TGT could be obtained, most probably due to their low solubility. 
Pteridine P1 was used as scaffold for a structure-based design approach [Brenk et 
al., 2003]84. First P4 was synthesized and tested. Although a slight affinity decrease 
was observed, this compound provided a starting point for further substitutions in 
position 7 to address the hydrophobic ribose 34 binding pocket formed by Val45 and 
Leu68. Of all tested compounds P5, substituted with a hydrophobic thiophene 
substituent showed the best affinity. Also for these compounds crystal structure 
analysis in complex with TGT was not successful. 
 
Due to the structural similarity of P1 with guanine, this compound was tested for non-
competitive inhibition. In a trapping experiment P1 was identified to stabilize the 
covalent TGT-tRNA intermediate. With an uncompetitive inhibition constant of 0.7 µM 
is one of the most potent uncompetitive inhibitors known to date. The competitive 
inhibition constant of 2.2 µM indicates that a guanine-type scaffold structure is more 
favourable for binding than the pyridazindione scaffold. Compared to the 
pyridazindione scaffold H1 a gain of affinity by a factor of 40 with respect to the 
competitive inhibition constant is observed for P1. For compound S1 the trapping 
experiment revealed that uncompetitive inhibition is not relevant. With respect to 
competitive inhibition (51 µM) this guanine derivative experiences a significant loss in 
affinity compared to P1. 
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Tab. 3.3 Pteridine-based inhibitors and virtual screening hits 
___________________________________________________________________ 
 
S5
S4
S3
S2
S1
72 ± 5*
156 ± 36*
8.1 ± 1.0*
37 ± 7*
Kic: 51 ± 13
2.7 ± 0.3*
0.45 ± 0.05*P5
5.6 ± 1.7*P4
3.8 ± 0.1*P3
0.25 ± 0.1*P2
Kic: 2.2 ± 0.6
Kiu: 0.7 ± 0.2
0.6 ± 0.2*
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3.2.3 Revalidation of quinazolinones 
3.2.3.1 Development of the quinazolinone-based inhibitor series 
 
The most potent TGT inhibitors were derived from the class of quinazolinones (3H-
chinazolin-4-on). This class was designed in a collaborative project with E. Meyer 
(group of Prof. F. Diederich, ETH Zürich). The compounds were synthesized in 
Zürich, structural and initial kinetic analysis were performed in Marburg by R. Brenk 
(group of Prof. G. Klebe, University of Marburg). 
Quinazolinones are characterized by inhibition constants in the lower micromolar 
range and suited for crystal structure analysis in complex with TGT [Meyer et al., 
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2002; Brenk et al., 2004, Meyer et al., 2004]1, 66, 85. The lead structure Q1 was 
developed via the combination of structural elements of H1 and preQ1 (Tab. 3.4). 
With an inhibition constant of 0.35 µM, following the former assay, Q1 appeared as a 
potent inhibitor. Crystal structure analysis of TGT⋅Q1 revealed a binding mode similar 
to TGT⋅H1 (Fig. 3.5a/c). However, one major structural difference could be observed. 
Asp102 is rotated into the binding pocket and engages in a bifurcated hydrogen bond 
to Q1. This binding mode resembles that of preQ1. Upon rotation of Asp102 the water 
molecules W4 and W5 are expelled from the binding site. 
Q2 lacks the 6-amino group of Q1. It was synthesized to probe for the relevance of 
the exocyclic amino group for binding [Meyer et al., 2004]66. With an inhibition 
constant of 20 - 50 nM, following the previous assay, it was a surprisingly tight 
binder, although in structural terms this could not be explained. The crystal structure 
of TGT⋅Q2 revealed a deviating binding mode compared to Q1 (Fig. 3.5d). This 
compound binds to the peptide switch with the amide oriented to the binding pocket. 
In contrast to the crystal structure of TGT⋅H6 the interstitial water molecule W1 is not 
found in this structure. 
Compounds Q1 and Q2 were used as starting points to further explore the binding 
site properties and to develop more potent inhibitors [Meyer et al., 2002; Brenk et al., 
2004, Meyer et al., 2004]1, 66, 85. Decorations at position 8 were intended to address 
the hydrophobic pocket formed by Val45 and Leu68. Q3 and Q4 served as starting 
points for a series of compounds modified in this position (Tab. 3.4). Repulsive 
interactions of the 8-methyl group of Q4 with Asp102 were identified in the TGT⋅Q4 
crystal structure. With an inhibition constant of 7µM, following the previous assay, Q4 
exhibited a significant loss of affinity [Meyer et al., 2004]66.  
Further substituted compounds in position 8 can be classified in two series with 
respect to the spacer and side chain properties. In the first series compounds with 
different spacers have been synthesized. Ethyl, sulfanylmethyl and phenoxymethyl 
spacers have been tested to link the scaffold with a phenyl substituent (Tab. 3.5). 
The second series is based on 6-amino-quinazolinone with a sulfanylmethyl spacer. 
In this series side chains with aliphatic, aromatic and polar substituents have been 
investigated (Tab. 3.6).  
Modifications at position 6 of the quinazolinone scaffold were synthesized to study 
the relevance of the peptide switch for inhibitor binding (Tab. 3.7). For synthesis 
quinazolinone with a phenylsulfanylmethyl substituent was used as core fragment. 
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TGT was identified to accept a broad variety of functionalities in this position (-CN, -
NH2, -OH, -H, -Br, CH2NH2). 
Crystal structure analyses of substituted inhibitors in complex with TGT was 
successful only in case of Q12, Q13, Q14 and Q15 as a result of enhanced solubility 
[Brenk et al., 2004]1. Although the quinazolinone scaffold is well defined in the 
binding pocket in all structures, the ligand side chains are not properly ordered. While 
for the spacer split conformations could be observed in some cases, additional side 
chains are disordered in all cases (Fig. 3.6). 
To estimate the relevance of uncompetitve inhibition for small sized inhibitors and the 
impact of ther detergent Tween 20 for substituted inhibitors, the revalidation of most 
compounds appeared essential. The revalidated affinity data was published by us in 
Meyer et al. (2006)65. 
 
3.2.3.2 Non-competitive inhibition by small-sized quinazolinones 
 
Ligands Q1 and Q2 were identified by the trapping experiment as uncompetitive 
inhibitors (see chapter 3.1.3). The Kiu constants indicate decreasing power to 
stabilize the covalent complex from Q1 (0.6 µM) to Q2 (1.7 µM) (Tab. 3.4). This 
descending order is also reflected by the intensities of the bands at 70 kDa in the 
SDS-PAGE of the trapping experiment (Fig. 3.2). Facing the competitive inhibition 
constants (Kic), Q2 (2.1 µM) shows a similar binding potency compared to Q1 (1.5 
µM). From these findings it can be concluded that the previously reported, very low 
inhibition constants of Q1 (350 nM) and Q2 (20 - 50 nM), [Meyer et al. 2004], resulted 
from neglecting the uncompetitive inhibition contribution in the former assay.  
Q1 and Q2 exhibit a similar uncompetitive inhibition potency as P1   (Kiu: 0.7 µM; 
Tab. 3.3). Obviously, this results from their similar chemical structures allowing to 
stabilize the covalent TGT-tRNA intermediate state. Also the competitive inhibition 
constants for P1, Q1 and Q2 are in a similar range. Compared to the pyridazindiones 
H1 and H6 (Kic: 60 - 80 µM) they gain affinity by a factor of 40 - 60 (Fig. 3.2). The 
comparison of the respective crystal structures in Figure 3.5 indicates that a guanine-
type scaffold structure is more favourable for binding by allowing Asp102 to rotate 
into the binding pocket and providing a better binding geometry for Asp156 .  
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To evaluate the impact of 8-substitution at the quinazolinone scaffold, Q4 was 
reevaluated as well (Tab. 3.4). It also shows non-competitive inhibition, but the 
competitive contribution dominates (Kic = 3.7 µM vs. Kiu = 19.1 µM). Consistently, the 
70 kDa covalent bands in the respective trapping experiment are less pronounced 
than for Q2 (data not shown). In structural terms this observation can be explained by 
spatial conflicts with the attached methyl group in Q4 most likely interfering with the 
ribose ring 34 of the covalently bound tRNA (c.f. Fig. 3.1b). This effect is even more 
pronounced for inhibitors bearing larger side chains at this position, which was 
confirmed by trapping experiments (Fig. 3.2). Therefore, the impact of uncompetitive 
inhibition is further reduced and can be neglected in the assay determination 
procedure (for more details see chapter 3.3.2.1). 
 
 Tab. 3.4  Competitive and uncompetitive inhibition constants of small-sized inhibitors 
___________________________________________________________________ 
 
Q4
Q2
Kic:   3.7 ± 0.9
Kiu: 19.1 ± 4.8
7.0 ± 1.8*
Kic: 2.1 ± 0.5
Kiu: 1.7 ± 0.4
0.02-0.05*
9.1 ± 1.0*Q3
Kic: 1.5 ± 0.4
Kiu: 0.6 ± 0.2
0.35 ± 0.12*
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 Kic in [µM] with average error;    (*): previous assay;     bold: modified assay 
3.2.3.3 Revalidation of substituted quinazolinones 
 
All substituted quinazolinones were identified as primarily competitive inhibitors via 
trapping experiments. The revalidation of inhibition constants revealed that they were 
modulated in a non-linear fashion, most probably due to contributions of non-specific 
inhibition resulting from low solubility [Meyer et al., 2006]65. In consequence, the 
previously made assumptions about structure – activity relationship had to be revised 
and corrected also for substituted inhibitor series [Brenk et al., 2004; Meyer et al., 
2004; Meyer et al., 2002]1, 66, 85. 
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Especially the previously reported large difference in binding affinity between S-, O- 
and C-atoms in the linker, that prompted to postulate a sulphur effect, is no longer 
evident [Meyer et al., 2002]85. Instead Q7, the compound with an ethylene linker, 
turned out to be the most potent inhibitor of this series, however with only a slight 
affinity advantage (Tab. 3.5).  
 
Tab. 3.5 Revalidation of 6-aminoquinazolinones – series with different spacers 
___________________________________________________________________ 
 
8.7 ± 3.0
4.6 ± 1.4*
5.7 ± 1.4
5.6 ± 0.4 *
Q7
Q9
Q6 2.6 ± 0.9
3.6 ± 1.2*
5.1 ± 1.3
0.25 ± 0.05*
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 Kic in [µM] with average error;    (*): previous assay;     bold: modified assay 
 
 
Additionally, the revalidation showed that compounds with substituents other than 
unsubstituted phenyl rings experience reduced affinity (Fig. 3.6). Whereas in the 
previous assay no preference for aromatic, aliphatic and polar substituents could be 
identified, the redetermined values indicates a preference for the phenyl-substituted 
compounds. Compared to Q5, aliphatic substituents (Q12) and polar substituents 
(Q13, Q14) loose affinity by factors of four to nine. But also further substitution of the 
phenyl ring of Q5 resulted in significantly weaker binding (Q10). 
 
 
3.2    Revalidation of structure – affinity data 
____________________________________________________________________                      
85
Tab. 3.6 Revalidation of series with aromatic, aliphatic and polar side chains 
___________________________________________________________________ 
 
14 ± 4
7.7 ± 1.6*
5.4 ± 0.6 *
Q14
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Q12
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22 ± 6
3.5 ± 0.9*
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With respect to modifications in position 6 the enzyme accepts a diverse set of 
functionalities without showing dramatic changes in binding (Tab. 3.7). The structural 
basis for this promiscuity, associated with the Leu231/Ala232 peptide switch, has 
already been discussed in detail in chapter 2.2 and supports the results form the 
pyridazindione-based inhibitor series (chapter 3.2.2). The only exception in the 
quinazolinone series is compound Q15 with a four-fold affinity loss compared to Q5. 
However, due to the enhanced solubility, most likely resulting from the charged 
amino-methyl group, crystal structure analysis of the compound in complex with TGT 
could be successfully performed [Brenk et al., 2004]1. It indicates repulsive van der 
Waals contacts of the 6-methyl group with the carbonyl group of Leu231 to be 
responsible for the affinity loss (Fig. 3.6) .  
 
 
 
  3.2    Revalidation of structure – affinity data 
____________________________________________________________________ 
86 
Tab. 3.7 Quinazolinones – modifications in position 6 to address the peptide 
   switch by Leu231/Ala232 
___________________________________________________________________ 
 
6.4 ± 1.6
4.1 ± 1.2*
5.1 ± 1.3
0.25 ± 0.05 *
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16 ± 4
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Fig. 3.6   Crystal structure of Q15 
in complex with TGT contoured at 
1.0σ in the 2 |Fo| - |Fc| density map 
(adapted from Brenk et al. (2004)1 
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3.3    Quinazolinone-based inhibitors 
 
The revalidation of structure – affinity data for a quinazolinone-based inhibitors 
series, as a consequence of the modified assay, was presented in chapter 3.2.3. 
Based on the quinazolinone scaffold three series of inhibitors have been developed 
and tested:  
 
7-amino-quinazolinones (3.3.1),  
lin-benzoguanines (3.3.2) and  
2-amino-lin-benzoguanines (3.3.3).  
 
All compounds presented in this section were developed in cooperation with 
Emmanuel A. Meyer and Simone Hörtner (group of Prof. François Diederich, ETH 
Zürich, Switzerland). 
 
 
3.3.1 7-Amino-quinazolinones  
 
The knowledge from the revalidated quinazolinones served as a starting point for a 
new design approach. Comparison of Q1 and Q2 clearly revealed that the presence 
of the 6-amino group is not associated with a significant gain in affinity (Tab. 3.7). 
Possibly, this is due to the structural adaptability of the binding pocket exemplified by 
the Leu231/Ala232 peptide switch (chapter 2.2). Additionally, substitution of the 
quinazolinone scaffold in position 8 clearly resulted in an affinity loss, due to 
repulsive interactions of the substituent with Asp102 [Meyer et al., 2004]66. To 
circumvent direct repulsion, a set of compounds was developed based on the 
quinazolinone scaffold Q2, substituted in position 7 (Fig. 3.7). An amine function was 
thought to serve as anchor fragment to address the hydrophobic ribose 34 pocket 
formed by Val45 and Leu68, avoiding the repulsive interactions observed for 
substitution in position 8. This compound series was synthesized by Simone Hörtner 
(group of Prof. F. Diederich, ETH Zürich). 
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Fig. 3.7   Design strategy and inhibition constants (Kic) for 7-substituted quinazolinones 
 
 
All newly designed compounds Q19 - Q22 were tested for uncompetitive inhibition in 
trapping experiments. No stabilization of the covalent complex could be observed. 
Thus, this series represents a set of predominantly competitive inhibitors.  
Substitution in 7-position seems to interfere significantly with the covalently bound 
ribose 34 in the TGT-tRNA complex, impeding uncompetitive inhibition. Concerning 
competitive inhibition all 7-substituted inhibitors showed significantly reduced affinity 
compared to the parent structure Q2. In case of Q19 affinity decreased by a factor of 
15, however phenyl substitution in case of Q21 could restore affinity by a factor of 4.   
Crystal structure analyses have been successfully performed with Q19 and Q21 as 
binary complexes with Z. mobilis TGT, resulting in crystals diffracting up to a 
maximum resolution of  2.0 – 2.15 Å (for methods see chapter 5.5; for 
crystallographic data see Tab. 6.2.2). 
In the crystal structure of TGT⋅Q19, the ligand is sufficiently well defined in the G34 
binding pocket (Fig. 3.8a). The most pronounced difference electron density is 
observed for the dimethylamino substituent next to Asp280, while the quinazolinone 
scaffold is less well defined. The resolution (2.15  Å) and the quality of the crystal 
structure (R-factor: 23.8 % and Rfree-factor: 35.0 %) is limited with high average B-
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values for both protein (58.4 Å2) and ligand (60.6 Å2). Such a reduced quality does 
not allow an unambiguous placement of crystal water molecules next to the binding 
pocket.  
 
 a                                                                   b 
Fig 3.8  a) Crystal structure of TGT⋅Q19 with the ligand contoured at 2.5σ in the |Fo| - |Fc| 
difference electron density map refined in the last step excluding ligand coordinates;              
b)  structural superposition of the active sites of TGT⋅Q19 and TGT⋅Q2  
 
In the crystal structure of TGT⋅Q21 only the quinazolinone scaffold is well defined in 
the difference electron density. The phenyl substituent is likely scattered over 
multiple conformations resulting in a rather diffuse difference electron density. In the 
last refinement cycle, an average B-value of 93.1 Å2 is assigned to its orientation 
presented in Figure 3.9a. Due to the higher resolution (2.0 Å) and the slightly better 
quality of the diffraction data (R-factor: 21.5 % and Rfree-factor: 30.3 %) the resulting 
average B-values for the protein (43.5 Å2) and the 7-amino-quinazolinone scaffold of 
the ligand (55.3 Å2) adopt more reasonable values compared to TGT⋅Q19. 
Additionally, it was possible to locate two crystal water molecules in the binding 
pocket, exhibiting average B-values of 45.0 Å2. The presence of these two water 
molecules adjacent to the hydrophobic ribose 34 pocket formed by Val45 and Leu68 
clearly indicates that the phenyl substituent is exposed to the solvent sticking towards 
the ribose 33 binding site. 
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Fig. 3.9  a) Crystal structure of TGT⋅Q21 with the ligand contoured at 2.0 σ in the |Fo| - |Fc| 
difference electron density map;  b) structural similarity of the quinazolinone inhibitor Q21 
and the pteridine inhibitor P5 (* Ki referring to former assay); c) structural superposition of the 
active sites of TGT⋅Q19 and TGT⋅Q1;  d) structural superposition of the active sites of 
TGT⋅Q19 and TGT⋅Q13 
 
The comparison of the binding mode of Q19 with the binding mode of Q2 reveals 
almost identical orientations for the ligands and the active site residues (Fig. 3.8b). 
Both compounds are bound to a protein conformer with the Leu231/Ala232 peptide 
switch in its amide exposing geometry. Thus, from the TGT⋅Q19 structure it is difficult 
to extract obvious reasons for the observed affinity loss.  
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The comparison of TGT⋅Q21 with the high resolution structure of TGT⋅Q1 (1.2 Å 
maximum resolution), however, provides an explanation for the affinity loss of the 7-
substituted quinazolinones (Fig 3.9c). The obvious difference in TGT⋅Q1 is that the 
Leu231/Ala232 peptide switch is present in the carbonyl exposing conformation. The 
important difference, however, seems that binding of Q21 expels a cluster of water 
molecules mediating interactions between Asp102 and Asp280 from the active site. 
In TGT⋅Q1 these polarizable waters, particularly W7 and W8, are thought to buffer 
and compensate for the negative charge of the nucleophile Asp280 and Asp102 
which recognizes the substrate and catalyzes the proton abstraction. In TGT⋅Q21 W7 
is expelled from the active site as its distance to the ligand’s methyl group would only 
amount 2.6Å. In consequence, Asp280 looses its H-bonding contact to Asp102 via 
W8.  
Crystal structure analyses of TGT⋅Q2 and TGT⋅Q4 had already shown that the          
8-methyl-substituted Q4 produces unfavourable contacts to the carboxy group of 
Asp102 and additionally disrupts the water network [Meyer et al., 2004]66. Subtracting 
the uncompetitive inhibitory contributions reveals an almost two-fold affinity decrease 
of Q4 (3.7µM) compared to Q2  (2.1 µM). Therefore, it can be concluded for TGT that 
besides unfavourable ligand – protein contacts perturbation of the crystal water 
network in between Asp280 and Asp102 is detrimental to binding. Both factors have 
to be compensated by favourable contacts experienced in other regions of the 
binding pocket.  
This assumption is underlined by the superposition of TGT⋅Q21 with TGT⋅Q13 (Fig. 
3.9d). In the latter structure the imidazole substituent penetrates into the hydrophobic 
ribose 34 pocket and all crystal water molecules are expelled from this site. The 
binding mode of the most potent substituted quinazolinone Q7 (2.6 µM) should be 
similar to that of TGT⋅Q13 (34 µM), however the former exposes a phenyl substituent 
into this pocket. Unfortunately, no crystal structure of Q7 could be determined. Its 
competitive inhibition constant is similar to that of Q1. Supposedly, the free enthalpy 
price paid for the replacement of the water cluster next to Asp280 and Asp102 is 
virtually compensated by additional favourable contacts formed by the added side 
chain. Obviously, in case of Q21 replacement of the water cluster is avoided and its 
phenyl substituent orients towards the ribose 33 binding site which opens to the 
solvent. Hydrophobic stacking of the Q21 phenyl substituent with the methyl group of 
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Ala231 is thought to stabilize this orientation and explains the four-fold affinity gain 
compared to Q19. 
The binding mode observed for Q21 also provides an explanation for the surprisingly 
low binding constant of P5 (Fig. 3.9b). With 0.45 µM it is the strongest binder from 
the pteridine series, although this inhibition constant still refers to the former protocol 
(Tab. 3.3) [Brenk et al., 2003]84. Due to the low solubility of P5 no crystal structure in 
complex with TGT could be determined. P5 was designed to bind in the hydrophobic 
ribose 34 pocket, but the structural similarity of P5 and Q21 suggests alike binding 
modes. Both substituents (thiophen and phenyl ring) are expected to orient towards 
the ribose 33 binding site minimizing the interference with the water cluster.  
In summary, the design concept  to substitute the quinazolinone skeleton at position 
7 was not as successful as expected with respect to inhibitory potency. However, 
from the affinity data and the crystal structures in complex with TGT valuable 
information for further design can be extracted. Firstly, substitution in position 7 
hampers uncompetitive binding. All 7-substituted derivatives predominantly compete 
with tRNA binding. Secondly, the water network in between Asp280 and Asp102 is 
an important structural element and should only be replaced by polar interactions. 
Thirdly, addressing the ribose 33 binding pocket instead of the ribose 34 pocket 
might result in stronger binding due to favourable interactions with Ala232. 
 
3.3.2 lin-Benzoguanines 
 
The 6-amino-quinazolinone scaffold Q1 was used as a starting point for the 
development of a new class of TGT inhibitors. Extended by an imidazole moiety lin-
benzoguanine (6-aminoimidazol[4,5-g]quinazolin-8(7H)-one) L1 was developed as 
putative scaffold (Tab. 3.8). In case of the quinazolinones, the most potent binders 
were decorated with aromatic side chains (Tab. 3.5 and 3.6). Therefore, systematic 
substitutions in 3- and 4-position by aromatic substituents attempted to address the 
hydrophobic ribose 34 binding pocket formed by Val45, Leu68 and Val282 adjacent 
to the G34 binding pocket (Tab. 3.6). For the 7-amino-quinazolinones it has already 
been demonstrated, that addressing this pocket is not favourable, due to the 
perturbation of a water cluster (chapter 3.3.1). But lin-benzoguanines and 7-amino-
quinazolines were developed and analyzed at the same time. Therefore, the 
considerations concerning the water cluster are equally relevant also for the lin-
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benzoguanines. All compounds presented in Table 3.8 were synthesized by E. Meyer 
(group of Prof. F. Diederich, ETH Zürich). Lin-benzoguanines represent potent TGT 
inhibitors (chapter 3.3.2.1) and allowed successful crystal structure analyses (chapter 
3.3.2.2 – 3.3.3.5). The binding of one inhibitor significantly interferes with the integrity 
of the TGT dimer interface (chapter 3.3.2.6). The inhibitor complexed crystal 
structures gave insight into the adaptability of the binding pocket and allowed to 
investigate the structural basis of induced-fit adaptations observed upon tRNA 
binding (chapter 3.3.2.7 and 3.3.2.8).  
3.3.2.1 Inhibition constants 
All lin-benzoguanine based inhibitors were tested in trapping experiments for 
uncompetitive inhibition. Uncompetitive inhibition is only relevant for the basic 
scaffold L1 (Kiu: 7.9 µM) although this value is already significantly reduced 
compared to Q1 (Kiu: 0.6 µM) (Tab. 3.8). Obviously, the extended scaffold interferes 
to some degree with ribose 34 covalently bound in the tRNA-TGT intermediate 
complex. To assess a possible uncompetitive contribution of substituted lin-
benzoguanine inhibitors, the Kiu of L2 has been determined. It is separated from 
competitive tRNA binding by a factor of 50 (Tab. 3.8). Obviously, for substituted 
compounds uncompetitive inhibition is still possible but on a very reduced level. In 
consequence, as this contribution appears only marginal, which was also indicated 
by the trapping experiments, only Kic values were determined for the remaining 
derivatives.  
Comparison of competitive inhibition constants (Kic) for lin-benzoguanine L1 (4.1 µM) 
with respect to 6-aminoqinazolinone Q1 (1.5 µM) shows a slight decrease of 
inhibitory potency with respect to the former. Substitution of L1 in position 4 as 
realized in L2, results in a slightly improved affinity (Tab. 3.8).  With a Kic of 1.0 µM 
L2 is the most potent TGT inhibitor of this series and slightly stronger than the 
equally substituted 6-amino-quinazolinone Q7 (2.6 µM). Compound L5 lacks the 
C(6)-NH2 group compared to ligand L2. Its three-fold loss in affinity demonstrates the 
beneficial contribution of this function for binding as it mediates polar contacts to 
Asp156 and Asp102. Additional substitutions of the phenyl ring in L2 by p-Me        
(L3, 6.9 µM) or p-OMe  (L4, 3.7 µM) appears detrimental to binding.  Immediate 
attachment of the phenyl group realized in L6 results in a substantial loss in activity 
(29 µM).  Similarly, the N(3)-substituted lin-benzoguanines experience a affinity loss 
(L7, 15.4 µM; L8, 7.3 µM).  Structural evidence for these trends will be discussed in 
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the following  chapters. Details for synthesis and inhibition constants recently have 
been published by us in Meyer et al. (2006)65. 
 
Tab. 3.8  Competitive inhibition constants of lin-benzoguanine based inhibitors 
___________________________________________________________________ 
 
L46.9 ± 1.71.0 ± 0.3
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3.3.2.2 Crystallization experiments 
 
Crystallization experiments have been performed with all new inhibitors as binary 
complexes with Z. mobilis TGT. For details see chapter 5.5. The improved solubility 
of the lin-benzoguanine derivatives with respect to the previously investigated          
6-amino-quinazolinone enhanced the chances for successful soaking. For L1, L2, L3 
and L4 soaking at a pH of 5.5 resulted in crystals diffracting to a maximum 
resolutions of 1.58 – 2.1Å.  Details of the data collection and refinement statistics are 
given in Table 6.2.3. In case of L5 and L6 no bound ligand could be identified in the 
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active site after soaking. In case of L7 and L8 the substitution at N(3) reduced 
solubility. For L7, no bound ligand could be detected after soaking, for L8 the binding 
pocket was partly occupied by the ligand. Nevertheless, most likely due to reduced 
population and/or structural disorder, the diffraction data was not sufficient for 
structural refinement.  
3.3.2.3 Crystal structure of lin-benzoguanine 
 
The assumed binding mode of lin-benzoguanines could be confirmed by crystal 
structure analysis of L1 in complex with TGT at a resolution of 1.7Å. The structure 
was solved and refined by Ruth Brenk (PhD Thesis, 2003)52. L1 is well defined in the 
G34 binding pocket and in tight contact with the protein forming 7 H-bonds and 60 van 
der Waals interactions. 94 % of its solvent accessible surface is buried upon 
complexation (Fig. 3.10a and Tab. 3.9).  
 
       a                                                          b 
Fig. 3.10  a)  Crystal structure of L1 in the binding pocket of TGT determined at 1.7Å 
resolution and contoured at 2.4σ in the |Fo| - |Fc| density map refined excluding ligand 
coordinates in the last refinement cycle;  b)  binding mode of Q1 in the binding pocket of 
TGT; coloured in grey: apo conformation, coloured in yellow: inhibitor bound conformation.  
 
The observed binding mode is similar to that of the natural substrate preQ1 or the 
initial lead Q1 (Fig. 3.10b). The residual electron density of L1 is better defined 
compared to Q1. Both, L1 and the residues forming the G34 binding pocket are 
properly ordered whereas for Q1 several split side chain conformations were 
observed [Brenk et al., 2004]1. It had been concluded that Q1 occupied not all 
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binding pockets in the crystal upon soaking due to reduced ligand solubility. Thus, 
the diffraction pattern, recorded as average for the entire crystal, comprises a 
superposition of the ligand-bound and the ligand-free binding pockets. The former 
was refined to 60 % occupancy. It shows, superimposed with the unoccupied pocket, 
for Asp102, Asn70 (Gly69-His73), Leu231 and Ala232 two alternative conformations. 
This gives rise to the interpretation that upon ligand binding Asp102 has to rotate 
towards the ligand and Asn70 moves concertedly together with the Val45-His73 
backbone strand by 2Å. Furthermore, the Leu231/Ala232 peptide bond is flipped to 
expose its carbonyl oxygen to H-bond the 6-amino group of Q1. In TGT·L1 the ligand 
is fully occupied. Binding pocket residues adopt only one conformation similar to 
TGT·Q1 in the ligand-bound state. Asp102 recognizes the ligand via a double 
hydrogen bond. The movement of Asn70 significantly extends the volume of the 
adjacent hydrophobic cavity formed by Val45 and Leu68. A similar cluster of crystal 
waters, particularly W7, W8 and W9, stabilize Asp102 and Asp280 in both structures 
(Fig. 3.10a/b). 
 
Tab. 3.9  Kic values for L1-4, average B-values for scaffold and substituent, 
number of formed  H-bonds, van der Waals contacts in the binding pocket and 
percentage of buried solvent accessible surface for the ligands.  
___________________________________________________________________ 
Compound L1 L2 u a L2 d a L3 u L4 d 
(TGT1) b 
L4 d 
(TGT2) b 
Kic [µM] 4.1 1.0 6.9 3.7 
av. B-value scaffold 20.2 15.2 15.0 21.3 39.0 29.3 
av. B-value substit. – 27.8 23.1 45.6 54.0 32.9 
Nr. of H-bonds 7 7 7 7 7 7 
Nr. of v. d. Waals 
contacts 
60 96 86 92 88 102 
buried solvent 
accessible surface 
[%] 
 
94 93 93 90 95 93 
 
a:  L2 was separately calculated for u- and d-conformation 
b:  L4 refers to the two symmetry independent dimers in TGT1⋅L4 and TGT2⋅L4  
___________________________________________________________________ 
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3.3.2.4 Substituted lin-benzoguanine crystal structures 
 
In consequence, further design concentrated on filling the enlarged hydrophobic 
cavity, simultaneously expelling the water cluster. Crystal structure analyses of 
TGT·L2 and TGT·L3 showed that this goal has been successfully achieved and the 
aromatic substituents occupy the cavity (Fig. 3.11a/c). In both structures, the basic 
lin-benzoguanine scaffold is located equally as in TGT⋅L1. Surprisingly, no significant 
gain in affinity was observed for the substituted compounds L2 - L4 (Tab. 3.8). 
Obviously, the expected entropic gain does not pay entirely for the enthalpic price of 
the replacement of the water cluster next to Asp280 and Asp102 (Fig. 3.10a), as 
already described in detail for the 7-amino-quinazolinones in chapter 3.3.2. The 
remaining cost virtually compensates for the additional contacts formed by the 
introduced ligand side chain (60 van der Waals interactions in L1 vs. 86 – 96 in L2 
and L3 – see Tab. 3.9). All substituted derivatives cross this region of the binding 
pocket with hydrophobic, hardly polarizable portions unable to form any polar 
interactions.  
For L7 and L8 the chemical structure provides a further explanation for the slight 
affinity loss compared to L1 (Tab. 3.8). In L1 – L4 N(1) is protonated and the  
Leu231/Ala232 peptide switch is present in the conformation allowing H-bonding via 
the Leu231 carbonyl group (Fig. 3.10a/c). Substitution at N(3) of the imidazole moiety 
of L7 and L8 would require N(1) to be present in deprotonated state, at least as long 
as this position of the ligand remains uncharged and N(1) does not pick-up a proton. 
In this unprotonated state, N(1) is not expected to induce a flip of the peptide switch 
and the amide nitrogen of Ala232 would remain exposed to the binding pocket. But in 
this conformation the methyl group of Ala232 limits space at the upper rim of the 
binding pocket for ligand accommodation (see TGT⋅Q2 in Fig. 3.5). The lin-
benzoguanine scaffold, however, requires extended volume in this region compared 
to Q2, thus proper hosting of L7 and L8 appears sterically unfavourable.  
To obtain further evidence for these assumptions, L8 was placed to the difference 
electron density of the partly occupied binding pocket of TGT⋅L8 and minimized in 
this orientation using MOLOC to test whether the assumed orientation could be 
correct. Both scaffold orientations are virtually identical (Fig. 3.10e). The 
superposition of TGT⋅L8 with the binding mode of TGT⋅L2 supports the assumptions 
made above. As a result of the Leu231/Ala232 peptide switch present in the NH-
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exposing orientation, the L8 scaffold is shifted and rotated  inside the binding pocket 
compared to L2 (Fig. 3.10f). 
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Fig. 3.11  a)  Crystal structure of TGT⋅L2 in the binding pocket of TGT contoured at 2.4σ in 
the |Fo| - |Fc| density map. The phenyl substituent adopts two conformations (grey=d, 
yellow=u) paralleled by two conformations for N70;  b)  electron density of the TGT⋅L2 N70 
loop contoured at 1.0σ in the 2 |Fo| - |Fc| density map. Associated with the split 
conformations of L2 the residues G69-H73 adopt two arrangements; c) crystal structure of 
TGT⋅L3 contoured at 2.4σ in the |Fo| - |Fc| density map. The phenyl substituent was only 
refined in up-conformation (yellow) although the binding pocket conformation also suggests 
presence of the down-conformation (grey);  d) electron density of the TGT⋅L3 N70 loop 
contoured at 1.0σ in the 2|Fo| - |Fc| density map. Residues G69–H73 adopt two almost 
equally distributed conformations;  e) structural superposition of the assumed binding mode 
of TGT⋅L8 indicated by the partly occupied binding pocket (grey) and minimization with 
MOLOC (yellow);  f)  structural superposition of the assumed binding mode of TGT⋅L8 and 
the crystal structure of TGT⋅L2  
 
3.3.2.5 Split conformations in TGT⋅L2 and TGT⋅L3 
 
Analysis of TGT⋅L2 and TGT⋅L3 reveals an unexpected conformational splitting for 
both, ligand and active site residues. Both structures were resolved to a resolution of 
1.58 Å, thus allowing the interpretation of partial occupancy. In Figure 3.11a/c the 
ligand coordinates were excluded from the last refinement to test the quality of the 
model. For reasons of visualization and comparability identical σ levels were applied 
for respective figures. 
With respect to a best plane defined by the lin-benzoguanine skeleton, the               
4-substituents orient either above (up-conformation = u) or below this plane (down-
conformation = d). Both orientations are observed side-by-side in the same crystal 
suggesting virtually equivalent energy content. Both orientations have already been 
reported for substituted quinazolinone-type inhibitors (e.g. Q15 – Fig. 3.6) [Brenk et 
al., 2004]1. However, in these cases structural disorder was too pronounced and the 
difference electron densities of ligand substituents and active site residue side chains 
were not well enough defined to unambiguously relate these split conformations to 
specific structural adaptations of the binding pocket.   
In TGT⋅L2 the d-conformation is slightly higher populated (occupancy of 56 %) and a 
low average B-value of 23.1 Å2 is found for the phenyl substituent. The                     
u-conformation was refined to an occupancy of 44 % with a slightly increased 
average B-value of 27.8 Å2 (Fig. 3.11a and Tab. 3.9). While in both conformations the 
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buried solvent accessible surface (93 %) and the number of H-bonds formed with 
active site residues (7) is identical, the amount of established van der Waals contacts 
in u-conformation is lower (86 vs. 96). This may provide an explanation for the lower 
occupancy of the u-conformation and possibly indicates a slight energetic 
disadvantage. The two observed conformations of the substituents correlate with two 
different binding site conformers involving the Asn70 backbone stretch from Gly69 to 
His73. They differ by 1.4 Å with respect to averaged Cα rmsd. In Figure 3.11b the 
shift of the Gly69 – His73 backbone is visualized with the most pronounced  shift of 
1.9 Å experienced by Thr71. For the d-conformation, Asn70 (N70d) is found in 
virtually the same position as in uncomplexed TGT. In the u-conformation Asn70 
(N70u) adopts a position similar to that in TGT·L1 and its carboxyamine group 
performs a parallel stacking with the phenyl ring of the substituent. Accordingly, both 
conformations are largely identical to either the ligand-bound or ligand-free 
conformations observed in TGT·Q1 (Fig. 3.10b). But in contrast to this structure, in 
TGT·L3 both protein conformers are accommodating the ligand.  
In the crystal structure of TGT·L3, u- and d-conformation split differently. Electron 
density suggests that the aromatic substituent favours u-conformation, however with 
reduced accuracy, as indicated by the rather diffuse side chain electron density (Fig. 
3.11c). With an average B-value of  45.6 Å2 the substituent exhibits a significantly 
higher value compared to the remaining scaffold atoms (21.3 Å2). The ligand is to 90 
% buried from solvent accessibility, forming 7 H-bonds and 92 van der Waals 
contacts (Tab.3.9). Surprisingly Asn70 is found almost equally distributed in u- and d-
conformation (Fig. 3.11d). Consulting TGT⋅L1 and TGT⋅L2 it can be concluded that 
the Asn70d conformer is only observed once the lin-benzoguanine scaffold is 
substituted. Therefore, we assume that also for L3, the d-conformation of the side 
chain is present, however distributed over multiple states, thus resulting in a rather 
blurred and inaccurately defined electron density. In consequence, this conformation 
was not included in the refinement. Nevertheless, we added its possible geometry in 
Figure 3.11c/d to show its putative contacts to Asn70d. Supposedly unfavourable 
contacts experienced by the additional para-methyl group in the d-conformation with 
Asn70d result in the less-well defined binding mode. Directly facing the orientation of 
Asn70d in TGT·L2 and TGT·L3 shows that this residue is further pushed out of space 
as a consequence of accommodating the extended para-methyl-phenyl substituent in 
L3 (Fig. 3.11a/c).   
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3.3.2.6 Destabilization of crystal contacts in TGT⋅L4 
 
A different crystal structure is observed for TGT⋅L4. This results from a space group 
transition observed upon soaking. TGT crystallizes in space group C2 with one TGT 
molecule per asymmetric unit and usually this crystal symmetry is conserved upon 
soaking. In crystals with this space group the TGT molecule is supplemented by a 
symmetry equivalent in the crystal packing to form a homodimer with a buried solvent 
accessible surface of 1,667Å2, as already described by Romier et al. (1996)25. Two 
dimers finally compose the C2 unit cell symmetry related by C centering (Fig. 3.12a). 
The putative relevance of dimer formation for catalysis has already been described in 
chapter 2.3.  
 
Legend on the following page 
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Fig. 3.12  a)  TGT⋅L2 in space group C2 with one TGT molecule per asymmetric unit. Two 
TGT molecules form a symmetric dimer via a two-fold axis. In the unit cell two identical 
dimers are present symmetry related by C centering;  b) In TGT⋅L4 C centering degenerates 
upon ligand soaking, reducing crystal symmetry to the space group P2. In consequence, two 
independent TGT dimers are found in the unit cell. In TGT2 helix α1 and loop β1-α1, involved 
in dimer interface formation, are disordered. In TGT1 helix α1 and the dimer interface are 
ordered, similarly to the dimers in C2;  c) The TGT1⋅L4 binding pocket is structurally similar to 
C2 complexes. L4 is contoured at 2.4σ in the |Fo| - |Fc| density map. W3 is found in an equal 
position to N70 as in TGT⋅L1;  d) The TGT2⋅L4 binding pocket (dimer with modified interface). 
L4 is contoured at 2.4σ in the |Fo| - |Fc| density map. Due to the disordered helix α1 V45-
T47, L68-N70 and Q107 adopt conformations that significantly extend the binding pocket 
size;  e)  Binding pocket and dimer interface of TGT1⋅L4. Helix α1 and loop β1α1 are fully 
ordered;  f)  Binding pocket and dimer interface of TGT2⋅L4. Helix α1 and loop β1α1 are 
disordered and in consequence, L4 penetrates deeper into the pocket and becomes properly 
ordered.   
 
Surprisingly, TGT⋅L4 displays two molecules, TGT1 and TGT2, per asymmetric unit in 
space group P2 (Fig. 3.12b). Binding of L4 interferes with dimer formation at least in 
one of the two dimers present in the C2 unit cell, thus reducing crystal symmetry by 
loss of the C centering. The cell dimensions in P2 remain virtually identical as in C2 
(cell parameters are given in Tab. 6.2.3). This provides an explanation for the 
surprising fact that the crystal did not crack upon soaking. In TGT2⋅L4 ligand binding 
extensively modifies the binding pocket as well as the dimer interface. Interestingly 
enough in TGT1⋅L4 neither the active site nor the interface are affected by ligand 
binding. Instead, they show a very similar geometry to all previously determined 
structures (e.g. TGT·L2 and TGT·L3) and will be discussed with respect to these, 
first. No split conformations are observed in TGT1⋅L4 as detected for L2 and L3. Only 
the d-conformation is present (Fig. 3.12c). The electron density of the phenyl-
methoxy substituent is defined with only limited accuracy and the average B-value of 
54.0 Å2 for the substituent is significantly higher than that of the remaining scaffold 
(39.0 Å2). Nevertheless, the ligand is buried to 95 % from solvent access and forms 7 
H-bonds and 88 van der Waals contacts with the protein (Tab. 3.9). Also Asn70 
adopts only the d-conformation and forms close contacts with the methoxy group of 
the substituent. Obviously this further size-expanded substituent (cf. L2 and L3) 
avoids accommodation in u-conformation. Thus, the substituent of L4 inverts the shift 
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of Asn70 towards u-conformation caused by the unsubstituted lin-benzoguanine 
scaffold in TGT⋅L1 (Fig. 3.10a). The position occupied by the carboxamine group of 
Asn70 in u-conformation in other structures is occupied in the present case by a 
water molecule (W3) mediating a contact towards Gln107 (Fig. 3.12c). The side 
chain of this residue is fully ordered in the present structure, unlike in TGT⋅L2 and L3 
where it adopts no uniquely defined conformation.  
The TGT2 dimer, however, exhibits one major structural distortion. Half of the loop 
β1-α1 and the whole helix α1 are not defined in the electron density (Fig. 3.12d/f). In 
TGT1 and other C2 crystallized structures Ala49, Thr50 and Lys52 residing in the β1-
α1 loop form interactions with Tyr330, His333, Leu334, Glu339 and Leu341 from the 
zinc binding-subdomain of the tightly bound dimer molecule. Especially notable is the 
charged interaction between Lys52 and Glu339 (Fig. 3.12e). Although the residues 
Ala49, Thr50 and Lys52 within loop β1-α1 are not ordered in TGT2, further 
interactions within the dimer interface maintain the structural integrity of the TGT2-
dimer arrangement (see chapter 2.3). Adjacent to Ala49-Lys52 the residues Val45-
Thr47 in loop β1-α1 are located at the outer rim of the active site, being part of the 
above discussed small hydrophobic ribose 34 binding site. In TGT1 the substituent of 
L4 is distributed over several states in the binding pocket, with high average B-values 
(scaffold: 39.0 Å2, side chain 54.0 Å2), whereas in TGT2 the ligand is well defined 
within the binding pocket (scaffold: 29.3 Å2, side chain 32.9 Å2 – see Tab. 3.9). 
Figures 3.12c/d illustrate this difference in binding accuracy. In all symmetric C2-
dimers the loop residues Val45–Thr47 stabilize the geometry of Leu68–Asn70 and 
obviously restrict the spatial extension of the binding pocket (Fig. 3.12e). In TGT2 
Val45–Thr47, the last ordered residues of loop β1-α1, point away from the binding 
pocket thus extending its size. This allows Leu68-Asn70 to shift away from the 
ligand. The Leu68 side chain rotates away from the ligand and H-bonding between 
the Asn70 and Gln107 side chain further stabilizes and extends the size of the 
binding pocket (Fig. 3.12f). As a result L4 penetrates deeper into the binding pocket 
of TGT2 than in TGT1 and adopts, most likely, a more favourable geometry than in 
the latter. This is also suggested by a increase of van der Waals contacts from 88 to 
102 (Tab. 3.9). 
From these observations it can be deduced that the binding of L4 interferes in one of 
the symmetry independent molecules with the geometry of the TGT-dimer interface. 
As both contact geometries are present side-by side in the same crystal it is possible 
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to directly compare both arrangements involving Val45-Lys52 in the β1-α1 loop. In 
TGT2 these residues adopt a geometry that allow a properly ordered geometry of L4 
in the binding pocket. Nevertheless, the extended binding pocket geometry takes 
influence on the TGT-dimer interface resulting in a structural disorder involving Ala48 
to the end of helix α1. In TGT1 this helix remains ordered and the dimer interface is 
found as in all previously determined structures, but L4 is not properly 
accommodated in the obviously too narrow binding pocket.  
To estimate whether both, dimer formation and destabilization, is a crystallographic 
artifact or whether it is of functional relevance that might be used in structure-based 
design, requires further investigations as already suggested in chapter 2.3. If 
homodimer formation turns out to be a prerequisite for catalysis in TGT, L4 provides 
an outlook to a new class of inhibitors, that interferes with TGT dimer formation. 
 
 
3.3.2.7 Induced fit adaptations and water molecules  
 
The induced-fit adaptations observed in TGT⋅L1 - L3 and TGT1⋅L4 can similarly be 
observed when TGT is bound to tRNA. Therefore, conformers of TGT observed upon 
inhibitor binding will be compared to the adaptations registered in due course of 
substrate binding. The structures of uncomplexed TGT, [Romier et al.,1996]25, and 
the one bound to a tRNA anticodon stem loop, [Xie et al., 2003)4, reveal a series of 
adaptations in the vicinity of the G34/preQ1 binding pocket (Fig. 3.13a). Asp102 
involved in H-bonding to Asn70 and Thr47 in the uncomplexed situation, rotates 
towards preQ1. Simultaneously, Asn70 and Thr47 engage in the stabilisation of the 
U35 phosphate group. During this transition Thr47 shifts by about 1.8 Å and the 
backbone strand from Gly69 to His73 is translocated by 1.0 Å  (Cα-rmsd 69 - 73). 
Additionally, the Thr47/Ala48 peptide bond is flipped. The carbonyl group of Thr47 is 
now binding to the main chain amide nitrogen of Asn70, thus stabilizing the shifted 
geometry of the Gly69-His73 backbone stretch. 
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Fig. 3.13  a)  Structural superposition of uncomplexed TGT (grey) and preQ1-tRNA-bound 
TGT (orange/red) reveals multiple conformational adaptations; b) structural superposition of 
uncomplexed TGT (grey), preQ1-bound tRNA (red), TGT⋅L2 in d-conformation (green) and 
TGT1⋅L4 (blue). L2 and L4 do not allow the shift of Q107 as in the tRNA bound state, due to 
stacking of the side chain to lin-benzoguanine. The Q107 side chain is either disordered 
(green) or W2 is not found in the binding pocket (blue); c) structural superposition of 
uncomplexed TGT (grey), preQ1-tRNA bound TGT (red) and TGT⋅L2 in u- and d-
conformation (green). Upon tRNA binding the H-bond network of D102-N70-T47 (grey) is 
disrupted. All residues are involved in substrate binding. In TGT⋅L2 N70u is similar to the 
tRNA-bound, N70d to the uncomplexed and T47 in an intermediate conformation;                  
d)  structural superposition of uncomplexed TGT (grey), preQ1-tRNA bound TGT (red) and 
TGT⋅L2 in u-conformation (green). W3 is stabilized by the amide group of Y72. In the tRNA 
bound state and in TGT⋅L2 N70 replaces W3 forming an H-bonding to the amide group of 
H73.  
 
a 
N70 T47
D102
W3 
L2u preQ1
L2d P35 
P34 
c 
Q107 
Y106
D102 
W2
ribose 34
L2u  L4
H73 
Q107
N70
T47 
Y106 
W2 
D102
preQ1 
ribose34 
b 
d 
flip
D102
W3
N70u
H73
Y72 
T71 
N70d
  3.3    Quinazolinone-based inhibitors 
____________________________________________________________________ 
106 
Tyr106, closing up the G34/preQ1 recognition pocket in the uncomplexed state 
performs a hydrophobic stacking with the ribose ring adjacent to preQ1 once tRNA is 
bound (Fig. 3.13a). In this state, the Tyr106 backbone is shifted by 1.9 Å compared 
to uncomplexed TGT. In consequence the neighbouring Gln107 side chain is no 
longer hydrogen-bonded to His73 which is located at the outer rim of the binding 
pocket. Instead Gln107 orients towards the G34/preQ1 recognition site to 
subsequently involve Asp102 in a water (W2) mediated interaction. Presumably, this 
water molecule is important in the catalytic mechanism assisting Asp102 and Gln107 
to shuffle a proton out of the binding pocket (Fig. 2.4).  
 
Inhibitor binding of TGT⋅L2, TGT⋅L3 and TGT1⋅L4 partially reflect these structural 
rearrangements, but obviously they do not proceed beyond these substrate-induced 
adaptations. The discussion will focus on Asn70/Thr47 and Tyr106/Gln107 as they 
monitor the underlying processes. The adaptations close to Asn70/Thr47 are 
associated with the rotation of Asp102 towards the base recognition site in a domino-
type rearrangement. All ligands interact with Asp102 similarly to preQ1 in its tRNA-
bound state (Fig. 3.13c). Asn70, after having lost Asp102 as binding partner, seeks 
for a new stable geometry. In the crystal structure of TGT⋅L2, the two almost equally 
populated conformations of Gly69 - His73 correspond closely (Cα-rmsd               
Gly69 - His73: ≤ 0.5Å) to the conformers found in either uncomplexed or tRNA-bound 
TGT which mutually differ by ≥ 1Å (Fig. 3.13c). In uncomplexed TGT and TGT1⋅L4 a 
water molecule (W3) is found in exactly the same position that the Asn70 side chain 
occupies in the tRNA-bound state (Fig. 3.20c/d). In uncomplexed TGT this water 
molecule is stabilized by contacts to the backbone amide of Tyr72 and the side chain 
of Asp102. In TGT1⋅L4 the latter contact is replaced by a contact to Gln107 as 
Asp102 is rotated towards the ligand. In the tRNA-bound TGT the shifted Asn70 
displaces this water and forms a backbone amide interaction to His73 (Fig. 3.13d). 
This interaction allows the Asn70 side chain to properly accommodate the binding of 
the U35 phosphate group that serves as one of the hinges controlling the rotation of 
ribose 34 (Fig. 2.3e). A similar backbone amide interaction to His73 is realized by 
Asn70u in TGT⋅L2, although here the carboxamide terminus is rotated by about 45° 
with respect to the tRNA-bound situation as the side chain stacks on top of the 
ligand’s phenyl ring (Fig. 3.13d). These findings underline the relevance of W3 in 
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stabilizing the uncomplexed binding pocket conformation and allowing by its 
substitution the modification of the binding pocket geometry. 
Also Thr47 has to reorient after losing close contact to the Asn70 side chain upon 
tRNA binding (Fig. 3.13a). In the crystal structure of TGT⋅L2, Thr47 is lacking a 
proper interaction partner (Fig. 3.13c). The residue remains rather mobile indicated 
by a poorly defined electron density and an augmented average B-value of 57.3 Å2. 
The backbone flip is observed similar as in the tRNA-bound state but no backbone 
shift can be observed. Thus, no H-bond towards the backbone of Asn70 is formed. 
Obviously this allows Asn70 to be present in two alternative conformations. However, 
within the domino-type rearrangement process the presence of a rather disordered 
residue points to the relevance of interaction partners to stabilize alternative 
geometries. 
The conformational changes observed for Tyr106/Gln107 in the inhibitor-bound 
states are less pronounced than those observed upon tRNA binding. This results 
from the fact that Tyr106 performs a hydrophobic stacking onto the lin-benzoguanine 
scaffold in inhibitor-bound states whereas it is stacking onto ribose 34 in the tRNA-
bound state (Fig. 3.13b). The latter requires a pronounced backbone shift with 
respect to the uncomplexed conformation (1.6 Å compared to uncomplexed TGT). 
The smaller shift of Tyr106 in inhibitor bound crystal structures (0.9 Å compared to 
uncomplexed TGT) results in deviating conformations of Gln107 that impede the 
water mediated contact by W2 towards Asp102 observed in the tRNA-bound state. In 
TGT⋅L2, the Gln107 side chain is not visible in the electron density but water 
molecule W2 can still be observed H-bonded to Asp102 (Fig. 3.13b – green). In 
TGT1⋅L4, the Gln107 side chain points directly towards Asp102 and no mediating 
water molecule can be detected (Fig. 3.13b – blue). Instead, H-bonding to W3 can be 
observed (Fig. 3.12c). Thus, the rotation and shift of Tyr106 out of the base 
recognition site triggers the rearrangement of Gln107 along with an appropriate 
orientation of the catalytically important water molecule W2. 
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3.3.2.8 Discussion and outlook 
 
In the presented crystal structures pronounced induced-fit adaptations could be 
observed resembling those experienced by TGT upon tRNA binding. In this context, 
the question arose whether the adaptations result as specific responses to the 
properties of each individual inhibitor or whether they point to structural adaptations 
potentially required by the protein in order to accomplish its functional task? If the 
latter assumption is correct, it can be assumed that these adaptations correspond to 
low energy transformations required for efficient functioning of the enzyme. Most of 
the studied inhibitors place their substituent in two alternative conformations into the 
hydrophobic ribose 34 binding pocket. With respect to the strand hosting Asn70 the 
protein responds differently to both placements: One geometry relates closely to the 
uncomplexed, the other to the tRNA-bound situation. Considering Tyr106/Gln107 and 
Thr47, these residues adopt conformations half-way in-between the uncomplexed 
and tRNA-bound situation. From this finding we can conclude for inhibitor binding: 
TGT is highly adaptive, however this multiplicity is obviously required to fulfill its 
functional role. A ligand to be bound selects one of the binding competent 
conformers of the protein and stabilizes this state in the complex. Very similar 
considerations have been suggested to rationalize the binding properties of different 
inhibitors to aldose reductase, [Urzhumzev et al.,1997; Howard et al., 2004; Sotriffer 
et al., 2004]86-88, or trypsin mutants [Rauh et al., 2002; Rauh et al., 2003]89, 90. 
Nevertheless, the picture might be more complicated as indicated by inhibitor L4. 
The destabilization of a whole structural element might point to adaptations beyond 
the naturally observed flexibility of the enzyme. 
A further conformational adaptation within the TGT binding pocket leads to another 
important aspect of ligand binding and catalytic activity: water molecules tightly 
associated with the binding pocket. The Leu231/Ala232 peptide flip controls 
substrate recognition and promiscuity [Stengl et al., 2005]54. Depending on the 
orientation of the peptide switch either the carbonyl- or the amide-group is exposed 
to the binding pocket.  In two uncomplexed TGT crystal structures exhibiting both 
orientations, due to deviating pH conditions used for crystallization, these functional 
groups are H-bonded to two distinct water molecules in deviating positions. Upon 
ligand binding, they either get replaced or mediate an interaction between the bound 
ligand and the exposed peptide bond functionality (W1 – Fig. 2.9a/b). The present 
study indicates further water molecules as important for the substrate or ligand 
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binding process. Water molecule W3 serves as a surrogate for an alternative protein 
side chain conformer that allows tRNA binding in the correct orientation (Fig. 3.13d). 
Water molecule W2 is only found in the active site when the substrate tRNA is 
bound, as its accommodation requires a conformational adaptation of the binding 
pocket (Fig. 3.13b). As W2 is likely to receive a proton from preQ1 during catalysis its 
presence is highly relevant for the enzymatic reaction (Fig. 2.4). In the ligand bound 
crystal structure of TGT⋅L1 two waters, W7 and W8 are bridging between Asp102 
and Asp280, the catalytic nucleophile. Attempts to replace them by hydrophobic 
ligand portions were geometrically successful, however, they did not parallel the 
expected increase in binding affinity. Despite the assumed entropic benefit for water 
release obviously the price for their replacement by a hydrophobic substituent 
appears detrimental to binding. Possibly, the waters compensate for the negative 
charge of Asp280 and should be replaced by polarizable ligand functionalities that 
are able to form polar interactions.  
In summary, these findings underline the structural and functional relevance of water 
molecules associated with the structural adaptability of the binding pocket. The 
knowledge from this inhibitor series should be considered in further design 
approaches, particularly in new attempts trying to address the hydrophobic ribose 34 
binding pocket.   
 
3.3.3 2-Amino-lin-benzoguanines 
 
Substitution of lin-benzoguanine L1 in position 2 resulted in the discovery of 2-amino-
lin-benzoguanine L10 as a potent new lead structure. The initially synthesized 
sample of L1 showed impurities due to a small amount of unexpected synthesis 
byproduct. Surprisingly, this impurity was detected by crystal structure analysis. 
Soaking of this compound sample into TGT crystals resulted in a difference electron 
density with additional density in position 2 with respect to the lin-benzoguanine 
scaffold (Tab. 3.14d). Thus, a new sample of  better purified L1 was synthesized. 
Soaking resulted in a crystal structure with a difference electron density 
corresponding to the chemical structure of L1 (Fig. 3.10a). Nevertheless, with a Ki of 
150 nM the inhibition constant for the previous impure sample was significantly lower 
than that of pure L1 ( 250 nM – values referring to the former assay setup) [Brenk, 
PhD Thesis, 2003]52. Unfortunately, the chemical structure of the byproduct could not 
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be identified from the sample, as it was present in a too small amount. However, from 
the observations it could be concluded that the 2-substituted byproduct of lin-
benzoguanine displayed a potent TGT inhibitor. Although present only in traces, it 
was capable of replacing L4 in the TGT crystals and resulted in significantly stronger 
inhibition of the base exchange reaction. 
 
Tab. 3.10 Competitive inhibition constants of 2-amino-lin-benzoguanines in 
comparison with other relevant compounds  
___________________________________________________________________ 
75 ± 15L12125 ± 50L101,000 ± 300L2
51,000 ± 13,000S1450± 50*P57,600 ± 3,700Q21
300 ± 75 L11L9 100 ± 254,100 ± 1,000
impure: 150* / pure: 250*
L1
N
NHN
H
N
O
NH2
2
4
N
NH
O
NH2N
N
H
NH2
N
NH
O
NH2N
N
H
N
H
N
NH
O
NH2N
N
H
N
H
N
NH
O
NH2N
N
H
N
NH
O
NH2N N N
N
H
NH
O
NH2
S
ClN
N
N
NH
O
NH2
S
S
N
NH
O
NH2N
N
H
Phe
 
___________________________________________________________________ 
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To test 2-substituted lin-benzoguanine compounds L9 and L10 have been 
synthesized. In further steps L10 was extended by a phenyl (L11) and a naphtyl 
(L12) moiety. All synthesis were performed by Simone Hörtner (group of Prof. F. 
Diederich, ETH Zürich). To identify the inhibition modes for the new inhibitor series, 
trapping experiments were performed. In contrast to L1, no stabilization of the 
covalent TGT-tRNA intermediate could be observed. Thus, 2-substituted lin-
benzoguanines represent competitive inhibitors of tRNA, binding to uncomplexed 
3.3    Quinazolinone-based inhibitors 
____________________________________________________________________                      
111
TGT. The competitive inhibition constant (Kic) for all compounds of the new series are 
in the nanomolar range (Tab. 3.10). Compared to the scaffold L1 (4,100 nM) the 
methyl-substituted L9 (300 nM) showed an affinity enhancement of more than a 
factor of 10. For the amino-substituted L10 (125 nM) the gain in affinity was even 
more pronounced.  Further substitution of the amino group, intending to address the 
ribose 33 binding site, resulted only in minor affinity gain (L11: 100 nM; L12: 75 nM). 
The results of the trapping experiments and affinity data for L9 and L10 were kindly 
provided by Tina Ritschel (group of Prof. Klebe, University of Marburg). 
Crystal structure analysis was successfully performed with L12 as binary complex 
with Z. mobilis TGT (chapter 5.5). Soaking resulted in crystals diffracting up to a 
maximum resolution of  1.95 Å (for crystallographic data see Fig. 6.2.4). In TGT⋅L12 
only the lin-benzoguanine scaffold is well defined (Fig. 3.14a). The scaffold forms 
seven H-bonds with residues of the binding pocket and one long H-bonding 
interaction to the carbonyl-group of Ala232 via the endocyclic 2-amino group 
(distance: 3.6 Å). The scaffold is well positioned in the binding pocket and exhibits an 
average B-value of 40.6 Å2. The average B-value of the protein is 28.2 Å2. The 
naphtyl substituent, however, is scattered over multiple conformations, sticking into 
the direction of the solvent exposed ribose 33 binding pocket. This is indicated by the 
rather diffuse difference electron density and makes it difficult to locate the 
substituent. In the last refinement step it exhibited an average B-value of 86.9 Å2 for 
the orientation shown in Figure 3.14a. Additionally, it was possible to locate crystal 
water molecules (W7 and W8) in the binding pocket (average B-value of 40.0 Å2).  
To find an explanation for the significant affinity gain, the crystal structure of TGT⋅L12 
was compared with other available TGT structures. The superposition with TGT⋅L1 
indicates similar orientations of the scaffolds (Fig. 3.14b). Also the binding pocket 
conformation is fairly identical. Similar to TGT⋅L1 the Gly69-His73 loop is shifted with 
respect to uncomplexed TGT, thus extending the size of the ribose 34 binding 
pocket. In both structures the water molecules W7 and W8 are present mediating an 
H-bonding contact between Asp280 and Asp102. In the 4-substituted lin-
benzoguanine inhibitor series the presence of these waters was identified to be 
highly relevant for binding affinity, as it might assist to compensate the charge on the 
nucleophile Asp280 (see chapter 3.3.2.4). However, in TGT⋅L12 only W7 and W8 
could be identified, most presumably resulting from the deviating orientation of the 
Asn70 side chain and the disordered naphtyl side chain of the ligand impeding proper 
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accommodation of W9 and further water molecules. Thus, the comparison of these 
two crystal structures does not provide an explicit explanation for the pronounced 
affinity gain for the 2-substituted lin-benzoguanines. 
 
 
 
 
Fig. 3.14  a) Crystal structure of TGT⋅L12 with the ligand contoured at 2.0σ in the  |Fo| - |Fc| 
difference electron density map refined in the last cycle excluding ligand coordinates to test 
the model;  b) structural superposition of the active sites of TGT⋅L1 and TGT⋅L12;                 
c)  crystal structure of TGT⋅L1 (impure sample) with the ligand contoured at 1.0σ in the         
2 |Fo| - |Fc| density map; additional difference electron density contoured at 2.5σ in the |Fo| - 
|Fc| difference electron density map indicates the presence of a small 2-substituted derivative 
of L1 in the binding pocket; d) structural superposition of the Leu231/Ala232 peptide switch 
of TGT⋅preQ1 and TGT⋅L12 indicates charge assisted binding. 
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An explanation for the affinity gain might be given by considering charge-assisted 
hydrogen bonds in case of the 2-substituted lin-benzoguanines. This is suggested 
taking possible pKa shifts of relevant functional groups into account. For preQ1 the 
positive charge on the exocyclic amino group supposedly assists binding (Fig. 
3.14d). The carbonyl group of Leu231 is stabilized in its orientation by the negatively 
charged side chain of Glu235 (chapter 2.2.1 - 2.2.2). Thus, the Leu231/Ala232 
peptide bond projects to some extend its negative charge into the binding pocket. 
The pKa value for an exocyclic amino-methyl group falls into the range of 10          
(cf. pKa of 1-amino-1-phenyl-methane: 10.5; Fig. 3.15). Thus, preQ1 is likely 
protonated under physiological pH and capable of compensating the negative charge 
of Glu235 mediated via the peptide bond. In general charge assistance is thought to 
contribute significantly to binding affinity [Böhm & Klebe, 1996]91. In contrast, for L1 
no charge assisted H-bond is expected. The pKa of the imidazole moiety in lin-
benzoguanine is 4.5 [Brenk, PhD Thesis, 2003]52. The assay, however, is applied at 
a pH of 7.3. Thus, L1 binds most likely deprotonated. Similar considerations hold for 
the anilin-type 6-amino group of  Q1 (pKa of 2-amino-naphthaline: 4.1; Fig. 3.15). 
Substitution of the lin-benzoguanine scaffold in position 2 is expected to significantly 
affect the pKa value of the imidazole moiety. In case of L9, a shift towards           
higher pKa is expected as suggested by the pKa differences of benzimidazole /                      
2-methyl-benzimidazole (5.4 vs. 6.1) or imidazole / 2-methyl-imidazole (7.0 vs. 7.8). 
The pKa value of the imidazole moiety will be further shifted by the adjacent 
negatively charged Glu235. This might result in protonation of the imidazole moiety at 
a  pH of 7.3. The resulting charge assisted H-bond could explain the ten-fold affinity 
gain going from L1 (4100 nM) to L9 (300 nM).  
For 2-amino-lin-benzoguanine an even more pronounced pKa shift can be expected, 
as indicated by the comparison of 2-amino-benzimidazole / benzimidazole (5.4 vs. 
7.5). The additional amino group generates a guanidinium functionality in the lin-
benzoguanine scaffold (pKa of guanidinium: 13.7; Fig. 3.15). Thus, 2-amino-lin-
benzoguanine should bind in its protonated form and mimic the charge assisted 
binding mode of preQ1. Compared to L9, for L10 an additional H-bond can be formed 
to the carbonyl-group of Ala232. This provides an explanation for additional, more 
than two fold affinity gain of L10 (125 nM).  
However, to test this hypothesis, determination of the exact pKa values for the 
inhibitors as well as in silico pKa calculations of the compounds in complex with TGT 
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are required. Additionally, L9 binding should be assayed at different pH conditions to 
assess a putative pH-dependence of the binding constants.  
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Fig 3.15  pKa values for nitrogen groups in relevant scaffold structures; values for fragments 
taken from [Brown et al., 1955; Albert et al., 1948; Bruice & Schmir, 1958]92-94  
 
The distinct orientation of the substituent towards the ribose 33 binding site marks 
the significant difference of this inhibitor series, resulting from the substitution of the 
lin-benzoguanine scaffold in position 2. All previously designed TGT inhibitors were 
substituted to address the hydrophobic ribose 34 binding pocket formed by Val45 
and Leu68 [Grädler et al., 2001; Brenk et al., 2003; Meyer et al., 2002]3, 84, 85.  Also 
the lin-benzoguanines, substituted at position 3 and 4 bind into this pocket (chapter 
3.3.2.4). In the present approach it was intended to direct the substituents towards 
the ribose 33 binding pocket, flanked by Ala232 and Gly261, to provide a scaffold 
that will allow further extension towards the uracil 33 binding pocket. However, 
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substitution at the 2-amino group, represented by L11 and L12, had only minor 
influence on affinity. From the TGT⋅L12 crystal structure in can be concluded that 
these substituents experience too little contact with the protein and remain solvent 
exposed. No significant contribution to binding can be expected.  
 
 
a                                                                             b 
 
Fig. 3.16  a) Structural superposition of the active sites of TGT⋅L12 and TGT⋅Q21;              
b) structural superposition of the binding modes of 4-substituted L2 and 2-substitued L12 in 
the binding pocket of TGT bound to preQ1-tRNA  
 
Compounds that might adopt binding modes similar to L12 have been identified in 
previous inhibitor series [Brenk et al., 2003, Brenk et al., 2003]2, 84. E.g. P5, S1 and 
Q21 possess substituents to be placed into the ribose 33 binding site (Tab. 3.10). For 
Q21 this binding mode was confirmed crystallographically, although unexpected, as 
the design intended to address the ribose 34 pocket (chapter 3.3.1). In TGT⋅Q21 the 
scaffold is well accommodated, whereas the phenyl substituent is not properly 
ordered. The structural superposition of TGT⋅Q21 and TGT⋅L12 suggests criteria to 
correlate affinity with structure (Fig. 3.16a). Q21 binds 100-fold weaker than L12 (75 
nM). One explanation for this drop is the missing charge assistance for Q21. The 
Leu231/Ala232 peptide switch adopts the amide exposing conformation and Glu325 
will be uncharged. Furthermore, Q21 places its N-methyl group in a region that 
interferes with the water cluster. The phenyl substituent of Q21 contributes 
significantly to binding. Compared to the unsubstituted scaffold Q19 (31,000 nM) a 
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Ala232 
Leu231 
Asn70 
Asp102 
Asp156 Gln203 
Asp280 
Gly230 
Leu68 
 
R-33  
R-34  
Ala232 
Asp267 
Lys264 
W8 
W7 
W9 
U-33 
R-35  
U-35 
L2  
L12 
  3.3    Quinazolinone-based inhibitors 
____________________________________________________________________ 
116 
four-fold stronger binding is experienced. Structurally this can be explained by 
hydrophobic stacking of the phenyl ring with the methyl group of Ala232. In TGT⋅L12 
a similar contact is given, however, it involves to some degree also the 2-amino 
group. This might explain the only marginal gain in affinity compared to the 
unsubstituted L10 (Tab. 3.10). In summary, the charge assistance and the 
unperturbed water network between Asp102 and Asp280 seem to be the key factors 
for the superior binding of L12. 
Similar arguments hold for the comparison of 2-substituted and 4-substituted lin-
benzoguanines (Fig. 3.16b). In case of the 4-substitution the water network between 
Asp280 and Asp102 is expelled from the binding pocket without providing 
appropriate structural compensation. Most presumably also charge assisted binding 
is not given for these derivatives.  
In  summary, the 2-amino-lin-benzoguanine scaffold provides a promising starting 
point for further design. However, the phenyl and naphtyl substituents should be 
replaced by better suited substituents specifically addressing the ribose 33 binding 
site and to reach out the uracil 33 binding pocket. 
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3.4    Benzimidazolin-2-one-based inhibitors 
3.4.1 Nitro-substituted virtual screening hits 
 
In a virtual screening based on Z. mobilis TGT interesting hits substituted with a nitro 
group were discovered (Tab. 3.11) [Brenk et al., 2004]1. Inhibition in the two-digit 
micromolar range made them suited to follow-up with an optimization program.  
 
Tab. 3.11 Nitro-substituted screening hits as potent TGT inhibitors 
___________________________________________________________________ 
 
S8
S7
S6
58 ± 15*
403 ± 33*
158 ± 17*
15.1 ± 0.1*N3
31 ± 5*N2
36 ± 24
27 ± 3*
N1
N
NHNH
O
NO2
NH
O
F3C
OH
N
H
NH
O
OH
NH
O
OH
O
O
N
NH
O
NO2
N
N
H
NH
O
NO2  
_______ ____________________________________________________________ 
 Kic in [µM] with average error;    (*): previous assay;     bold: modified assay;       
 
In this virtual screening scenario the positions of several crystal waters next to 
Asp102 and Asp156, observed in TGT⋅H1, were considered in a pharmacophore 
hypothesis (Fig. 3.17a). The water positions W4 and W6 were translated as acceptor 
groups into the pharmacophore, potentially interacting with Ser103 and Gly104.  
Six screening hits were selected for testing (Tab. 3.11). The most potent compounds 
exhibit nitro groups (N1 - N3). The modelled binding modes of N1 and N2 are given 
in Figure 3.17b/c. The nitro groups of both compound are assumed to form 
interactions with Ser103 and Gly104.  
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a                                               b                                            c 
Fig. 3.17 a)  Protein-based pharmacophore hypothesis considering the hydrophobic centre 
from H1 and the water molecules W4 and W6; the size of the spheres corresponds to the 
allowed matching tolerance;  b) superposition of the docking mode of N2 with H1; assumed 
H-bonds are depicted as lines; coloured isopleths indicate favourable interaction sites of 
donor groups as suggested by DrugScore;  c) docking mode of N1 oriented perpendicularly 
with respect to the principle molecular axis of N2 and H1 with rectangular orientation of the 
scaffold structure N1 compared to H1;  (figures adapted from Brenk et al., 20041). 
 
Unfortunately no crystal structure could be obtained of any of these screening hits in 
complex with TGT. Docking simulations suggested a binding mode for N1 with the 
principle molecular axis orientated perpendicular to that of H1 or N2 (Fig. 3.17b/c). 
This observation, together with the good synthetic accessibility of N1, prompted us to 
select N1 as novel lead for further optimization.  
3.4.2 N1 – scaffold evaluation 
 
N1 (5-nitro-3H-imidazo[4,5-b]-pyridin-2-(1H)one), initially determined to 27 µM  
[Brenk et al., 2004]1, showed under the modified assay conditions no uncompetitive 
inhibition (stabilization of the covalent TGT-tRNA complex). Likely this results from 
the fact that N1 blocks Asp102 from rotation into the active site, a conformational 
prerequisite for covalent tRNA binding (Fig. 3.1). This finding speaks in favour of the 
assumed binding mode of N1 (Fig. 3.17c). The competitive inhibition constant was 
determined to 36µM which agrees within the assumed error range with the former 
evaluation (Tab. 3.11). 
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Prior to modifications of N1 the suggested binding mode was revised and compared  
with the crystal structure of TGT⋅H2 to better estimate the role of water molecules 
found in the binding pocket. In TGT⋅H2 they mediate contacts between ligand and 
protein (Fig. 3.18a). W4 is hydrogen-bonded to the amide nitrogen of Ser103 and the 
ligand, W5 to the side chain of Ser103 and the ligand. A third water molecule, W6, is 
buried deeply in the G34 binding pocket stabilizing the side chain geometries of 
Asp156, Ser103 and the position of W4. The docked binding mode of N1 suggests 
that the nitro group of the ligand replaces W4 and W5. The urea-type scaffold is 
stabilized via H-bonds to Gly230, Gln203 and Asp156. W6 appears to remain in the 
binding pocket (Fig. 3.18b).  
 
     a                                                                 b 
Fig. 3.18  a) Stabilization of a cluster of crystal waters in the TGT⋅H2 binding pocket;          
b) assumed binding mode of N1 (docking and MOLOC minimization); W4 and W5 are 
thought to be replaced upon inhibitor binding. 
  
To investigate the influence of the nitro group on binding derivatives of N1 were 
synthesized by Tim Larsen (Prof. A. Link, University of Greifswald) (Tab. 3.12). 
Compound B2 (143 µM) clearly demonstrates the relevance of the nitro group for 
binding. As it was intended to replace the nitro group also by other functional groups 
the scaffold had to be modified. To simplify synthesis a phenyl ring was introduced 
resulting in B1 (5-nitro-benzimidazolin-2-one; ‘B’ for benzimidazole) exhibiting very 
similar affinity. Obviously the pyridine nitrogen is not significantly contributing to 
binding. Subsequently, the nitro-group was replaced by a cyano group  (B3) or a 
methyl group (B4). The assumed binding modes for B1-B4 (minimized with MOLOC) 
are all very similar to that of N1 (Fig. 3.19).   
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Tab. 3.12  benzimidazolin-2one-based scaffold series ( Kic in [µM]) 
___________________________________________________________________  
T4 
25 ± 10
T3 
8.0 ± 3.6
T2 
5.0 ± 1.2
T1 
12 ± 4
B4 
33 ± 10
B3 
91 ± 29
B2 
143 ± 49
B1 
40 ± 17
N1 
36 ± 24
27 ± 3 *
N
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O
N
NH NH
S
NHNH
O
NO2
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N
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___________________________________________________________________ 
  (*) inhibition constant refers to previous assay 
 
 
Fig. 3.19   Superposition of assumed binding modes of  N1, B1 – B4 and T1 - T4 (MOLOC 
minimization)   
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In a second series the urea carbonyl function of B1 was replaced by a thiourea unit 
(benzimidazolin-2-thione-based inhibitor series T1 - T4; ‘T’ for -thione). Initial 
minimizations of T1 - T4 indicated similar binding modes to B1-B4, despite of the 
deviating size and binding properties of sulphur (Fig. 3.19). Surprisingly, all thioureas 
bind significantly better than the respective oxygen analogues (Tab. 3.12). T1 (12µM) 
gains three-fold affinity compared to B1. The most pronounced difference is 
observed for the pyridine analogue T2 which departs from B2 by a factor of 30. With 
an inhibition constant of 5.0 µM it is one of the most potent inhibitor of the series.  
To verify the assumed binding modes, crystallization trials for T1, T2 and compounds 
presented in the following (B7, B15, T5, T17) were performed. Neither soaking nor 
cocrystallization was yet successful. No difference electron density in the G34 binding 
pockets of the studied crystal structures, indicating the presence of a ligand, could be 
observed. Accordingly, any further design has to be based on the assumed docking 
modes. 
3.4.3 Substituted inhibitor series 
 
To address further parts of the binding pocket and to stabilize the binding geometry 
of the novel scaffold, substituted derivatives of B1 and T1 have been synthesized. In 
a first series polar and aliphatic substituents have been attached (Tab. 3.14). In all 
cases the inhibition constants determined for the thiourea derivatives are lower than 
of the equivalent oxy analogues. All inhibition constants are similar to the parent 
structures or increased by factors of two to four. Only for T5 a significant gain in 
affinity compared to the unsubstituted scaffold could be observed. With an inhibition 
constant of 2.0µM, it is the best inhibitor of this series.  
Unfortunately, also in this case soaking into TGT crystals was not successful. The 
minimized binding mode of T5 suggests an additional H-bond to be formed by the 
acetamide substituent with the carbonyl group of  Leu231 which might contribute to 
some degree to binding (Fig. 3.20a). 
In a second series aromatic substituents have been attached to the scaffold. Using 
phenyl substituted side chains, binding affinity increases significantly (Tab. 3.13). 
B14 showed limited solubility at higher concentrations under the assay solution. Even 
presence of detergent Tween 20 could not compensate the low solubility (chapter 
3.1.1.1). B13 and T13, substituted with piperonyl moieties, are more promising. The 
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inhibition constant of B13 is similar to that of B1. T13 gains affinity by a factor of two 
(5.1 µM) compared to the scaffold T1. The assumed binding modes of the latter 
compounds indicate stacking interactions with Tyr106 (Fig. 3.20b).  
 
a                                                               b 
Fig. 3.20  a) Assumed binding mode of T5 (MOLOC minimization);  b) comparison of 
assumed binding modes of  T1, T13 and B13 (MOLOC minimization) 
 
Tab. 3.13  Aromatic derivatives of B1 and T1 ( Kic in [µM]) 
___________________________________________________________________ 
T15 
35 ± 9
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5.1 ± 3.1
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Tab. 3.14  Polar and aliphatic derivatives of B1 and T1 ( Kic in [µM]) 
___________________________________________________________________ 
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T12 
21 ± 5
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37 ± 13
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3.4.4 Sulfonamide-substituted scaffolds 
 
Another aspect of the synthesis program attempted the replacement of the nitro 
group by functional groups with tetrahedral geometry (Tab. 3.15). In particular 
substitution with a sulfonamide moiety appeared favourable. The structural 
superposition suggests the two sulfonamide oxygens in an appropriate geometry to 
replace W4 and W5. 
 
Tab. 3.15 Benzimidazolin-2-one /-thione series with trifluor and sulfonamide   
  substituted scaffold ( Kic in [µM]) 
___________________________________________________________________ 
T19 
in synthesis
T18 
71 ± 38
T17
52 ± 38
T16 
15 ± 9
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___________________________________________________________________ 
 
In case of B16 and T16 a CF3 group was attached to the scaffold. The inhibition 
constants are similar to those observed for scaffolds with a nitro group. In case of the 
sulfonamides reverse trends in affinity might favour urea-series instead of the 
thioureas. T18 is a three fold weaker binder than B18. For the corresponding pair of 
nitro derivatives the thiourea derivative is favoured (T9: 13 µM) / B9: 56 µM). Other 
pairs from both series still have to be synthesized. Possibly they will confirm the 
indicated trends.  
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3.4.5 Outlook for benzimidazolin-2-ones 
 
To confirm the assumed binding modes for the benzimidazolin-2-one inhibitor series 
crystal structure analysis is definitely required. In particular B13 / T13 might be likely 
candidates due to their good solubility and the assumed stacking interaction with 
Tyr106. Of the sulphonamide series, B18 seems to be suited best for crystallization 
trials. 
Furthermore, synthesis of other substituted derivatives appears mandatory. 
Particularly the free amines of  B5 / T5 might contribute with a charged side chain, 
similar to preQ1, to binding affinity and stabilize the urea-scaffold in the binding 
pocket.  
 
3.5    Apigenin-based inhibitors 
3.5.1 Ligand fishing 
 
In collaboration with Daniela Heller (group of Prof. R. Matusch, University of 
Marburg) apigenin-based inhibitors of TGT have been investigated. Putative 
inhibitors of TGT were isolated from plant extracts applying the method of ligand 
fishing. This method was developed in the group of Prof. Matusch [Lenz, PhD Thesis, 
1999]95. Daniela Heller adjusted the method of ligand fishing to TGT [Heller, PhD 
Thesis, 2005]96. In a first step TGT is incubated with compounds from a plant extract 
to allow specific binding to the enzyme (Fig. 3.21). In following centrifugation and 
washing steps using microcon centrifugal filter units all compounds that are not 
specifically bound to TGT are washed off from the enzyme. In a last step the enzyme 
is denatured releasing specific binders which can be identified by CapLC. Via 
preparative HPLC these substances are then isolated directly from the plant extract.   
Twelve plant species were selected that were described in literature to be used in 
dysentery treatment by indigenous peoples or showed antibacterial activity. Plant 
extracts of the respective species were produced or purchased. Out of the plant 
extracts from Passiflora incarnata L., Centella aquatica (L.) URBAN and Solanum 
dulcamara L. compounds binding to TGT could be identified. The chemical structure 
of the compound isolated from P. incarnata was determined as isovitexin-2’’-O-β-
glucosid which belongs to the flavonoids of the apigenin type. Flavonoids are present 
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in amounts of 0.5 to 2.5 % in the extract of ‘Passiflorae herba’, among them 
predominantly C-glycosids of apigenin and luteolin (Tab. 3.16) [Heller, PhD Thesis, 
2005]96.   
 
 
Fig. 3.21  Work flow for ligand fishing (figure adapted from Heller (PhD Thesis, 2005)96) 
 
Tab. 3.16     Chemical structure of flavonoids of the apigenin type 
           (C-Gluc: C-glycosidic β-D-glucose;  C-Arab: C-glycosidic α-L-arabinose) 
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Vitexin H C-Gluc 
Schaftosid C-Gluc C-Arab 
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Isovitexin-2’’-O-β-glucosid C-Gluc-O-β-Gluc H 
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3.5.2 Determination of inhibition constants 
 
The inhibition constant of the isolated isovitexin-2’’-O-β-glucosid was determined 
together with those of the parent structures isovitexin and apigenin. To identify 
specificity and selectivity determining features the inhibition constants of vitexin, 
schaftosid and isoschaftosid, structurally related C-glycosids of apigenin, were 
determined as well. For apigenin, vitexin, isovitexin, schaftosid and isoschaftosid the 
commercially available pure compounds were used in the assay. 
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Fig. 3.22  Competitive inhibition constants of flavonoids of the apigenin type (values refer to 
the modified assay protocol) 
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In an initial experiment, it was discovered that apigenin is a non-specific inhibitor of 
the TGT base exchange reaction (see chapter 3.1.1). Due to a chemical structure 
similar to quercetin, (Fig. 3.22), which was identified as non-specific inhibitor of 
relevant pharmaceutical targets, this experiment appeared essential [McGovern et 
al., 2002]77. In the absence of the detergent Tween 20, the inhibition constant of 
apigenin was determined to 7.4µM, compared to 78µM in the presence of Tween 20  
(values refer to the former assay protocol – see chapter 3.1.4). This finding clearly 
demonstrates the ability of apigenin to inhibit TGT which is, however, overestimated 
in the absence of a detergent.  
Isovitexin-2’’-O-β-glucosid is the most potent inhibitor of all tested compounds with a 
Kic of 20µM. Isovitexin exhibits a similar binding affinity as isovitexin-2’’-O-β-glucosid, 
whereas the parent structure apigenin looses affinity by a factor of four. The              
8-substituted apigenins (vitexin, schaftosid, isoschaftosid) are capable to inhibit TGT 
as well, but the inhibitory potency remains similar to that of the apigenin scaffold. All 
values given in Figure 3.22 refer to the modified assay protocol (chapter 3.1.4). 
Facing the only small affinity differences, it remains not understood why Isovitexin-2’’-
O-β-glucosid can be isolated by ligand fishing, although all other compounds are 
known to be present in the Passiflora plant extract as well. 
3.5.3 Docking experiments 
 
To identify the binding modes of isovitexin-2’’-O-β-glucosid and isovitexin, crystal 
structure analysis in complex with TGT have been performed. In particular   
isovitexin-2’’-O-β-glucosid seemed to be suited for the experiments due to its good 
solubility in water. However, neither soaking nor cocrystallization were successful. No 
difference electron density in the binding pocket, indicating the presence of a ligand, 
could be identified. 
To get some ideas about putative binding modes, docking experiments were 
performed with GOLD using apigenin and isovitexin-2’’-O-β-glucosid as ligands.  
The crystal structure of TGT⋅H2 (Fig. 3.18a), after removing the ligand and all water 
molecules, was used for docking. Applying standard settings in GOLD 3.0.1 twenty 
solutions were created for apigenin in a region of 20Å surrounding the G34 binding 
pocket. For isovitexin-2’’-O-β-glucosid the number of accepted solutions was 
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increased to 25 to take the higher flexibility of the compound into consideration 
(chapter 5.6.2).  
For apigenin 19 of 20 solutions cluster together. The only exception is found on rank 
19. Apigenin is rotated by 180° with respect to the orientation found in the main 
cluster (Fig. 3.23b). All solutions are located in the G34 binding pocket of TGT 
stabilized via hydrophobic stacking interactions with Tyr106 and Met260. In all 
solutions the 2-hydroxyphenyl ring points out of the binding pocket (Fig. 3.23d). The 
best solution, according to the GOLDScore scoring function, forms the following 
interactions with the active site (Fig. 3.23c). The 4-carbonyl group is H-bonded to 
Gly230, the 5-hydroxy group interacts with Gln203 and Asp156, and the 7-hydroxy 
group is forming an H-bond with Ser103. 
 
 
Fig. 3.23  a)  Chemical structure of apigenin;  b)  superposition of 20 docking solutions for 
apigenin from GOLD; the solution with reversed orientation is shown in green;  c)  binding 
mode of the apigenin docking solution ranked on position 1;  d)  comparison of docking 
solutions ranked on the positions 1, 13 and 19;  
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the orientation of the 2-hydroxyphenyl group. Two solutions from rank 18 and 25 form 
O
O OH
OH
OH
7
54
2
Apigenin 
 
L231 
M260 D102 
Q203 
G230 
D156 
rank1 
rank1  rank13 
rank19 
S103 
D280 
Y106 
A232 
 
L231 
D102 
Q203 
G230 
D156 
D280 
Y106 
A232 
S103 
a b
c d
  3.5    Apigenin-based inhibitors 
____________________________________________________________________ 
130 
a small cluster. The main cluster comprises all other solutions (Fig. 3.24a). The 
superposition of the best ranked solutions from the two clusters with the TGT-bound 
tRNA shows that in the main cluster the 2-hydroxyphenyl substituent points into the 
G34/preQ1 binding pocket (Fig. 3.24b). In the second cluster this substituent is located 
in the U33 binding pocket. For the binding geometry found on rank 1 only a few 
specific interactions with the G34-binding site are encountered (Fig. 3.24c). The         
2-hydroxyphenyl substituent is H-bonded to Gln203 and Asp156. Two H-bonds are 
formed by the apigenin scaffold with Ala232 and Asp280. The second glucose 
moiety, however, fits well into the subpocket formed by Val45 and Val282.  
 
 
Fig. 3.24  a)  Superposition of 25 docking solutions for isovitexin-2’’-O-β-glucosid from 
GOLD;  b)  superposition of representatives from the two clusters (orange and green) on 
tRNA bound to TGT (blue);  c)  binding geometry of isovitexin-2’’-O-β-glucosid  (orange) 
found on rank 1;  d) superposition of binding geometries of apigenin (green) and isovitexin-
2’’-O-β-glucosid (orange) found on rank 1  
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The comparison of the first rank docking solutions of apigenin and isovitexin-2’’-O-β-
glucosid reveals a surprising inversion of the apigenin scaffold orientation (Fig. 
3.24d). While the apigenin scaffold addresses most of the residues involved in the 
recognition of G34, in case of isovitexin-2’’-O-β-glucosid the interactions with this 
pocket are reduced. Due to the scaffold inversion interactions are dominated by 
hydrophobic stacking with Tyr106 and Met260.  
The suggested structure - affinity model could be tested using C-glycosides 
structurally similar to isovitexin-2’’-O-β-glucosid, but based on alternative flavonoid 
scaffolds. In case of quercetin (Fig. 3. 22), for instance, the additional hydroxy group 
of the 2-phenyl ring would be suited to form additional interactions with the G34 
binding site. 
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4. Summary and Outlook 
 
4.1    Summary 
 
In this study structure-based drug design approaches for Zymomonas mobilis      
tRNA - guanine transglycosylase (TGT) are presented. Functional analysis and a 
mutational study provided deeper insight into the catalyzed reaction to support 
design strategies. Structurally, the Z. mobilis enzyme is highly homologous to the 
TGT from Shigella sp., the causative agent of bacterial shigellosis, for which no 
crystal structures are available. The development of TGT inhibitors, one of the key 
pathogenicity factors of Shigella sp., could result in a potent new antibiotic. 
The detailed understanding of functional properties of TGT is highly relevant for 
structure-based design as it provides valuable information about the binding pocket. 
TGTs are evolutionary ancient enzymes, present in all kingdoms of life, that catalye 
guanine exchange within their cognate tRNAs by modified 7-deazaguanine bases. 
The eubacterial TGT catalyzes the exchange of guanine 34 in four specific tRNA 
molecules by the modified base preQ1. Although distinct bases are incorporated into 
tRNA at different positions in a kingdom-specific manner, the catalytic subunits of all 
TGTs are structurally conserved (chaper 2.1).  
Crystal structures of QueTGT and ArcTGT in complex with tRNA became available 
during this thesis and revealed a misinterpretation of previous data [Xie et al., 2003]4. 
Asp280, instead Asp102, is the nucleophile of the base exchange reaction. 
Therefore, the model of the base exchange mechanism required revision. However, 
no comprehensive interpretation was available. Analysis of TGT crystal structures 
and sequences were performed and provided a new functional model concerning the 
molecular basis of the reaction mechanism and the residues involved in this process 
(chapter 2.1). Substrate binding modes indicate an evolutionarily conserved base 
exchange mechanism in all kingdoms of life with the conserved aspartate 280 
(following  Z. mobilis numbering) serving as nucleophile via covalent binding to C1’ of 
the guanosine ribose in an intermediate state.  
Eubacterial TGT exhibits substrate promiscuity compared to archaebacterial TGT. In 
addition to the natural substrate preQ1, also the biochemical precursor preQ0 can be 
incorporated into tRNA. The structural prerequisite for promiscuity was identified 
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(chapter 2.2.1). A peptide switching functionality is present in the active site, gated by 
the general acid/base Glu235. The flip of the Leu231/Ala232 peptide bond modifies 
the properties of the binding pocket to allow accommodation of tRNA-bound guanine 
and preQ1. The binding pocket that accepts guanine, however, is also capable to 
recognize preQ0. As no kinetic data for preQ0 and preQ1 was available, selectivity 
regulation remained unresolved. Therefore, the missing data for the wild type were 
determined. To invert selectivity a TGT(E235Q) mutated enzyme was constructed 
(chapter 2.2.2) This mutant was intended to stabilize the peptide switch in a 
geometry favouring the binding of preQ0. The kinetic characterization and the 
crystallization of the TGT(E235Q) in complex with preQ0 allowed a detailed 
comparison with the wild type enzyme. In TGT(w.t.), preQ1 and preQ0 exhibit similar 
Km values. Selectivity in favour of preQ1 is guaranteed via turn-over rates. In the 
mutated enzyme the Km value for preQ1 was significantly higher while the Km of 
preQ0 remained virtually identical. In the TGT(E235Q) crystal structures, the peptide 
switch is stabilized by the glutamine side chain and permanently arrested in a 
geometry suited for preQ0 binding. The observed geometry, however, differes 
significantly from the expectation. Concerning kcat, preQ1 is still the preferred 
substrate in the mutated enzyme. This suggests that substrate recognition is 
obviously regulated by Glu235. However, once accommodated in the active site the 
reaction rate of the base exchange is determined by other factors. Regarding kcat/Km, 
an indicator for the catalytic efficiency, the overall selectivity is inverted in favour of 
preQ0 for TGT(E235Q). 
From the detailed analysis of TGT crystal structures and sequences it can be 
hypothesized that for eubacterial and the eukaryotic TGTs, dimer formation is 
relevant to perform the catalytic reaction (chapter 2.3). In all available crystal 
structures of Z. mobils TGT homodimers are present in the crystals. Also in the 
crystal structure of Thermotoga maritima TGT homodimers are present exhibiting an 
almost identical interface geometry. Detailed analyses of these contacts and 
consulting available TGT sequences from Eubacteria and Eukaryota revealed 
conservation across the contacting residues. This suggests that eubacterial and 
eukaryotic TGT most probably act as homodimers in catalysis. It is hypothesized that 
one unit of the dimer performs the catalytic reaction. The second is required to 
recognize and properly orient the bound tRNA for the catalytic reaction likely via 
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other conserved residues that were identified in docking studies. These assumptions, 
however, need further experimental validation. 
The tRNA-bound crystal structures of ArcTGT and QueTGT allow, due to their 
substrate binding modes, the extraction of valuable information about the 
evolutionary origin of the TGT superfamily (chapter 2.4). Although the TGT 
superfamily is not involved in metabolism, as almost all other enzymes with TIM 
barrel fold, it shares a standard phosphate binding (SPB) motif with other 
homologous superfamilies [Nagano et al., 2005]72. The structural comparison of the 
tRNA-bound TGT structures with other TIM barrel enzymes reveals conserved 
phosphate binding modes that confirm the previously made assumptions. 
Additionally, a model for the evolution within the TGT superfamily has been 
developed. 
Results from structural and functional analysis are highly relevant for structure-based 
design approaches and inhibitor evaluation. In case of TGT, the new insight into the 
base exchange mechanism required the modification of the previously applied 
protocol to determine inhibition constants (chapter 3.1). The base exchange reaction 
was identified to follow a ping-pong mechanism [Goodenough-Lashua & Garcia, 
2003]53. Therefore, competitive and uncompetitive inhibition contributions have to be 
considered depending on the ligand’s size and properties. Uncompetitive inhibition is 
predominantly relevant for small-sized compounds with molecular size and properties 
similar to guanine or preQ1. To face these complications the previously applied assay 
was modified. In trapping experiments uncompetitive binders can be identified. The 
new assay setup allows the separate evaluation of competitive and uncompetitive 
inhibition contributions with respect to tRNA binding. Additionally, to avoid the effects 
of non-specific inhibition, the detergent Tween 20 is used in the assay. Such a type 
of inhibition is often observed for compounds with low solubility – and most of the 
tested compound series, presented in this study, exhibit low solubility. As a 
secondary effect, however, the protein solubility is significantly increased by the 
detergent. Therefore, the kinetic parameters were redetermined and corrected values 
were applied in the assay. Concerning Km values no significant differences could be 
identified, however, concerning Vmax a dramatic increase was detected.  
Due to the required modifications of the assay protocol, inhibition constants for 
already crystallized and characterized compounds were redetermined and their 
structure – activity relationship was revalidated (chapter 3.2). In particular small-sized 
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inhibitors have been overestimated concerning their inhibitory potency due to the 
previously neglected uncompetitive contribution. However, uncompetitive inhibition is 
only relevant for inhibitor classes with scaffold structures similar to guanine. In 
particular inhibitors from the class of quinazolinones have been revalidated as this 
scaffold served as template for further structure-based design approaches described 
in this study. For substituted compound series the revalidation revealed that inhibition 
constants are modulated in non-linear fashion. Most presumably contributions of non-
specific inhibition resulting from low solubility were compensated by the detergent 
Tween 20. The above described only small affinity differences for the Leu231/Ala232 
peptide switch were confirmed in this series. However, the previously reported 
sulphur effect, [Meyer et al., 2002]85, could not be confirmed. Instead, the 
accommodation of the ribose 34 binding pocket has only minor influence on binding 
affinity. 
Based on the quinazolinone scaffold three new TGT inhibitor series were developed 
(chapter 3.3). The compounds were synthesized by E. Meyer and S. Hörtner (group 
of Prof. F. Diederich, ETH Zürich).  
A series of 7-substituted-quinazolinones (chapter 3.3.1) exhibits a decreasing 
inhibitory potency. Nevertheless, some valuable information for further design cycles 
is available from this series. Firstly, substitution in position 7 disables uncompetitive 
inhibition of the base exchange reaction. Secondly, successful crystal structure 
analysis of one compound in complex with TGT revealed that a water network inside 
the binding pocket in the neighbourhood of the nucleophile Asp280 is highly relevant 
for binding affinity and should only be replaced by means of polar interactions. 
Unexpectedly, the substituent of one crystallographically analyzed derivative points 
into the direction of the ribose 33 binding site and not, as planned, towards the ribose 
34 pocket. 
A series of lin-benzoguanines (chapter 3.3.2) exhibits a similar inhibitory potency as 
derivatives of 6-amino-quinazolione scaffold compounds. Inhibition constants are in 
the single digit micromolar range. Due to an improved solubility of the                     
lin-benzoguanines four crystal structures in complexes with TGT have been 
determined up to a resolution of 1.58 Å – 2.1 Å. These structures give insight into the 
structural flexibility of TGT necessary to perform catalysis. In three of the structures 
molecular rearrangements are observed that match with conformational changes 
also noticed upon tRNA substrate binding. Several water molecules are involved in 
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these rearrangement processes. Two of them, W2 and W3, demonstrate the 
structural and the catalytic importance of water molecules during the TGT base 
exchange reaction. In the fourth crystal structure the inhibitor influences interactions 
of TGT dimers present in the crystals, due to the rearrangement of a protein loop. 
This loop is involved in inhibitor binding as well as in dimer interface formation. In due 
course of this rearrangement a space group transition compared to uncomplexed 
crystals can be observed upon soaking. 
Substitution of lin-benzoguanine in position 2 resulted in an inhibitor series with 
significantly enhanced binding affinity (chapter 3.3.3). With inhibition constants up to 
the two digit nanomolar range it is the most potent TGT inhibitor series yet known. 
The successful crystal structure analysis of one compound in complex with TGT 
provides some explanations for the significant affinity gain. Substitution in position 2 
is not interfering with the above mentioned crucial water cluster in the neighbourhood 
of Asp280 and the ribose 34 binding pocket. Instead, the substituents orient towards 
the U33 binding channel, although no specific interactions are formed. The 
assumption of a charge assisted binding mode might be the key element to explain 
the significant affinity gain. Lin-benzoguanines are binding via their imidazole moiety 
to the Leu231/Ala232 peptide switch in an orientation that requires Glu235 to be 
negatively charged. In case of lin-benzoguanine the pKa of this moiety is 4.5. Most 
presumably this moiety is uncharged at the assay condition of pH of 7.3. Substitution 
of the scaffold in 2-position supposedly causes a raise of the pKa which results in 
protonation and charge-assisted binding. 
A structurally very different series of inhibitors was realized based on a scaffold 
structure identified by virtual screening (chapter 3.4). Modification of this scaffold 
resulted in a benzimidazolin-2-one based inhibitor series. 1- and 5-substituted 
derivatives of benzimidazolin-2-one and benzimiazolin-2-thione were synthesized by 
T. Larsen (Prof. Link, University of Greifswald). The inhibition constants of these 
compounds are in a range of 2 – 150µM. Crystallization attempts of selected 
compounds in complex with TGT were not successful. Thus, any structure – activity 
relationships have to be based on docking results. These do not yet provide a fully 
conclusive picture. 
Applying an alternative screening method, described as “ligand fishing”, a compound 
binding to TGT could be discovered and identified from a plant extract (chapter 3.5). 
Isolation and characterization were performed by D. Heller (group of Prof. R. 
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Matusch, University of Marburg). This compound, isovitexin-2’’-O-β-glucosid, exhibits 
an inhibition constant of 20 µM. Unfortunately, crystallization in complex with TGT 
was not successful. Docking studies do not suggest a fully convincing specific 
recognition of this residue in the active site of TGT. Therefore, the exact binding 
mode still remains to be elucidated. 
 
4.2    Outlook 
 
Concerning the reaction rate of the base exchange, preQ1 is incorporated ten fold 
faster into tRNA than preQ0 (chapter 2.2.2). Tyr258 which is stabilizing the binding 
geometry of the nucleophile Asp280 in QueTGT could be involved in the regulation of 
turn-over rates. This is indicated by structural comparisons with ArcTGT where this 
tyrosine is conservatively replaced by histidine. To test this hypothesis TGT(Y258F) 
and TGT(Y258H) mutants could be constructed. 
 
Eubacterial TGTs are supposed to form functional dimers (chapter 2.3). Whether 
dimers are only present in crystals or whether they can also be observed in solutions 
in the presence of tRNA could be tested by gel filtration or dynamic light scattering. 
 
2-Amino-lin-benzoguanine is a very promising scaffold for further inhibitor design 
cycles that might result in subnanomolar inhibitors. To validate the assumption of a 
charge assisted binding mode for this compound determination of the exact pKa 
values as well as in silico pKa calculations of the compound in complex with TGT are 
required. Additionally, inhibition constants should be assayed at different pH 
conditions to assess a putative pH-dependence of the binding constants. 
The substituents  added to the 2-amino-lin-benzoguanine scaffold orient into the 
uracil 33 binding site without forming specific interactions. Introduction of substituents 
that specifically address residues of the ribose 33 and uracil 33 binding pocket might 
result in inhibitors with inhibition constants in the lower nanomolar range. 
Potent inhibitors of this series should be tested for inhibition of S. flexneri TGT or 
alternatively the almost identical E. coli TGT. 
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For the benzimidazolin-2-one based inhibitor series no distinct binding mode could 
be identified. To confirm the assumed binding modes further crystal structure 
analyses are required. In particular B13 / T13 might be likely candidates due to their 
good solubility and the assumed stacking interaction with Tyr106. Of the 
sulphonamide series, B18 seems to be suited best for crystallization trials. 
Furthermore, synthesis of other substituted derivatives appears mandatory. 
Particularly the free amines of  B5 / T5 might contribute with a charged side chain, 
similar to preQ1, to binding affinity and stabilize the urea-scaffold in the binding 
pocket.  
For  isovitexin-2’’-O-β-glucosid binding modes can only be assumed from docking. 
The suggested structure - affinity model could be tested using C-glycosides 
structurally similar to isovitexin-2’’-O-β-glucosid, but based on alternative flavonoid 
scaffolds. In case of quercetin, for instance, the additional hydroxy group of the        
2-phenyl ring would be suited to form additional interactions with the G34 binding site. 
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5. Materials and Methods 
 
For additional information concerning the applied methods see also Grädler (PhD 
Thesis, 2000)51 and Brenk (PhD Thesis, 2003)52. 
5.1    Chemicals and materials 
 
Chemicals used in this study were purchased at Sigma-Aldrich, Merck and Roth. 
Plastic materials (pipette tips and reaction cups) were autoclaved before use (30 min, 
121 °C, 1.3 bar).   
 
5.2    Biochemical methods 
 
5.2.1 Media and stock solutions 
 
LB-Medium:   1.0 % (w/v) bacto-trypton 
    0.5 % (w/v) yeast extract 
    0.5 % (w/v) NaCl 
All media were autoclaved immediately after preparation (30 min, 121°C, 1.3 bar). 
For the preparation of agar-media 1.5 % (w/v) agar was added to the solution. 
 
Ampicillin (Amp):  100 µg/mL in aqua bidest. 
Chloramphenicol (Cm): 34 µg/mL in ethanol 
Kanamycin (Km):  30 µg/mL in aqua bidest. 
The antibiotic stock solutions were filtered with a 0.2 µm filter. 
The antibiotic stock solutions were added at 0.1% (v/v) to the respective media 
solutions. 
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5.2.2 Determination of concentrations  
 
Absorptions of biological polymers in aqueous solutions were determined via 
photometry to determine their concentrations. The absorption maximum for DNA is at 
260 nm, for proteins at 280 nm. 
 
DNA solution (empirical formula for double stranded DNA): 
 
 µg DNA / mL = A260 × 50 µg/mL × factor of dilution 
 
 The purity was estimated from the A260/A280 ratio.  
 At a ratio of 1.8 – 2.0 the purity is in the range of 70 - 95 %. 
 [Sambrook et al., 1989]97 
 
 
E. coli tRNATyr solution [Curnow et al., 1993]98: 
 
 1 µM tRNATyr ≡ 0,703 A260 
  
 The purity was estimated from the A260/A280 ratio.  
 At a ratio of 1.8 – 2.0 the purity is in the range of 90 %. 
 [Sambrook et al., 1989]97 
 
Z. mobilis TGT solution 
 
 1 mg/mL (23,4 µM) Z. mobilis TGT (w.t.) ≡ 0,778 A280 
 
The absorption coefficient was calculated from the TGT amino acid sequence. 
[Cantor & Schimmel, 1980]99  
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5.2.3 Strains and plasmids 
 
Tab. 5.1  E. coli strains used in this study. 
 
 
Strain 
 
 
Description 
 
 
Origin 
XL2-blue (mcrA)183(mcrB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 
lac[F’proAB laqIq Z∆M15 Tn5(Kmr)] 
 
Stratagene 
 
BL21(DE3) pLysS 
 
 
F- dcm ompT hsdS(rB−mB−)galλ(DE3) 
[pLys Kmr] 
 
Stratagene 
 
 
TG2 
 
[supE hsd∆5 thi ∆(lac-proAB) ∆(sre-
recA) 306::Tn10 (Tetr) F' (traD36pro AB+ 
lacIq lacZ∆M15)] 
 
Stratagene 
 
 
 
Tab. 5.2 Plasmids used in this study 
  
 
 
Plasmid 
 
 
Description 
 
 
Origin 
pET9d-ZM4 Cmr, Kmr; ColEI-origin, tac-promotor, 
coding for laqIqmalE lacZα; inserted tgt 
gene as 1.3 kb BamHI/NcoI-fragment in 
pET9d 
 
[Reuter & 
Ficner, 1995]68 
 
pET9d-ZM4- 
E235Q 
 
Cmr, Kmr; TGT-E235Q  
 
this study  
ptRNA2 Ampr; E. coli 
tRNATyr as BstNI-fragment under control 
of T7-promotor in pTZ18U 
 
[Curnow et al., 
1993]98 
. 
 
Glycerol stocks were prepared by mixing 200 µL glycerol with 800 µL bacteria culture 
and stored at -80 °C. 
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5.2.4 Cloning techniques 
 
QuikChangeTM site-directed mutagenesis (Stratagene) was used to introduce the 
desired glutamine mutation of glutamate 235 into the wild-type TGT expression 
plasmid pET9d-ZM4 (Tab. 5.3). The template plasmid was expressed in 15 mL 
overnight culture of E. coli BL21(DE3) pLysS / pET9d-ZM4 (chapter 5.2.3) in LB-
medium containing Cm and Km (chapter 5.2.1) and harvested with QIAprep Spin 
Miniprep Kit (Qiagen) following protocols of the vendor. For site-directed 
mutagenesis 10 ng of template plasmid were mixed with 1 µL dNTP-mix supplied by 
the vendor, 125 ng forward- and 125 ng reverse primer (Tab. 5.3), 5 µL 10x-Pfu-
buffer, 1 µL PfuTurboTM DNA-polymerase and 37µL aqua bidest, following the 
Stratagene protocol. The solution was subjected to 20 PCR cycles of the following 
temperature sequence: 93 °C for 0.5 min, 45 °C for 1 min, 72 °C for 14 min. To digest 
the template plasmid 0.1 unit of DpnI was added. The mixture was kept for 1 h at 
37°C. 1 µL of the PCR product was transformed into 100 µL of E. coli XL2blue cells. 
The mixed solutions were stored for 30 min on ice, subjected to a 42 °C heat shock 
for 0.5 min and cooled down for 2 min on ice. 2 mL of autoclaved LB-medium was 
added for cell recovery and the solution was stored for 1 h at 37 °C. The transformed 
cells were spread on agar plates containing Km and Cm (5.2.1) and incubated at     
37 °C for 1-2 days. Individual colonies were transferred into 15 mL LB-medium 
containing Cm and Km and grown over night. The plasmid was isolated from 10mL 
over night culture (see above) and glycerol stocks were prepared and stored at          
-80 °C. Sequencing of the entire tgt gene (MWG, Ebersberg) confirmed the presence 
of the desired mutation as well as the absence of any further unwanted mutation. 
Subsequently, the mutated plasmid pET9d-ZM4-E235Q was transformed into E. coli 
BL21(DE3) pLysS cells. These cells were used for the preparation of the TGT 
enzyme (chapter 5.2.5). 
 
Tab. 5.3 PCR-primers for site-directed mutagenesis (mutation underlined) 
___________________________________________________________________ 
primer sequence 
E235Q-s 5’-GGGGGATTGGCTGTGGGTCAAGGACAGGATGAAATG-3’ 
E235Q-a 5’-CATTTCATCCTGTCCTTGACCCACAGCCAATCCCCC-3’ 
___________________________________________________________________ 
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5.2.5 Preparation of TGT 
 
Preparation of TGT was performed following the method described by Romier et al. 
(1996)100. 
 
The following buffers were used: 
 extraction buffer 20 mM Tris-HCl pH 7.8, 10 mM EDTA, 1 mM DTT 
    per 50 mL 1 tablet of CompleteTM (Roche) protease  
    inhibitor cocktail 
 TGT-buffer A 10 mM Tris-HCl pH 7.8, 1 mM EDTA, 1 mM DTT 
 TGT-buffer B TGT-buffer A + 1.0 M NaCl 
 TGT-buffer C TGT-buffer A + 1.0 M (NH4)2SO4 
 high-salt-buffer TGT-buffer A + 2.0 M NaCl, 0.01% (w/v) NaN3 
 
A 6-L culture of E. coli BL21(DE3) pLysS / pET9d-ZM4 (5.2.3) was grown in           
LB-medium containing Km and Cm at 37°C with vigorous shaking to an A600 of 0.8. 
Subsequently, the temperature was lowered to 14 °C and overexpression of the Z. 
mobilis tgt gene was induced by the addition of IPTG at a final concentration of          
1 mM. After another 24 h at 14 °C, the cells were harvested by centrifugation 
(Beckman Coulter, JA10, 4.000 rpm, 10 min, 4°C).  
The cell pellet was resuspended in 50 mL of extraction buffer and the cells were 
disrupted with a Branson sonifier during storage on ice. After two centrifugation steps 
(Beckman Coulter, JA25.50, 20.000 rpm, 45 min, 4 °C) the supernatant was drop 
wise diluted with a saturated (NH4)2SO4 solution to a final concentration of 80%. After 
centrifugation (JA25.50, 25.000 rpm, 30 min, 4 °C) the protein pellet was 
resuspended with extraction buffer (without  CompleteTM) and dialyzed over night 
against 5 L TGT-buffer A + 0.01% (w/v) NaN3 (cutoff 10,000 kDa).  
The enzyme was purified in two subsequent chromatographical steps using ÄKTA 
FPLC device (Amersham Pharmacia Biosciences). In the first step the dialyzed 
protein solution was loaded onto a Q-sepharose  column (XK 26, bed volume: 53 mL, 
Amersham) and washed with TGT-buffer A. The enzyme was eluted with a linear 
gradient of 0 to 100 % TGT-buffer B with a flow rate of 4 mL/min. The TGT enzyme 
eluted at 300 mM NaCl. Fractions containing TGT were identified by SDS-PAGE, 
combined and (NH4)2SO4 was added to a concentration of 1.0 M. In the second 
column chromatography step a phenyl-sepharose column (XK 16, bed volume: 
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16mL, Amersham) was equilibrated with TGT-buffer C. Subsequently, the TGT-
containing fractions were loaded onto the column. The enzyme was eluted with a 
linear gradient of  0 to 100 % TGT-buffer A with a flow rate of 2 mL/min. The enzyme 
eluted at 500 mM (NH4)2SO4.  
The fractions containing TGT were identified by SDS-PAGE, combined and 
concentrated to ~ 3 mg/mL using Centriplus YM30 (Milipore). The concentrated 
fractions were dialyzed over night in 15 mL Slide-A-LyzerTM cassettes (Pierce) 
against 5 L of TGT-buffer A + 0.01 % (w/v) NaN3. Upon dialysis microcrystals of TGT 
appeared. The microcrystals were centrifuged (JA25.50, 4.000 rpm, 20 min, 4 °C) 
and redissolved in high-salt-buffer to the desired TGT concentrations. The enzyme 
was stored at -20 °C. 
 
 TGT for crystallization:   20 mg/mL  30 µL  (chapter 5.5) 
 TGT for labelling-assay:     4 mg/mL    5 µL  (chapter 5.3) 
 TGT for SPR-assay:    5 mg/mL    5 µL  (chapter 5.4) 
 
5.2.6 Preparation of tRNATyr 
 
Preparation of E. coli tRNATyr (ECY2) via in vitro transcription was done following the 
method described by Curnow et al. (1993)98. 
  
The following buffers were used: 
 NaAc-buffer  3.0 M NaAc pH 5.3 
 tRNA-buffer A 10 mM HEPES pH 7.3 
 tRNA-buffer B tRNA-buffer A + 2 M NaCl 
 tRNA-buffer C tRNA-buffer A + 1 mM MgCl2 
 10x Tx-buffer 400 mM Tris-HCl pH 8.0, 200 mM MgCl2, 50 mM DTT, 
    10 mM spermidine 
To inactivate nucleases glass materials used during the preparation were sterilized 
for 4h at 180 °C. 
Frequently applied precipitation of DNA and tRNA solutions was performed as 
following: 2.5 volumes of ethanol p.a. and 0.1 volumes of NaAc-buffer were added. 
For precipitation this mixture was stored at -20°C. The precipitated nucleobases were 
centrifuged (Beckman Coulter, JA-25.50, 15.000 rpm, 30 min, 4 °C) and after 
decantation the pellet was dried at room temperature for 15 min. 
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To produce the template plasmid required for in vitro transcription a 2-L culture of E. 
coli TG2 / ptRNA2 (5.2.3) was grown in LB-medium containing Amp (chapter 5.2.1) 
at 37 °C for 19 h. The cells were harvested by centrifugation (Beckman Coulter, JA-
10, 4.000 rpm, 10 min, 4 °C).  
The plasmid was extracted using a QIAGEN Plasmid Mega Kit (QIAGEN, Hilden), 
following the protocol of the vendor. The plasmid containing solution was precipitated 
as described above, stored over night, centrifuged (Beckman Coulter, JA-25.50, 
10.000 rpm, 30min, 4°C) and redissolved in 10 mL aqua bidest. After another 
precipitation step, following the procedure described at the beginning of this chapter 
the plasmid pellet was dissolved in water to a final concentration of 1 mg/mL (chapter 
5.2.2). 
Restriction digestion was performed using the endonuclease BstNI. Aliquots of 250 
µL plasmid solution (1 mg/ml) were incubated 5 µL BstN I (10.000 U/ml ; New 
England Biolabs), 50 µL buffer #2 (New England Biolabs), 2.5 µL BSA (100 µg/ml ; 
New England Biolabs), 250 µL aqua bidest. and stored over night at 60°C. The 
digestion mixture was then extracted with equal volumes of Roti-Phenol (Roth) and 
choloroform:isoamylalcohole (24:1). The aqueous supernatant was extracted again 
with an equal volume of choloroform:isoamylalcohole (24:1). The aqueous 
supernatant of this extraction was precipitated and stored over night.  
After centrifugation the dried pellet was dissolved in water to a final concentration of 
0.6 mg/mL. In vitro transcription of ECY2  was carried out in 15 mL falcon tubes. 
Aliquots of 1 mL restricted template were incubated together with 600 µL 10x Tx-
buffer, 240 µL ATP (100 mM), 240 µL CTP (100 mM), 240 µL UTP (100 mM), 240 µL 
GTP (100 mM), 25 µL inorganic PPase (Roche Diagnostics), 5 µL RNAse-inhibitor 
(10,000 U/mL, Roche Diagnostics), 6000 U T7 RNA Polymerase (Amersham 
Bioscience) ad 6mL aqua bidest. The mixture was allowed to incubate at 37 °C for 
approximately 7 h. Successful transcription was confirmed with agarose gel 
electrophoresis and staining with ethidium-bromide. The mixture was extracted in two 
steps following the method described above and precipitated at -20 °C over night.  
The transcribed ECY2 was purified by column chromatography. Therefore, the 
centrifuged and dried pellet was dissolved in 10 mL tRNA-buffer A and loaded onto 
an anion-exchange column (SOURCE 15Q, HR 10/10, Pharmacia). After washing 
with tRNA-buffer A ECY2 was eluted with a linear gradient of 0 to 100% tRNA-buffer 
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B with a flow rate of 1.5 mL/min. The tRNA eluted at 450 mM NaCl. Fractions 
containing ECY2 were identified by gel electrophoresis, combined and precipitated.  
After centrifugation (JA-25.50, 10.000rpm, 1 h, 4 °C) the pellet was dissolved in 
tRNA-buffer A to a final concentration of < 20 µM. For the following monomerization 
step ECY2 was transferred into a water bath and within 45 min the temperature was 
risen to 70 °C. For another 30 min the tRNA was stored at this temperature. After 
addition of MgCl2 to a final concentration of 1 mM the tRNA was stored for 2 h on ice. 
The solution then was precipitated and stored for 1 h at -20 °C. 
After centrifugation the pellet was dissolved in tRNA-buffer 3 to a final concentration 
of ~ 200 µM (chapter 5.2.2). Purity of the sample was confirmed photometrically 
(chapter 5.2.2) and aliquots were stored at -20 °C.  
 
5.3 Kinetic parameters and inhibition constants  
 
The method has been modified according to the initial procedures described by 
Reuter et al. (1994)101 and Grädler et al. (2001)3.  
 
The following buffer was used: 
 TGT assay buffer 200 mM HEPES pH 7.3, 20 mM MgCl2,  
     2.95 µM = 5 % CMC Tween 20 (Roth) 
5.3.1 Workflow of the labelling assay 
 
The determination of TGT activity was carried out in 75 µL mixtures containing        
150 nM Z. mobilis TGT and variable concentrations of E. coli tRNATyr, guanine           
(7.5% radio-labelled [8-3H]-guanine (Hartmann Analytik)) and inhibitor in TGT assay 
buffer.  Inhibitors that were added to the assay solution were, due to limited solubility 
in aqueous solutions, dissolved in DMSO. The final assay solution contained up to    
5 % DMSO. Reactions were started by adding tRNA and guanine/[8-3H]-guanine to 
the protein solution. Prior to addition of the substrate, protein and protein/inhibitor 
mixtures were preincubated at 37 °C for 10 min to adjust the solution to the assay 
temperature. The reacting mixture was kept at 37 °C, and 15 µL aliquots were taken 
at intervals of 1 to 4 min. Aliquots were immediately transferred to glass fiber (GC-F) 
filters (Whatman) and quenched with 10 % (w/v) trichloroacetic acid at 0 °C for        
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15 min. Unbound guanine was washed from the filters in 7 min intervals twice with 
5% (w/v) trichloroacetic acid (TCA) and twice with ethanol. Filters were dried at 60° 
for 45 min and then transferred in 4 mL of scintillation cocktail for lipophilic samples 
(Roth). Tritium incorporated into tRNA was quantified using liquid scintillation 
counting (Results from the aliquots were used to calculate initial velocity using 
GraFit102.  
5.3.2 Kinetic parameters 
 
Michaelis-Menten parameters for tRNA and guanine were determined separately in 
triplicate and average values were calculated. Kinetic parameters for guanine were 
measured using 150 nM TGT, 15 µM tRNA, and variable concentrations of  guanine 
(7.5 % [8-3H]-guanine) in the range of 0.5 - 20 µM. Kinetic parameters for tRNA were 
measured using 150 nM TGT, 20 µM guanine/[8-3H]-guanine, and variable 
concentrations of tRNA (0.25-15 µM). Initial velocities in counts per minute were 
transferred to [µM/min] using a calibration constant derived from liquid scintillation 
counting of guanine/[8-3H]-guanine solutions with variable concentrations. Kinetic 
parameters were determined via double-reciprocal linearization using the method of 
Edie-Hofstee and linear regression using GraFit102. 
Michaelis-Menten parameters for preQ0 and preQ1 were calculated via monitoring of 
[8-3H]-guanine excorporation from tRNATyr radio-labelled in position 34. To produce 
radioactively labelled tRNA 50 µM unmodified tRNATyr was incubated with 500 nM 
TGT and 10 µM [8-3H]-guanine in TGT assay buffer for 1 h. TGT is extracted from 
the reaction mixture by the addition of equal volumes of Roti-Phenol (Roth) and 
choloroform:isoamylalcohole (24:1). The aqueous supernatant is once again 
extracted with an equal volume of choloroform:isoamylalcohole (24:1). The aqueous 
supernatant containing the radioactively labelled tRNA is separated from guanine /  
[8-3H]-guanine via gel filtration using NAP-columns (GE Healthcare, Life Science) 
and TGT assay buffer. The labelled tRNA was dried by vacuum centrifugation and 
dissolved in tRNA-buffer C (chapter 5.2.6) to a final concentration of 200 µM. Kinetic 
parameters for preQ0 and preQ1 were measured using 150 nM TGT(w.t) / 
TGT(E235Q) and 15 µM labelled tRNATyr. For preQ0 the concentration was varied in 
a range of 0.5 - 15 µM. For preQ1 variable concentrations in a range of 0.5 - 15 µM 
for TGT(w.t.) and 2 - 80 µM for TGT(E235Q) were applied. Initial velocities in counts 
per minute were calculated from the decreasing tritium labelling level of tRNA due to 
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the incorporation of the respective substrate bases. Initial velocities were transferred 
to [µM/min] using a calibration constant derived from liquid scintillation counting of 
guanine/[8-3H]-guanine solutions with variable concentrations. Kinetic parameters 
were determined via double-reciprocal linearization using the method of Eadie-
Hofstee and linear regression using GraFit102. 
5.3.3 Trapping experiment 
 
To distinguish pure competitive from non-competitive inhibitors an initial trapping 
experiment followed by SDS-PAGE was performed with each inhibitor. 5 µM             
Z. mobilis TGT, 100 µM E. coli tRNATyr, and 1 mM of the respective inhibitor 
(dissolved in DMSO) in 10 µL of 100 mM HEPES buffer, pH 7.3, 20 mM MgCl2, and 5 
mM dithiothreit were incubated for 1 h at 25°. A total of 10 µL SDS loading buffer was 
added and incubated for another 1 h at 25°. 10 µL of each sample were loaded onto 
a 15% SDS gel. After electrophoresis gels were stained with Coomassie blue. 
 
 
5.3.4 Inhibition constants 
 
5.3.4.1 Inhibition constants for pure competitive inhibition 
   
The inhibition assay was performed using 150 nM TGT, 20 µM guanine/[8-3H]-
guanine, and tRNA at two concentrations (1 µM and 1.5 µM). Six reaction mixtures 
for each tRNA concentration were prepared.  To five of them, inhibitor dissolved in 
DMSO (5% final volume) at variable concentrations was added. Initial velocities for 
the reaction mixtures were determined, and Kic determination was performed using 
Dixon plots. As Vmax determination is only possible with limited accuracy for 
independent measurements, the modified equation (5) published by Grädler et al. 
(2001)3 was used to calculate Kic.  
Linear regression of data points derived from this equation with GraFit102 resulted in a 
straight line with the slope 1/Kic. 
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v0 Km 1
1
[S] (· [I]Kic )·
+
vi
=
Km
+ +
[S]
Km
 
v0 initial velocity at given [S] concentration in the absence of inhibitor, vi initial velocity at given [S] 
concentration in the presence of inhibitor, [S] tRNA concentration, [I] inhibitor concentration, Km 
Michaelis-Menten constant of tRNA, Kic competitive inhibition constant  
  
5.3.4.2 Inhibition constants for mixed inhibition 
 
The inhibition assay was performed using 75 nM TGT, 20 µM guanine/[8-3H]-
guanine, and variable tRNA concentrations (0.25 - 15 µM).  Kinetic parameters were 
determined once in the absence of inhibitor (Km, Vmax) and twice in the presence of 
specific inhibitor concentrations [I] to calculate (Kmapp, Vmaxapp) via double-reciprocal 
linearization and linear regression using GraFit102. Contributions of Kic and Kiu 
towards non-competitive inhibition can be calculated from the following equations (2) 
and (3): 
Km 1+(· [I]Kic)=Km
app
 
Vmaxapp
Vmax
( )1+ [I]Kiu
=
 
 
Vmax maximum velocity of uninhibited reaction, Vmaxapp apparent maximum velocity of inhibited reaction, 
Km Michaelis-Menten constant of tRNA, Kmapp apparent Michaelis-Menten constant of tRNA in the 
presence of inhibitor, [I] inhibitor concentration, Kic competitive inhibition constant, Kiu uncompetitive 
inhibition constant  
 
Due to the elaborate Ki determination procedure inhibition constants were determined 
only in duplicate or triplicate. Estimated standard deviations σ were calculated from 
the range R of the resulting inhibition constants [Fischer & Hannappel, 1996]103. 
 
  σ  = R ⋅ 0.896 (for double measurements) 
  σ  = R ⋅ 0.596   (for triple measurements) 
 
(5) 
(2)
 
 
 
(3)
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5.4    SPR-based assay 
 
The SPR-spectroscopic experiments were performed using Jandratek device at        
22 °C. 
 
The following buffers were used: 
 
 Phosphate-buffer 120 mM NaCl, 30 mM NaH2PO4 / (Na)2HPO4 pH 7.3 
 SPR-buffer  98 % Phosphate buffer + 2 % high-salt-buffer  
    (chapter 5.2.5) 
 
 
TGT for SPR-assay (chapter 5.2.5) was mixed with 245 µL of Phosphate-buffer to a 
final concentration of 100 µg/mL. Linker G1 (3.2.5) was dissolved in SPR-buffer to a 
final concentration of 20 µg/mL. Streptavidin was dissolved in SPR-buffer to a final 
concentration of 500 µg/mL. 
A biotinylated gold chip was mounted into the test chamber and washed with 10 µL of  
SPR-buffer for 10 min. Then the buffer was removed. 10 µL of streptavidin solution 
were filled into the test chamber and incubated for 15 min. Unbound streptaviden 
was washed from the chip in five washing steps using 10 µL of SPR-buffer. 10 µL of 
linker G1 solution was filled into the test chamber and incubated for 15 min. Unbound 
linker was washed from the chip in 5 washing steps using 10 µL of SPR-buffer. 10 µL 
of TGT solution was filled into the test chamber. The solution in the chamber was 
stirred for 6 min and then incubated for another 10 minutes. Unbound TGT was 
washed from the chip in 5 washing steps using 10 µL of SPR-buffer. The resonance 
signal was permanently monitored and used to calculate the amount of bound 
protein. 
 
Protein binding (empirical formula for Jandratek device): 
 
 1 Resonance Unit ≡ 1 pg protein ⋅ mm-2 
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5.5    Crystal structure analysis 
 
5.5.1 Growing of crystals 
 
TGT crystals suitable for ligand soaking were produced in a two step procedure. 
Droplets were prepared by mixing 2 µL of concentrated protein solution (14 mg/mL 
TGT in high-salt-buffer (chapter 5.2.5)) with 2 µL reservoir solution of the respective 
seeding buffer (S-buffer). Micro-crystals were grown at 273 K using the hanging-
drop, vapour diffusion method in the presence of 1 mL of reservoir solution of the 
respective seeding buffer. Micro-crystals of 0.05 mm3 grew within two weeks. 
 
     S-buffer pH 5.5  100 mM morpholino ethylsulfonate (MES), pH 5.5,  
    1 mM DTT, 8 % (w/v) PEG 8.000, 10 % (v/v) DMSO 
     S-buffer pH 6  100 mM MES, pH 6,  
    1 mM DTT, 8 % (w/v) PEG 8.000, 10 % (v/v) DMSO 
     S-buffer pH 8.5  100 mM Tris, pH 8.5, 1 mM DTT, 13 % (w/v) PEG 8.000, 
    10 % (v/v) DMSO 
 
 
Subsequently macro-seeding was performed under similar conditions. Again droplets 
were prepared by mixing 2 µL of concentrated protein solution with 2 µL reservoir 
solution of the respective macro-seeding buffer (MS/CC-buffer). One micro-crystal 
was transferred into this solution. Single crystals with a size of approximately          
0.7 x 0.7 x 0.2 mm3 grow within two to four weeks per droplet. Small sized 
compounds were dissolved in DMSO and added to the droplet to a final 
concentration of 2 mM to allow soaking. Crystals were soaked  at 293 K for one day. 
 
     MS/CC-buffer pH 5.5 100 mM MES, pH 5.5, 1 mM DTT,  
    5 % (w/v) PEG 8.000, 10 % (v/v) DMSO 
     MS/CC-buffer pH 6 100 mM MES, pH 6, 1 mM DTT,  
    5 % (w/v) PEG 8.000, 10 % (v/v) DMSO 
     MS/CC-buffer pH 8.5 100 mM Tris, pH 8.5, 1 mM DTT, 5 % (w/v) PEG 8.000, 
    10 % (v/v)DMSO 
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Cocrystallization was performed under similar conditions. Droplets were prepared by 
mixing 2µL of concentrated protein solution with 2µL reservoir solution of the 
respective cocrystallization buffer (MS/CC-buffer). Additionally, small sized 
compounds were dissolved in DMSO and immediately added to the droplet to a final 
concentration of 2 mM. One micro-crystal was transferred into this solution. Single 
crystals with a size of approximately 0.7 x 0.7 x 0.2 mm3 grow within two to four 
weeks per droplet.  
 
5.5.2 Data collection 
 
For data collection, crystals were cryoprotected using glycerol; 4 µL of the 
crystallization droplet were well mixed with 2.2 µL of glycerol resulting in a 35 % 
glycerol solution. The soaked crystal was transferred for 10 seconds into this solution 
and subsequently flash-frozen in liquid N2. Data sets were collected at cryo 
conditions (100 K) with CuKα radiation. (λ = 1.5418Å)  using a Rigaku RU-300 
rotating-anode generator at 50 kV and 90 mA equipped with either focusing mirrors 
(MSC, USA) and a R-AXIS IV + + image-plate system or with Xenocs focussing 
optics and a R-AXIS IV detector. All tested crystals exhibit monoclinic symmetry in 
space group C2 containing one monomer per asymmetric unit with Matthews 
coefficients of 2.3 - 2.4. One crystal soaked with L4 showed the monoclinic space 
group P2 containing two symmetry independent monomers per asymmetric unit with 
a Matthews coefficients of 2.3. All data processing and scaling were performed using 
the HKL2000 package [Ottinowski & Minor, 1997]104. For all refined structures unit 
cell dimensions for the crystals, data collection and processing statistics are given in 
chapter 6.2. 
 
5.5.3 Structure determination and refinement 
 
For TGT⋅L4 (space group P2) molecular replacement with the coordinates of apo 
TGT crystallized at pH 5.5 (PDB-code: 1P0D) was performed using AMoRe [Navaza, 
1994]105. For C2 crystals grown at pH 5.5 or pH 6 coordinates of the apo TGT crystal 
structure grown at a pH of 5.5, (PDB-code: 1P0D) were directly applied for initial 
rigid-body refinement of the protein molecule followed by repeated cycles of 
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conjugate gradient energy minimization, simulated annealing and B-factor refinement 
using the CNS program package [Brunger et al.,  1998]106. For C2 crystals grown at 
pH 8.5 the coordinates of the apo TGT crystal structure grown at a pH of 8.5 (PDB-
code: 1PUD) were applied. For TGT⋅L1 and TGT⋅L4 this program was also used in 
further refinement cycles to include the ligand and the water molecules to generate 
the final model. Refinement at the later stages for all other structures was performed 
with SHELXL [Sheldrick & Schneider, 1997]107. Here, up to 20 cycles of conjugate 
gradient minimization were performed with default restraints on bonding geometry 
and B-values: 5 % of all data were used for Rfree calculation. Amino acid side-chains 
were fit to σA-weighted 2 |Fo| - |Fc| and |Fo| - |Fc|  electron density maps using O 
[Jones et al., 1991]108. Water and glycerol molecules as well as the ligand were 
located in the difference electron density and added to the model for further 
refinement cylces. During the last refinement cycles, riding H-atoms were introduced 
for the protein residues (not for ligand) without using additional parameters.  All final 
models were validated using PROCHECK [Laskowski et al., 1993)109. Data 
refinement statistics are given in chapter 6.2. 
 
5.6    Computational methods 
 
5.6.1 Minimization 
 
For some compounds crystal structure are not available. To suggest binding 
geometries the compounds were placed in an available TGT binding pocket and 
minimized with the MAB force field as implemented in MOLOC [Gerber & Müller, 
1995]110. For minimization the binding pocket was kept rigid. Only the side chains of 
Asn70, Asp102, Ser103, Tyr106, Asp156 and Gln203 were kept flexible to allow 
limited induced fit events. 
The following binding pockets after removing ligand and water molecules were used 
for minimization: TGT⋅H2 (PDB: 1F3E), TGT⋅preQ1 (PDB: 1P0E ), TGT⋅H7 (PDB: 
1N2V), TGT⋅ tRNA (PDB: 1Q2S) and TGT⋅L1 (PDB: 2BBF).  
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5.6.2 Docking 
 
Docking experiments were performed with GOLD 3.0.1. The crystal structure of 
TGT⋅H2, after removing the ligand and all water molecules, was used for docking.  
Applying standard settings in GOLD, 10 – 25 solutions were created in a region of 
20Å in the vicinity of Arg286. Solutions were ranked according to the GOLDScore 
scoring function. 
 
5.6.3 Alignment of structures 
 
Structural alignments of dissimilar sequences (ArcTGT and QueTGT) were 
performed by means of the program suite SYBYL 7.0 (Tripos Inc., St. Louis, MO.). 
Alignment of structures with similar or identical sequences was performed with the 
alignment function implemented in Pymol (http://www.pymol.org). 
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6. Appendix 
 
6.1    Structural alignment of 21 TGT sequences 
 
21 TGT sequences were selected as representatives of major eubacterial and 
eukaryotic subdivisions. The sequences were retrieved from SWISS-PROT and 
aligned using CLUSTAL_W 69.  
 
Escherichia              ------------MKFELDTTDGRARRGRLVFDRGVVETPCFMPVGTYGTVK-GMTPEEVE 
Vibrio                   ----------MKLKFELKKKNGNARRGQLIFERGTVQTPAFMPVGTYGTVK-GMTPEEVK 
Pseudomonas              ------------MNFELLATDGKARRGRLTFPRGVVETPAFMPVGTYGTVK-GMLPRDIE 
Neisseria                -----------MLKFTLHKKDGYARRGTLELNHGKIETPVFMPVGTYGSVK-AMNPQNLH 
Agrobacterium            --------MHEKFTFTLKSTSGGARLGEVAMPRGVIRTPAFMPVGTVGTVK-AMYLDQVR 
Rickettsia               ---------MSKFSFNIHHQHKKARSGIIVTAHGEMRTPAFMPVGTRGTVK-AMLPESVA 
Zymomonas                VEATAQETDRPRFSFSIAAREGKARTGTIEMKRGVIRTPAFMPVGTAATVK-ALKPETVR 
Helicobacter             ------------MDFQLQATDNNARAGLLNLAHSQVATPVFMPVGTQGCIKSLDATDAQE 
Gloeobacter              --------MTASFAFTIEHRDGEARAGTFATPHGPVYTPCFMPVGTQATVK-TLTPAQLA 
Thermotoga               ------------MEFEVKKTFGKARLGVMKLHHGAVETPVFMPVGTNASVK-LLTPRDLE 
Chlamydia_pneu.          --------MALKFHLIHQSKKSQARVGQIETSHGVIDTPAFVPVATHGALK-----GVID 
Chlamydia_trac.          --------MALRFEILHQSKKSRARVGRIETAHGYIDTPAFVPVATNGALK-----GVLD 
Treponema                -----MKEKKEIFTLLHQDAASPARTGVLELPHGKVLTPAFMPVGTAATVKAMTKDDLDE 
Bacillus                 -----MAEQPIRYEFIKECKQTGARLGKVHTPHGSFETPVFMPVGTLATVK-TMSPEELK 
Lactobacillus            ------MEPAIKYRLIKKEKHTGARLGELITPHGTFPTPMFMPVGTQASVK-SLAPEELD 
Clostridium              -----------MYTLIKKCGN--AKRGRFETPHGTIETPVFMNVGTLGVIKGAVSSMDLK 
Schizosaccharomyces      ---MASSFPALQFKVVARCSTTRARVTDIQLPHGLVESPVFMPVGTQASLK-GVLPEQLD 
Caenorhabditis           ------------MRYDVLARAGFARRGNLHLPHSIVETPVFMPVGTQGTMK-GIVPEQLV 
Drosophila               --MGPSHIPPLTYKVVAECSVSKARAGLMTLRHSEVNTPVFMPVGTQGTLK-GIVPDQLI 
Mus                      ------------MRLVAECSRSGARAGELRLPHGTVATPVFMPVGTQATMK-GITTEQLD 
Homo                     ------------MRLVAECSRSRARAGELWLPHGTVATPVFMPVGTQATMK-GITTEQLD 
                                                *:   .   :. . :* *: *.* . :*   
 
        
                                  70     77             92       102  107 
Escherichia              ATGAQIILGNTFHLWLRPGQEIMKLHGDLHDFMQWKGPILTDSGGFQVFSLGD------- 
Vibrio                   ETGAQILLGNTFHLWLRPGQEVMKMHGDLHDFMNWQGPILTDSGGFQVFSLGD------- 
Pseudomonas              DIGAQIILGNTFHLWLRPGTEVIQRHGDLHDFMQWKGPILTDSGGFQVFSLGA------- 
Neisseria                DIKAQIILGNTYHLWLRPGLEVVEQFGGLHGFIGWDKPILTDSGGFQVFSLSD------- 
Agrobacterium            ELGADIILGNTYHLMLRPGPERVARLGGLHELIRWPHPILTDSGGFQVMSLSG------- 
Rickettsia               ETGADILLGNTYHLMLQPTAERIVQLGGLHKFMNWDKPILTDSGGFQVMSLSK------- 
Zymomonas                ATGADIILGNTYHLMLRPGAERIAKLGGLHSFMGWDRPILTDSGGYQVMSLSS------- 
Helicobacter             ILGAKLILANTYHMYLRPGEKVVEELGGLHRFAQFYGSFLTDSGGFQAFSLSD------- 
Gloeobacter              ETGAQMILANTYHLSLQPGADIVAGAGGLHGFMQWPGPILTDSGGFQVFSLSS------- 
Thermotoga               EAGAEIILSNTFHLMLKPGVEIIKLHRGLHNFMGWKRPILTDSGGFQVFSLPK------- 
Chlamydia_pneu.          HSDIPLLFCNTYHLLLHPGPEAVAKLGGLHQFMGRQAPIITDSGGFQIFSLAYGSVAEEI 
Chlamydia_trac.          HSNIPLMFCNTYHLIVHPGAEAIAAMGGLHQFIGRNAPIITDSGGFQIFSLAYGSVAEEI 
Treponema                IG-FEIILANTYHLFLRPGIEVIKAAGGLHGFSDWKKNFLTDSGGFQVFSLSQ------- 
Bacillus                 AMDAGIILSNTYHLWLRPGQDIVKEAGGLHKFMNWDRAILTDSGGFQVFSLSK------- 
Lactobacillus            AMGAGVILSNTYHLWLRPGEQIVKEAGGLHQFMNWKKGILTDSGGFQVFSLAK------- 
Clostridium              EIGCQVELSNTYHLHLRPGDEVIKKMGGLHKFMNWDRPILTDSGGFQVFSLAK------- 
Schizosaccharomyces      ALGCKIMLNNTYHLGLKPGQEVLDTVGGAHRFQSWNKNILTDSGGFQMVSLLK------- 
Caenorhabditis           SMDCRILLCNTYHLGHRPGHERVKAAGGLHKMMNWNRSILTDSGGFQMVSLSK------- 
Drosophila               ELNCQILLGNTYHLGLRPGIETLKKAGGLHKFMGWPRAILTDSGGFQMVSLLQ------- 
Mus                      SLGCRICLGNTYHLGLRPGPELIRKAQGLHGFMNWPHNLLTDSGGFQMVSLFS------- 
Homo                     ALGCRICLGNTYHLGLRPGPELIQKANGLHGFMNWPHNLLTDSGGFQMVSLVS------- 
                              : : **:*:  :*  . :    . * :      ::*****:* .**          
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                                              125    132                     156 
Escherichia              -----------IRKITEQGVHFRNPINGDPIFLDPEKSMEIQYDLGSDIVMIFDECTPYP 
Vibrio                   -----------IRKITEEGVHFRNPVNGDKIFMDAEKSMEIQKDLGSDIVMIFDECTPYP 
Pseudomonas              -----------MRKIKEEGVTFASPVDGAKVFMGPEESMAVQRALGSDIVMIFDECTPYP 
Neisseria                -----------MRKLTEEGCTFKSPINGDKLFLSPEISMKIQTVLNSDIAMQLDECTPGE 
Agrobacterium            -----------LRKLDEKGVTFKSHVDGSLHHMSPERSIEIQGMLDSDIQMQLDECIALP 
Rickettsia               -----------LCKITEEGVSFSSHINGDKYMLTPERSTEIQYLLGSTITMAFDECTPYP 
Zymomonas                -----------LTKQSEEGVTFKSHLDGSRHMLSPERSIEIQHLLGSDIVMAFDECTPYP 
Helicobacter             -----------NVKLQEDGIVFKSHIDGSKHLFTPAKVLDIQYSLNSDIMMVLDDLVGLP 
Gloeobacter              -----------LRTIDDDGVTFREPKSGALVRFTPEHAVAVQNALGADVIMAFDECPPYP 
Thermotoga               -----------IR-IDDEGVVFRSPIDGSKVFLNPEISMEVQIALGSDICMVFDHCPVPD 
Chlamydia_pneu.          KSCGKKKGMSSLVKITDEGAWFKSYRDGRKLFLSPELSVQAQKDLGADIIIPLDELLPFH 
Chlamydia_trac.          KSCGKKKGGNTIIKVNDDGVHFKSYRDGRKLFLSPEISVQAQKDLGADIILPLDELLPFH 
Treponema                -----------LRKITEEGVKFQSHIDGSRQFLSPEIAVELQTGFNSDIQMQLDICSSFG 
Bacillus                 -----------FRNIEEEGVHFRNHLNGDKLFLSPEKAMEIQNALGSDIMMAFDECPPYP 
Lactobacillus            -----------NRDITEEGVHFKNHLNGSKMFLSPEKAIQIENDLGPDIMMSLDECPPFF 
Clostridium              -----------IRKIQEEGVYFNSHIDGRRIFMGPEESMRIQSNIASTIAMAFDECIPNP 
Schizosaccharomyces      -----------LATITEDGVTFLSPRDGTPMLLTPEHSISLQNSIGSDIMMQLDDVVHTL 
Caenorhabditis           -----------LMTVDENGVNFESPHTGEMMALPPEKSIEIQQALGADIMMQLDHVIHVL 
Drosophila               -----------LAEIDEHGVNFRSPFDNSQCMLTPEHSIEIQNAIGGDIMMQLDDVVKTT 
Mus                      -----------LSEVTEEGVHFRSPYDGEETLLSPERSVEIQNALGSDIIMQLDHVVSST 
Homo                     -----------LSEVTEEGVRFRSPYDGNETLLSPEKSVQIQNALGSDIIMQLDDVVSST 
                                         :.*  * .   .    : .      :  :   : : :*    
 
    
                                                                    203 
Escherichia              ADWDYAKRSMEMSLRWAKRSRERFDSLG-------NKNALFGIIQGSVYEDLRDISVKGL 
Vibrio                   ATHDEAKKSMEMSLRWAKRSRDHFDKLE-------NPNNLFGIVQGGVYEDLRDVSVKGL 
Pseudomonas              ADHDVAKRSMELSLRWAKRSK--IAHGD-------SPSALFGIVQGGMHEDLRLRSLDGL 
Neisseria                ATREQARKSLQMSLRWAERSKKAFEDLK-------NPNALFGIVQGAMYEDLREESLKGL 
Agrobacterium            AERKEIERAMEMSLRWAERCRVAFGEQ--------PGKAMFGIVQGGDQPDLRIRSAEGL 
Rickettsia               ATFEEAKTSMQLTTRWANRSRNAFVKR--------EGYAQFGIIQGSVYEELREQSAKDL 
Zymomonas                ATPSRAASSMERSMRWAKRSRDAFDSRKEQA----ENAALFGIQQGSVFENLRQQSADAL 
Helicobacter             APLKRLEESIKRSAKWAN-MSLEYHKEKNR-----PSNNLFAIIQG--GTHLKMRSLSVG 
Gloeobacter              ADREQVEGAVERTLRWFERCVEAHRRSD---------QALFGIVQGGVWPDLRRRCAEGL 
Thermotoga               ADYEEVKEATERTYRWALRSKKAFKTEN---------QALFGIVQGGIYPDLRRESALQL 
Chlamydia_pneu.          TDQEYFLTSCSRTYVWEKRSLEYHRKDP-------RHQSMYGVIHGGLDPEQRRIGVRFV 
Chlamydia_trac.          ADPTYFHQSSQRTYVWEKRSLDYHLKNP-------GIQSMYGVIHGGTFPDQRKLGCKFV 
Treponema                ISKTQTLADLKITMNWLDRAFAAWHNTPHE-----YDGALFPIVQGGFFEDLRLQSLEAI 
Bacillus                 AEYDYMKRSVERTSRWAERCLNAHNRQ--------DEQGLFGIVQGGEYEDLRTQSAKDL 
Lactobacillus            ESYDYVSKSVARTSRWAERGLKVHQHP--------DYQGLFGIVQGAGFKDLREQSAKDL 
Clostridium              STREYVENSVARTTRWLERCKKEMDRLNSLPDTINKKQMLFGINQGGTYEDIRKAHAKTI 
Schizosaccharomyces      TESKRMEEAMYRSIRWLDRCIQAHKRPE--------TQNLFCIIQGGLDKRLREICCREM 
Caenorhabditis           TTGDIVKEAMHRSIRWLDRCKVAHTR-D--------DQAMFPILQGGLNLELRKECAKEM 
Drosophila               TTGPRVEEAMERTIRWVDRCIEAHARDD--------DQSLFPIVQGGLDVPLRQRCVSAL 
Mus                      VTGPLVEEAMHRSVRWLDRCIAAHKHPD--------KQNLFAIIQGGLNADLRTTCLKEM 
Homo                     VTGPRVEEAMYRSIRWLDRCIAAHQRPD--------KQNLFAIIQGGLDADLRATCLEEM 
                                     :  *                        : : :*      :        
 
 
                                    230  235                      260 
Escherichia              VDIG-FDGYAVGGLAVGEPKADMHRILEHVCPQIPADKPRYLMGVGKPEDLVEGVRRGID 
Vibrio                   TEIG-FDGYAVGGLAVGEPKEDMHRVLEHTCPQLPEDKPRYLMGVGKPEDLVEGVRRGID 
Pseudomonas              QEIG-FDGLAIGGLSVGEPKEEMIRVLDFLPPQMPADKPRYLMGVGKPEDLVEGVRRGVD 
Neisseria                EELD-FPGLAIGGLSVGEPKPEMYRMLRAVGPILPEHKPHYLMGVGTPEDLVYGVAHGVD 
Agrobacterium            KELD-LKGYAVGGLAVGEPQDVMLGMLDITLPVLPTEKPRYLMGVGTPDDILKSVARGID 
Rickettsia               VELD-FEGYAIGGLAVGEGQELMFKVLDYAPEFLPQNKPRYLMGVGKPVDIIGAVSRGID 
Zymomonas                AEIG-FDGYAVGGLAVGEGQDEMFRVLDFSVPMLPDDKPHYLMGVGKPDDIVGAVERGID 
Helicobacter             LTHEGFDGYAIGGLAVGESADEMLETIAHTAPLLPKDKPRYLMGVGTPENILDAISLGVD 
Gloeobacter              VAAD-LPGYAIGGVSVGEPQTLIERVVRVTAPLLPEHKPRYLMGVGTFREMAQAVAVGVD 
Thermotoga               TSIG-FDGYAIGGLSIGEERSLTLEMTEVTVEFLPEDKPRYFMGGGSPELILELVDRGVD 
Chlamydia_pneu.          EDEP-FDGSAIGGS-LGRNLQEMSEVVKITTSFLSKERPVHLLGIGDLPSIYAMVGFGID 
Chlamydia_trac.          EDLP-FDGSAIGGS-LGKNLQDIVEVVGVTAANLSAERPRHLLGIGDLPSIWATVGFGID 
Treponema                LKHE-PRGIAIGGLSIGEPKDLYQEYLSFTAKHIPKNKPLYVMGIGTPDYILEAVKNGVD 
Bacillus                 ISLD-FPGYAIGGLSVGEPKDVMNRVLEFTTPLLPKDKPRYLMGVGSPDALIDGAIRGVD 
Lactobacillus            VSLD-FPGYSIGGLSVGESKAEMNHVLDFTTPLLPENKPRYLMGVGSADALIDGAIRGVD 
Clostridium              VDMD-LDGYAIGGLAVGETHEEMYRVIDEVAPIFPDNKPLYLMGVGLPSNILEAVDRGVD 
Schizosaccharomyces      VKRN-TPGIAVGGLSGGEEKHAFCETVYTCTSILPDNKPRYLMGVGYAEDLVVCVALGMD 
Caenorhabditis           AKRA-KVGIAIGGLSGGEEKDHFWRVVAACCAALPPHLPRYVMGVGFPVDLVICSFLGAD 
Drosophila               MERQ-VRGFAVGGLSGGESKHDFWRMVDVCTGYLPKDKPRYLMGVGFAADLVVCVALGID 
Mus                      TKRD-VPGFAIGGLSGGESKAQFWKMVALSTSMLPKDKPRYLMGVGYATDLVVCVALGCD 
Homo                     TKRD-VPGFAIGGLSGGESKSQFWRMVALSTSRLPKDKPRYLMGVGYATDLVVCVALGCD 
                                * ::**   *.               :. . * :.:* *    :      * * 
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                          280                                       318  323 
Escherichia              MFDCVMPTRNARNGHLFVTDG----VVKIRNAKYKSDTGPLDPECDCYTCRNYSR----- 
Vibrio                   MFDCVMPTRNARNGHLFVTGG----VIKIRNAAHKTDTTPLDPHCDCYTCKNYSK----- 
Pseudomonas              MFDCVMPTRNARNGHLFVDSG----VIKIRNSVHKHDDSTLDPTCDCYTCKHFSR----- 
Neisseria                MFDCVMPTRNARNGWLFTRFG----DLKIKNAKHKLDKRPIDESCTCYACQNFSR----- 
Agrobacterium            MFDCVMPTRSGRHGLAFTRRG----RVNIRNARHAEDMRPLDEQSNCPASRDYSR----- 
Rickettsia               MFDCVIPTRSGRNGQAFTKYG----TVNIRNSKYADDNKPLEHDCLCPACRNYSK----- 
Zymomonas                MFDCVLPTRSGRNGQAFTWDG----PINIRNARFSEDLKPLDSECHCAVCQKWSR----- 
Helicobacter             MFDCVMPTRNARNATLFTHSG----KISIKNAPYKLDNTPIEENCACYACKRYSK----- 
Gloeobacter              LFDCVMPTRVARHGSALLLGTGGDRRINLKNAQFRRDYEPLDCVCPCYTCRHFSR----- 
Thermotoga               MFDSVFPTRIARHGTALTWNG----KLNLKASYNKRSLEPVDERCGCYTCKNFTR----- 
Chlamydia_pneu.          SFDSSYPTKAARHGLILSKAG----PIKIGQQKYSQDSSTIDPSCSCLTCLSGISR---- 
Chlamydia_trac.          SFDSSYPTKAARHGMILTSQG----PLKINNQRYSSDLNPIEPGCSCLACSQGITR---- 
Treponema                IFDCVLPSRNARNGNLFTHEG----AISIKRKEYEFDFNPIDSQCKCKVCRQYTR----- 
Bacillus                 MFDCVLPTRIARNGTVFTAEG----RLNMKNAKFERDFRPIDEECDCYTCKNYTR----- 
Lactobacillus            MFDCVLPTRIARNGTCMTSHG----RLVVKNAAYAHDFTPLDDNCDCYTCRNFTR----- 
Clostridium              FFDCVLPARNGRHGHVFTKYG----KINLMNAKFELDGNPIDEGCECPACKHYSR----- 
Schizosaccharomyces      MFDCVYPTRTARFGNALTRKG----VINLRNQKFRNDIGPLEEGCSCPCCKTELEGGWGI 
Caenorhabditis           MFDCVYPTRTARFGTAMVRRGG---LMQLNQKRYKEDFLPIDKKCECNTCKNYTR----- 
Drosophila               MFDCVFPTRTARFGCALVDSG----QLNLKQPKYKLDMEPIDKDCDCSTCRRYTR----- 
Mus                      MFDCVYPTRTARFGSALVPTG----NLQLKKKQYAKDFSPINPECPCPTCQTHSR----- 
Homo                     MFDCVFPTRTARFGSALVPTG----NLQLRKKVFEKDFGPIDPECTCPTCQKHSR----- 
                          **.  *:: .* .  :         : :       .  .::  . *  .           
 
 
                           330334   339   345 349 
Escherichia              --AYLHHLDRCNEILGARLNTIHNLRYYQRLMAGLRKAIEEGKLESFVTDFYQRQGREVPP 
Vibrio                   --SYLHHLDRCNEILGARLNTIHNLRYYQRLMESIRKAIDEDRFDQFVAEFYARRNREVPP 
Pseudomonas              --AYLHHLDKCGEMLGSMLNTIHNLRHYQRVMAGLREAIQQGTLAAFVDAFYAKRGLPTPP 
Neisseria                --AYLHHLHRAGEILGAQLNTIHNLHFYQVIMAEMREAVEQGKFADWQAQFHENRARGTD- 
Agrobacterium            --AYLHHLTRSNEALGGMLLSWHNLAYYQELMQGIRTSIEEGRFADFYAETIEMWARGDID 
Rickettsia               --AYLHHLVRIGEILGSMLMTWHNLTYFQNLMSRIRAYIKLGKDFDFDS------------ 
Zymomonas                --AYIHHLIRAGEILGAMLMTEHNIAFYQQLMQKIRDSISEGRFSQFAQDFRARYFARNS- 
Helicobacter             --AYLHHLFRAKELTYARLASLHNLHFYLELVKNARNAILEKRFLSFKKEFLEKYNSRSH- 
Gloeobacter              --AYLAHLVRSEEILAMTLLSIHNVATLTRFAALLRCAIATGSFAQEFAHYLQSGPEPVLS 
Thermotoga               --SYIHHLFDRGEVLGQILLTIHNINFMISLMKEVRRSIESGTFKELKSKVVEVYSSGGVN 
Chlamydia_pneu.          --AYLRHLFKVREPNAAIWASIHNLHHMQQVMKEIREAILKDEI----------------- 
Chlamydia_trac.          --AYLRHLFKVHEPNAGIWASIHNMHHMQKVMREIREGILNDRI----------------- 
Treponema                --AYLRHLFRTKEILYSMLATYHNLAFLYSMVQDIREAIQNDSFNDYYKNFLKKYENRLD- 
Bacillus                 --AYIRHLIRCNETFGLRLTTYHNLHFLLHLMEQVRQAIREDRLGDFREEFFERYGYNKPN 
Lactobacillus            --AYIRHLIKADETFGLRLTSYHNLYFLLHLMKQVRQAIMDDNLLEFRQNFFEMYGFNDKN 
Clostridium              --AYIRHLFKAKEMLAMRLCVLHNLYFYNKLMEDIRKAIEGDYFKEFKEEKLHNWSGKA-- 
Schizosaccharomyces      TRAYF-NSLVSKETVGANLMTIHNVHFQLQLMRDMRESIIKDEFPSFVKNFFHEWNHGDKS 
Caenorhabditis           --AYI-HSIVGKETVGCHLVSVHNIKHQLDLMRDVRQAIQSNSVEQFLKQFLYDYYGPIQS 
Drosophila               --SYLHHIATN-ESVSSSLLSIHNVAYQLRLMRSMREAIQRDEFPQFVA-DFMARHF-KAE 
Mus                      --AFLHALLHSDNTTALHHLTVHNIAYQLQLLSAVRSSILEQRFPDFVR-NFMRTMYGDHS 
Homo                     --AFLHALLHSDNTAALHHLTVHNIAYQLQLMSAVRTSIVEKRFPDFVR-DFMGAMYGDPT 
                                     :         **:     .    *  :                       
 
 
 
Escherichia              LNVD-------------------------------------------------------- 
Vibrio                   LQKDKA------------------------------------------------------ 
Pseudomonas              LDA--------------------------------------------------------- 
Neisseria                ------------------------------------------------------------ 
Agrobacterium            PV---------------------------------------------------------- 
Rickettsia               ------------------------------------------------------------ 
Zymomonas                ------------------------------------------------------------ 
Helicobacter             ------------------------------------------------------------ 
Gloeobacter              N----------------------------------------------------------- 
Thermotoga               V----------------------------------------------------------- 
Chlamydia_pneu.          ------------------------------------------------------------ 
Chlamydia_trac.          ------------------------------------------------------------ 
Treponema                ------------------------------------------------------------ 
Bacillus                 AKSF-------------------------------------------------------- 
Lactobacillus            PKNF-------------------------------------------------------- 
Clostridium              ------------------------------------------------------------ 
Schizosaccharomyces      N------------YPSWAVDALRMVNIDLLA----------------------------- 
Caenorhabditis           ENPSKQDSEKMREVPQWVRDAVDHMGYKLDF----------------------------- 
Drosophila               P------------VPAWIREALSAVNIQLPADPERIDEQDQKPKTEKRRETEDVAEEQVA 
Mus                      L------------CPAWAVEALASVGIMLT------------------------------ 
Homo                     L------------CPTWATDALASVGITLG------------------------------ 
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6.2    Crystal data 
6.2.1 Crystal data for TGT(E235Q) 
 
Crystal data E235Q pH 6.0 E235Q pH 8.5 E235Q⋅ preQ0 (pH 6) 
A. Data collection and processing    
No. crystals used 1 1 1 
Wavelength (Å) 1.5418 1.5418 1.5418 
Space group C2 C2 C2 
Unit cell parameters    
a (Å) 90.66 90.76 90.45 
b (Å) 65.22 65.18 65.22 
c (Å) 70.38 70.46 70.44 
β (deg.) 96.28 96.12 96.33 
B. Diffraction data    
Resolution range (Å) 20–1.57         
(1.60–1.57) 
20–1.55       
(1.58–1.55) 
20–1.7              
(1.73–1.70) 
Unique reflections 51,910 56,732 44,097 
R(I)sym  (%) 3.9 (16.3) 5.8 (19.1) 7.5 (42.8) 
Completeness (%) 91.1 (71.0) 95.6 (78.5) 98.3 (96.7) 
Redundancy 2.5 (2.1) 2.3 (1.6) 2.8 (2.6) 
I/σ(I) 22.4 (3.6) 15.6 (3.8) 12.3 (2.3) 
C. Refinement    
Program used for refinement SHELXL SHELXL SHELXL 
Resolution range (Å) 20–1.57  20–1.55  10–1.7  
Reflections used in refinement 51,482/2,587 56,092/2,843 42,493/2,125 
Final R values    
Rfree (%) 20.2 21.4 24.4 
Rwork (%) 16.5 17.4 19.6 
No. of atoms (non-hydrogen)    
Protein atoms  2,871 2,883 2,883 
Water molecules 292 304 246 
Ligand atoms --- --- 13 
RMSD, angle (deg.) 2.4 2.4 2.3 
RMSD, bond (Å) 0.011 0.011 0.008 
Ramachandran plot     
most favoured regions (%) 94.9 95.3 92.5 
additionally allowed regions (%) 4.8 4.0 6.5 
generously allowed regions (%) 0.3 0.6 0.9 
Mean B-factors (Å2)    
Protein atoms 23.1 21.6 23.4 
Water molecules 30.2 29.9 28.9 
Ligand atoms  --- --- 27.6 
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6.2.2 Crystal data for 6-amino-quinazolinones  
 
Crystal data TGT⋅Q19 (pH 5.5) TGT⋅Q21 (pH 5.5) 
A. Data collection and processing   
No. crystals used 1 1 
Wavelength (Å) 1.5418 1.5418 
Space group C2 C2 
Unit cell parameters   
a (Å) 88.09 88.64 
b (Å) 63.44 64.03 
c (Å) 71.12 70.70 
β (deg.) 93,297 93.00 
B. Diffraction data   
Resolution range (Å) 20–2.15         
(2.20–2.15) 
20–2.0          
(2.05–2.00) 
Unique reflections 20,948 25,282 
R(I)sym  (%) 3.9 (47.6) 5.5 (44.8) 
Completeness (%) 97.0 (99.5) 94.2 (97.5) 
Redundancy 2.5 (2.4) 2.5 (2.3) 
I/σ(I) 19.2 (2.3) 15.0 (1.8) 
C. Refinement   
Program used for refinement SHELXL SHELXL 
Resolution range (Å) 10–2.15  10–2.0  
Reflections used in refinement 18,987/918 23,226/1,123 
Final R values   
Rfree (%) 35.0 30.3 
Rwork (%) 23.8 21.5 
No. of atoms (non-hydrogen)   
Protein atoms  2,804 2,773 
Water molecules 47 73 
Ligand atoms 15 21 
RMSD, angle (deg.) 1.6 1.9 
RMSD, bond (Å) 0.005 0.016 
Ramachandran plot    
most favoured regions (%) 90.2 92.7 
additionally allowed regions (%) 8.9 7.3 
generously allowed regions (%) 1.0 0.0 
Mean B-factors (Å2)   
Protein atoms 58.4 43.5 
Water molecules 51.7 39.8 
Ligand atoms  60.6  67.9(55.3 ;93.1) 
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6.2.3 Crystal data for lin-benzoguanines  
 
Crystal data TGT⋅L1(pH 5.5) TGT⋅L2(pH 5.5) TGT⋅L3(pH 5.5) TGT⋅L4(pH 5.5) 
A. Data collection and processing     
No. crystals used 1 1 1 1 
Wavelength (Å) 1.5418 1.5418 1.5418 1.5418 
Space group C2 C2 C2 P2 
Unit cell parameters     
a (Å) 91.20 90.59 90.92 71.11 
b (Å) 65.59 64.93 65.25 64.21 
c (Å) 69.81 70.12 69.97 88.08 
β (deg.) 96.07 95.83 95.98 95.11 
B. Diffraction data     
Resolution range (Å) 20–1.7         
(1.76–1.70) 
20–1.58       
(1.61–1.58) 
20–1.58       
(1.61–1.58) 
20–2.1         
(2.14–2.10) 
Unique reflections 44,525 53,824 53,930 44,873 
R(I)sym  (%) 4.3 (16.7) 6.9 (39.4) 4.2 (22.1) 5.9 (35.7) 
Completeness (%) 98.7 (99.3) 97.1 (78.4) 96.4 (69.3) 96.4(98.5 ) 
Redundancy 2.3 (1.7) 2.2 (1.6) 2.4 (1.8) 2.4 (2.1) 
I/σ(I) 20.6 (4.2) 12.4 (1.7) 21.4 (3.6) 13.4 (2.4) 
C. Refinement     
Program used for refinement CNS SHELXL SHELXL CNS 
Resolution range (Å) 20–1.7  10–1.58  20–1.58  20–2.1  
Reflections used in refinement 44,059/4450 51,398/2624 52,915/2681 42,047/2118 
Final R values     
Rfree (%) 22.0 21.2 19.6 25.5 
Rwork (%) 19.6 17.0 15.9 22.1 
No. of atoms (non-hydrogen)     
Protein atoms  2870 2880 2823 5568 
Water molecules 368 275 333 243 
Ligand atoms 15 23 24 25 
RMSD, angle (deg.) 1.2 2.3 2.4 1.2 
RMSD, bond (Å) 0.005 0.009 0.011 0.006 
Ramachandran plot      
most favoured regions (%) 94.1 95.8 95.7 92.8 
additionally allowed regions (%) 5.6 3.9 4.0 6.9 
generously allowed regions (%) 0.3 0.3 0.3 0.3 
Mean B-factors (Å2)     
Protein atoms 20.6 20.7 21.0 32.6 
Water molecules 34.1 31.0 31.4 34.6 
Ligand atoms  20.2 18.7 29.4 37.9 
PDB-code 2BBF 1Y5V 1Y5W 1Y5X 
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6.2.4 Crystal data for 2-amino-lin-benzoguanines 
 
Crystal data TGT⋅L12 (pH 5.5) 
A. Data collection and processing  
No. crystals used 1 
Wavelength (Å) 1.5418 
Space group C2 
Unit cell parameters  
a (Å) 89.87 
b (Å) 64.97 
c (Å) 70.94 
β (deg.) 93.20 
B. Diffraction data  
Resolution range (Å) 20–1.95      
(2.00–1.95) 
Unique reflections 29,427 
R(I)sym  (%) 8.2 (43.5) 
Completeness (%) 98.8 (97.8) 
Redundancy 2.4 (2.4) 
I/σ(I) 10.9 (2.0) 
C. Refinement  
Program used for refinement SHELXL 
Resolution range (Å) 10–1.95  
Reflections used in refinement 27,447/1,336 
Final R values  
Rfree (%) 25.9 
Rwork (%) 19.8 
No. of atoms (non-hydrogen)  
Protein atoms  2,796 
Water molecules 187 
Ligand atoms 27 
RMSD, angle (deg.) 2.0 
RMSD, bond (Å) 0.006 
Ramachandran plot   
most favoured regions (%) 94.4 
additionally allowed regions (%) 5.3 
generously allowed regions (%) 0.3 
Mean B-factors (Å2)  
Protein atoms 28.2 
Water molecules 32.4 
Ligand atoms  59.5(40.6 ;86.9) 
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6.3    Nomenclature for amino acids 
 
 
 
 
 
amino acid 
 
 
three letter code 
 
one letter code 
   
alanine Ala A 
arginine Arg R 
asparagine Asn N 
aspartic acid (aspartate) Asp D 
cysteine Cys C 
glutamine Gln Q 
glutamic acid (glutamate) Glu E 
glycine Gly G 
histidine His H 
isoleucine Ile I 
leucine Leu L 
lysine Lys K 
methionine Met M 
phenylalanine Phe F 
proline Pro P 
serine Ser S 
threonine Thr T 
tryptophan Trp W 
tyrosine Tyr Y 
valine Val V 
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Marburg, den 31. Mai 2006                             ___________________________            
 
        ( Bernhard Stengl ) 
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